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ABSTRACT
JULIE C. LAUFFENBURGER: Dabigatran and warfarin for stroke prevention in atrial
fibrillation: Use, switching, and clinical effects following new market entry in real-world patients
(Under the direction of Gang Fang)
Patients with atrial fibrillation frequently benefit from anticoagulation to prevent stroke
and systemic embolism. For decades, warfarin was the primary oral anticoagulant option despite
its narrow therapeutic index requiring monitoring and drug-drug interactions. Dabigatran’s
recent availability provides practical advantages including no monitoring and fewer interactions;
however, it lacks a convenient reversal agent for bleeding events. Currently, it is unclear what
factors have driven anticoagulant utilization since dabigatran’s introduction, and little real-world
evidence on the agents’ comparative effectiveness and safety is available. The objectives were to
describe dabigatran and warfarin’s utilization and switching patterns and assess their
comparative effectiveness and safety.
A cohort of non-valvular atrial fibrillation patients initiating anticoagulation from a
large US database of commercial and Medicare supplement claims from 2009-2012 was
extracted. We first examined factors associated with anticoagulant selection using a retrospective
cohort design and multivariable regression. We then evaluated the effectiveness and safety of
dabigatran compared with warfarin using multivariable Cox proportional hazards regression and
propensity score weighting. Finally, we evaluated the clinical effects of switching anticoagulants
compared with non-switching using a time-varying exposure design and multivariable Cox
proportional hazards regression.
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Of the 64,935 patients included in the cohort, 32.5% used dabigatran. Dabigatran users
were less likely to have high ischemic stroke or bleeding risk or other clinical comorbidities.
Switching anticoagulation was also less frequent among patients with higher ischemic stroke or
bleeding risk. Dabigatran was associated with a lower risk of ischemic stroke or venous
thromboembolism, and no relation was seen between anticoagulant and harmful outcomes
including bleeding events or acute myocardial infarction. However, dabigatran was also
associated with a higher risk of gastrointestinal bleeding. Compared with non-switchers, no
relation was seen between switching anticoagulants and an increased risk of stroke, systemic
embolism, bleeding events, or myocardial infarction.
Despite the rapid uptake of dabigatran, these results highlight that patients initiating
dabigatran were generally healthier than those initiating warfarin. Dabigatran may be considered
a safe and possibly more effective alternative to warfarin in patients with atrial fibrillation;
despite encouraging results from the observed lack of increased adverse outcomes from
switching anticoagulants, caution is still recommended.
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CHAPTER 1: INTRODUCTION

1.1. OVERVIEW
Atrial fibrillation (AF), a heartbeat irregularity, is typically managed by oral
anticoagulants to prevent clot formation in the upper atria chambers of the heart when blood is
pumped inefficiently.1 To prevent ischemic stroke and thromboembolism in atrial fibrillation,
current clinical guidelines support the use of warfarin, a Vitamin K antagonist which has been
available since the 1950s; however, recently newly-approved oral anticoagulants (known as
“novel oral anticoagulants” or “target-specific oral anticoagulants”) have been recommended as
alternatives and as even first-line options.2-5 Use of warfarin in atrial fibrillation has been shown
to prevent up to 68% of ischemic stroke and lead to a significant reduction in mortality risk.6,7
Despite its effectiveness, warfarin has a narrow therapeutic index, leading to some safety issues
and potential drug-drug interactions, requiring frequent monitoring.8-10 Initiation of warfarin and
subsequent medication adherence, the extent to which patients take their medications as
prescribed, to warfarin has also been shown to be low, possibly because of the high perceived
risk of bleeding.11,12 Maintaining patients on chronic warfarin therapy has its challenges, and
alternatives to warfarin have been sought for easier monitoring and management.
Since 2010, newer oral anticoagulants have emerged as potential treatment options for
atrial fibrillation. Dabigatran etexilate13,14, a direct thrombin inhibitor that entered the US market
in October 2010, has shown superior or similar efficacy in stroke prevention over warfarin in
treatment naïve patients with AF in randomized-controlled clinical trials, depending on the dose
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studied.14-16 Moreover, dabigatran requires less frequent monitoring, may have fewer drug-drug
interactions, and may be easier for patients to manage.17,18 However, dabigatran has also been
thought lead to higher risk of dyspepsia, bleeding, and myocardial infarction than warfarin.19
Uncertainty also remains about its relative safety, because, unlike warfarin, dabigatran lacks a
direct reversal agent in the event of bleeding complications.20 Regardless, the utilization and
clinical effectiveness of dabigatran in the management of atrial fibrillation compared with
warfarin is unclear in real-world clinical practice, despite current clinical guidelines offering
dabigatran as a possible anticoagulant alternative to warfarin.
First and foremost, to examine the comparative effectiveness of anticoagulants
necessitates the understanding of factors associated with the choice of a particular treatment,
especially new pharmaceuticals. If certain characteristics are significantly associated with use of
one therapy versus another, the apparent comparative effectiveness could be affected,
particularly if these characteristics cannot be fully measured. Secondly, optimal treatment
selection may differ in specific patient populations; understanding the risk of clinical outcomes
among subgroups can help patients and providers in decision making when managing AF. The
factors associated with the uptake of novel pharmaceuticals have been studied in other
contexts.21-23 Certain providers have been shown to be more likely to prescribe therapies with a
new mechanism of action or those used for chronic illnesses; both of these situations apply to
dabigatran.24
Switching to a new medication may also carry an increased risk of therapeutic failure and
toxicity25, especially for a therapy with a narrow therapeutic window, such as warfarin. Early
case reports of patients switching from dabigatran to warfarin suggest an overall increased risk of
bleeding on dabigatran.26,27 Yet, the clinical effects of switching between warfarin and an
anticoagulant of a different drug class are still somewhat unclear, as most guidelines have
2

recommended that patients stabilized on warfarin generally should remain on warfarin.5 Expert
opinion suggests that if switching is necessary, additional monitoring is warranted.28 By
comparison, even switching between warfarin product formulations (e.g., brand to generic) has
been studied and is thought to be potentially problematic.28-32 Studies have suggested that
switching between warfarin formulations may be possible without avoiding any major adverse
consequences while others have found a slight increased risk of bleeding.31-33 Given this
underlying controversy, it is possible that switching between entirely different anticoagulants
may lead to an increased risk of adverse events, especially in the absence of validated dosing
conversion standards between anticoagulants. Regardless, there is still minimal evidence
regarding the factors and consequences associated with switching between warfarin and a
different anticoagulant (or vice versa), particularly among patients in the US.34,35

1.2. SIGNIFICANCE AND INNOVATION
More than 460,000 individuals in the United States are newly-diagnosed with AF
annually. Meanwhile, AF is only increasing in prevalence and incidence as the population ages.36
An estimated $26 billion dollars is spent by the US health care system annually on the
management of AF.37 As the use and effects of dabigatran in the management of atrial fibrillation
are unknown outside of small clinical trials with limited patient diversity, further examination of
possible clinical and safety effects is needed. Optimizing anticoagulation in atrial fibrillation is a
critical public health need.
Understanding the factors associated with the use of anticoagulants may also help further
future patient-centered research by examining areas where treatment effect heterogeneity may
exist. Comparative effectiveness research has also been thought to be affected by changing
patterns of use in newly-launched therapies.38,39 While the factors associated with use of
3

dabigatran versus warfarin for anticoagulation management are still unclear, particularly in the
US, some limited evidence is suggesting some channeling away from dabigatran for patients
with higher comorbidity burden.40,41
Furthermore, the effectiveness and safety of dabigatran compared with warfarin in AF
has not been studied extensively outside of randomized-clinical trials (RCTs) or meta-analyses of
these RCTs. Concerns have been raised about an increased excess risk of bleeding and
myocardial infarction in patients with AF treated with dabigatran, but once adjusted for renal
impairment, dabigatran may not carry the same risk.42,43 Moreover, the Food and Drug
Administration (FDA) approved dabigatran at doses of 150mg or 75mg (renally-adjusted) twice
daily for AF; however, dabigatran has not been studied at the 75mg dose – either in RCTs or
observational studies.43 Given the potential for many patients being placed on this dose, using
secondary data from real-world settings can provide additional evidence for this previously
unstudied strength.
Moreover, the introduction of these new anticoagulants may carry increased risks of
bleeding or ischemic stroke and have implications for patients and providers in the management
of transitioning patients from warfarin to dabigatran. In practice, many patients may not be
treatment-naïve to anticoagulants, and the actual effectiveness and safety of transitioning AF
patients between drug products should be examined. The clinical effects of switching between
warfarin to an entire different drug product in AF patients in the period following the medication
transition is still largely unclear, and switching from dabigatran to warfarin is even less studied.
The goal of this study is to investigate the factors associated with new use and switching
between anticoagulants, comparative effectiveness of new use of anticoagulants, and the clinical
effects of switching anticoagulants following new market entry of dabigatran. The contribution
of the proposed research is expected to help inform patients, clinicians, researchers, and third4

party payers of the real-world utilization, comparative effectiveness and safety of dabigatran
compared to warfarin, to help improve clinical practice. Because of the increasing prevalence of
AF and the rapid introduction of new anticoagulants, understanding their comparative
effectiveness and safety is of imperative importance.

1.3. SPECIFIC AIMS AND HYPOTHESES
Specific Aim #1: Assess and investigate patient factors associated with new use of either
warfarin or dabigatran and switching between anticoagulants in patients with atrial fibrillation.
Hypothesis 1: Clinical prediction risk scores (e.g., ischemic stroke and bleeding risk) will not
differ between new users of warfarin compared with dabigatran.
Hypothesis 2: Clinical prediction risk scores (e.g., ischemic stroke and bleeding risk) will not
differ between new users who switch anticoagulants within 12 months compared with those who
do not switch.
Proposed contribution to the literature: This aim is designed to describe the clinical and
demographic characteristics associated with use of anticoagulants in the setting of
dabigatran market introduction while focusing on ischemic stroke and bleeding risk
predictions. Because new users are by definition naïve to anticoagulation, individuals
using warfarin therapy post-dabigatran approval may be markedly different than those
using dabigatran. Previous users of warfarin who switched to dabigatran post-approval
may be those more likely to have had adverse events, but these characteristics have not
been studied. Examining for potential differences may lend additional insight into realworld drug utilization patterns.

5

Specific Aim #2: Investigate the comparative clinical outcomes (risk of harm and clinical
effectiveness) following new use of either warfarin or dabigatran, adjusting for baseline patient
factors.
3.6.3.1 Hypothesis
Hypothesis 3: There are no significant differences in the risk of clinical effectiveness
outcomes or harm outcomes or acute myocardial infarction in new users of warfarin
compared with users of dabigatran.
Proposed contribution to the literature: The comparative effectiveness and safety of
dabigatran versus warfarin have not yet been examined outside of RCTs for newlyinitiating patients. By examining clinical effectiveness outcomes (such as ischemic stroke
or venous thromboembolism), safety outcomes (such as bleeding events) and acute
myocardial infarction, this research is expected to provide insights on real-world
outcomes to inform clinical practice.

Specific Aim #3: Explore the comparative clinical outcomes (risk of harm and clinical
effectiveness) of switching from warfarin to dabigatran or dabigatran to warfarin compared with
non-switchers, adjusting for patient clinical and demographic factors.
Hypothesis 4: Switching from warfarin to dabigatran will not be associated with increased risk of
harm or clinical effectiveness outcomes compared with those who remain on warfarin.
Hypothesis 5: Switching from dabigatran to warfarin will not be associated with an increased
risk of harm or clinical effectiveness outcomes compared with those who remain on dabigatran.
Proposed Contribution to the Literature: Because many warfarin patients may not be
treatment-naïve and may have different clinical risk profiles than new users, examining
the clinical effects of switching oral anticoagulants would provide additional insight on
6

the role of dabigatran post-approval. Said another way, the comparative effectiveness and
safety of switching anticoagulants may differ than initiating therapy for the first time.

1.4. SUMMARY
Retrospective, observational examination of the use and outcomes of dabigatran
compared with warfarin will allow for understanding the generalizability of findings from RCTs
to patients in the US health care system. Previous research has been narrowly focused on specific
patient populations due to limitations in randomized-controlled designs, such as small sample
sizes, restrictive inclusion and exclusion criteria, and the inability to measure real-world
utilization. Understanding the utilization of each drug in patients with atrial fibrillation may
allow a better approach to managing such patients.
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CHAPTER 2: LITERATURE REVIEW

The following chapter outlines the background of atrial fibrillation (AF) as follows: how
AF is diagnosed, risk factors for developing AF and outcomes of atrial fibrillation to explain
which types of AF will be examined in this research. The pharmacologic and non-pharmacologic
management of AF is also discussed through published randomized-controlled trials (RCTs),
observational studies of anticoagulation use to prevent ischemic stroke, and recent guideline
recommendations. These findings will be used to outline which dependent variables, covariates
and potential confounders will need to be measured as part of this research in Chapter 3. Any
published literature about the uptake of dabigatran is also discussed, along with controversies
which currently exist in using dabigatran for AF to highlight the types of studies which have
already been conducted and underscore what knowledge gaps currently exist which this research
will help address.

2.1. ATRIAL FIBRILLATION
2.1.1. Definition and diagnosis
Atrial fibrillation, the most common arrhythmia seen clinically, is characterized by
irregular electrical impulses which generate irregular heartbeats.44 AF may be discovered by
measuring a pulse on clinical exam, but clinicians generally confirm AF using an
electrocardiogram (ECG).45 On the ECG, the replacement of consistent P waves with rapid
oscillations or fibrillatory waves of irregular, frequently rapid ventricular responses identifies an
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AF diagnosis.3,46 Pathogenically, AF is initiated by a “trigger”, an abnormal automaticity arising
from non-cardiac sites, including most commonly pulmonary veins, but also other venous sites
or autonomic ganglia.47 While the exact mechanism causing potential “triggers” is unknown,
these automaticities may eventually lead to atrial remodeling, causing a permanent change in
atrial function or structure.48 Correspondingly, AF may be considered reversible or irreversible,
depending on the atrial “substrate” etiology, other electrophysiological factors, and other clinical
conditions. The goal of many treatments for AF is to prevent triggers and control this atrial
modeling – to ultimately reduce the likelihood of adverse outcomes.46
Major clinical guidelines have generally recognized four different classifications of AF:
first detected AF, paroxysmal AF, persistent AF and permanent AF.3,46,49 First detected AF is
often characterized by only one diagnosed episode. If the first detected AF terminates
spontaneously but a second episode occurs, then the patient is considered to have paroxysmal
AF, whereby most cases are still short and self-limiting. However, if the paroxysmal AF episode
is sustained longer than 7 days, then the patient is classified as having persistent AF, which
generally requires cardioversion to terminate. If a patient has undergone cardioversion
unsuccessfully or is not a candidate for one, then the patient is considered to have permanent
AF.49
In addition to the above definitions, AF has also been classified by clinical guidelines as
lone atrial fibrillation, indicating the absence of other clinical findings or other cardiovascular
disease, non-valvular AF, whereby AF occurs in the absence of other mitral valve disease or
prosthetic heart valves, and secondary AF, in which AF occurs secondarily from another primary
condition including acute myocardial infarction, previous surgery, pulmonary embolism,
pneumonia, hyperthyroidism or other pulmonary disease.49 AF etiology may also differ broadly
between those with primary AF versus secondary AF. Thus, many studies incorporate baseline
9

factors prior to AF diagnosis when examining treatment outcomes or study those patients with
primary AF or those patients with non-reversible causes of AF.45,46 For instance, long-term
treatment goals of AF may differ when patients develop AF post-operatively versus those
without any acute perturbations or illness. When a patient has 2 or more episodes, regardless of
classification, the patient is considered to have recurrent AF.46
While these categories are not considered to be mutually exclusive, the duration of AF
seems to be particularly important in determining the management for AF. Pharmacologic or
non-pharmacologic management is not considered to clinically change the classification of a
patient’s AF, though in some cases the AF episodes may terminate permanently.44,49 Clinicians
can often diagnose AF within a single inpatient or outpatient encounter, where thyroid, renal, and
hepatic functions are also measured as part of the evaluation.46,50 As will be discussed in later
sections, anticoagulation is typically reserved for cases of persistent, permanent, or recurrent AF,
while dabigatran specifically is indicated by the FDA for non-valvular AF only.3,4 Thus, the
proposed research will focus on patients with irreversible persistent or permanent non-valvular
AF classifications.
By comparison, atrial flutter, may occur via similar mechanisms, but is pathogenically
and prognostically different even though the atrial fibrillation and atrial flutter may convert back
and forth to each other.3,4,46 Atrial flutter is usually distinguishable from atrial fibrillation based
ECG patterns and is often not treated indefinitely with anticoagulation. For this reason, atrial
flutter will not be examined in the context of the proposed research.

2.1.2. Epidemiology, costs, and quality of life
Developing atrial fibrillation is associated with an increased risk of ischemic stroke and
thromboembolism through emboli from the atria.1 AF primarily affects middle aged adults and
10

older. Thought to impact 3 million Americans, more than 460,000 individuals are newlydiagnosed with AF annually.36 This number is only expected to grow as the population ages. The
lifetime risk is 1 in 4 for persons over the age of 40 years in the United States, and the median
age of AF patients is thought to be about 75 years.
Managing atrial fibrillation can also be expensive and burdensome to individuals. The US
health care system spends an estimated $26 billion dollars annually on care related to AF.37 One
study found that approximately 350,000 hospitalizations, 5 million office visits, and 276,000
emergency room visits are annually attributable to AF and its complications.51 Having atrial
fibrillation and developing one of its complications can also lead to a decreased quality of life.
Measured in quality-adjusted life-years [QALYs], AF can decrease quality of life by up to
20%.52 Moreover, ischemic stroke, a complication of AF and a main reason for the use of
anticoagulation in AF, results in estimated QALYs of 0.87, 0.68, and 0.52 for major ischemic
stroke, moderate ischemic stroke, and minor ischemic stroke, respectively, compared with a
QALY of 1.0 for those in perfect health.53

2.1.3. Risk factors
A number of cardiovascular risk factors have been associated with the development of
atrial fibrillation. Commonly-cited cardiovascular risk factors include hypertension, valvular
disease, coronary artery disease, cardiomyopathy/heart failure, congenital heart disease,
myocardial infarction, post-surgical complications, pulmonary embolism, and use of a
pacemaker.54,55 Of these, congestive heart failure (CHF), hypertension, valvular disease, and
previous myocardial infarction appear to be the most studied risk factors. CHF has been
associated with odds ratios of 4.5 in men and 5.9 in women compared with patients without
CHF, suggesting a vastly increased likelihood of developing AF with CHF.50 Valvular disease
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has been associated with odds ratios of 1.8 in men and 3.4 in women, while previous myocardial
infarction has also been shown to increase the risk of developing AF by 40%.50 Concomitant
hypertension increases the AF risk by approximately 50% compared with those without
hypertension.50 Because of its sheer prevalence, hypertension is thought to contribute to a greater
AF burden than any other risk factor.56
However, some patients with AF have no underlying cardiovascular disease – in fact, as
many as 12% of all diagnosed AF patients have no identifiable history of cardiovascular disease.
45,57

Published literature has identified diabetes mellitus, hyperthyroidism, chronic lung disease,

chronic kidney disease, alcohol withdrawal, pharmacologic agents (e.g., stimulants, digoxin
toxicity, and illicit drugs), smoking, excessive physical exertion, and recent surgery as
commonly-cited non-cardiovascular causes contributing to AF.54,55,58 Though not considered to
be independent causal factors, male sex, elevated inflammatory markers, advanced age, sleep
apnea, and obesity have also been thought to increase the likelihood of developing AF.57 The
odds ratio of developing AF has been shown to be 2.1 for men and 2.2 for women for each
additional decade of life.50 Having diabetes mellitus doubly increases one’s risk, with differences
in risks between sexes. Men have a 1.5 times the likelihood of developing AF compared with
women.50,56 In addition, obesity and smoking are associated with a 50%and 40% greater risk of
AF, respectively.59
While many risk factors for AF have been elucidated, some recent efforts have focused
on identifying additional risk factors. Some patients with AF have none of the aforementioned
risk factors. Approximately 30-45% of cases of paroxysmal AF and 20-25% of cases of
persistent AF occur in patients without underlying disease (e.g., “lone AF”).45 As a result,
researchers are continuing to search for other underlying reasons for developing AF.
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2.1.4. Outcomes
Having atrial fibrillation is primarily associated with an increased risk of systemic
embolism leading to ischemic stroke. While less common due to the physiologic nature of
developing acute myocardial infarction (AMI), atrial fibrillation may be associated with an
increased risk of AMI. Congestive heart failure (CHF) is also thought to be exacerbated by AF,
due to the increased potential for clot formation in general.60,61 While AF is most often
associated with the aforementioned cardiovascular causes, AF may also lead to a significantly
increased risk of hyperthyroidism54 and dementia62. Studies have also shown associations with
increased risk of mortality through multiple intermediate outcomes, including ischemic stroke,
congestive heart failure, and myocardial infarction.47,63 In particular, the mortality rate of AF
patients has been estimated to be twice that of patients with normal sinus rhythm.60 These
outcomes will be discussed further in subsequent sections.

2.1.4.1. Systemic Embolism/Ischemic Stroke
One of the most serious adverse complications of AF is systemic thromboembolism
leading to ischemic stroke, which is a distinct consequence from either deep vein thrombosis
(DVT) or pulmonary embolism (PE). While treatments for AF are similar for these other embolic
conditions, AF itself mechanistically does not lead to an increased risk of either DVT or PE,
because these clots form in different locations than the atria.64 This will be discussed more in the
management section below.
Atrial fibrillation increases the risk of developing ischemic stroke, mechanistically
occurring through blood vessel obstruction to the brain. The rate of ischemic stroke among
patients with non-valvular AF averages approximately 5% per year, which is thought to be 2 to 7
times that of the general US population.7 In fact, 1 out of every 6 ischemic strokes in the US
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occurs in patients with AF.65 Compared with those with normal sinus rhythm, patients with AF
have at least twice the increased risk of developing systemic embolism than those without AF –
independent of other cardiac risk factors for AF.6
In patients with non-valvular atrial fibrillation, common risk factors for developing
ischemic stroke also include: congestive heart failure or ejection fraction ≤35%, hypertension,
advanced age, diabetes, stroke, transient ischemic attack (TIA), or systemic emboli.36,44 In
patients with AF, prior stroke or TIA has been shown to be the strongest independent factor in
developing ischemic stroke (Relative Risk [RR]: 3.0) in patients with non-valvular AF.46
Diabetes mellitus significantly increases the risk of ischemic stroke and systemic embolism (RR:
1.7). By comparison, hypertension (RR: 1.6), heart failure (RR: 1.4), and advanced age (RR: 1.4)
can also significantly increase the risk of systemic embolism.46 An AF event lasting greater than
5.5 hours on any given day in the last 30 days has also been associated with a 2-fold increase in
the risk of thromboembolism.66 While the risk of embolic stroke in AF can also be enhanced by
other AF risk factors, the risk is higher in patients with AF relative to other causes. Worse,
ischemic stroke may spontaneously devolve into conditions leading even to death.6 The risk of
ischemic stroke also increases with age, as demonstrated by the Framingham Heart Study. In this
study, the annual risk of stroke attributable to AF increased from 1.5% in those 50-59 years to
23.5% in those aged 80-89 years.47,60 Age has also been shown to be a modifier of the
relationship between hypertension and female gender with ischemic stroke, again increasing the
risk of ischemic stroke in these individuals.47

2.1.4.2. Congestive heart failure
Another serious complication of AF is the development of or worsening of CHF.
Mechanistically, AF can disrupt cardiac contractility, exacerbating congestive heart failure.60 As
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a result, AF can lead to tachycardia-induced heart failure (HF). The co-occurrence of AF and HF
has been shown to be increasing in incidence and consequence in the population, especially
among older adults.67 In fact, as many as 39.7% of hospitalized CHF patients had a history of
AF.61 The proportion of heart failure with concomitant AF has been shown to increase over time
from 1995 to 2004. The prognosis in AF and CHF together is also thought to be grim.67 The
conditions’ co-occurrence also been shown to reduce survival and decrease health-related
quality-of-life.67-69 Patients with HF and AF together are at an increased risk of in-hospital and
post-discharge mortality.61 Consequently, guidelines suggest taking co-occurrence of CHF into
consideration when treating AF patients, but anticoagulation management is unlikely to have any
major beneficial effect on this condition.67

2.1.4.3. Acute myocardial infarction
While less-commonly considered a direct outcome of AF, patients with newly-diagnosed
atrial fibrillation are thought to be especially prone to AMI, possibly through excess cardiac
demand.70 New-onset atrial fibrillation may increase oxygen demand over the short term,
potentially explaining the increased propensity to develop AMI.70 The resulting irregular heart
rhythms may also further hamper coronary circulation and left ventricular function or lead to
severe ventricular tachyarrthymias.71,72 Concomitant AF diagnoses have been difficult to
quantify, but studies have reported that 2.3-21.0% of patients experiencing AMI also had a
concomitant AF diagnosis. 72 One study found that AF was newly-diagnosed within 2 weeks
prior to 7.1% of index AMI hospitalizations, which was higher than expected. 70
In addition, patients with AF developing AMI appear to have a different risk profile than
general patients experiencing AMI. Patients with atrial fibrillation experiencing AMI are more
likely to be of advanced age, produce heart failure symptoms, increased heart rate upon AMI
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admission, and have left ventricular dysfunction compared with those without AF.69,72
Guidelines recommend accounting for risk of AMI during treatment for the prevention of
ischemic stroke in atrial fibrillation.46,73 On the other hand, despite the possible cardiac
worsening from AF, anticoagulation treatment for stroke prevention may have beneficial a
secondary effects in providing overall emboli prevention advantageous to reducing AMI risk.74
Thus, risk of AMI should be considered when considering management options for AF.

2.2. MANAGEMENT OF ATRIAL FIBRILLATION
2.2.1. Overview
Management of AF patients usually involves a 3-pronged approach: 1) prevention of
thromboembolism; 2) rate control; and 3) consideration of rhythm control.44,46 The strategy for
managing AF primarily includes therapies to prevent thromboembolism and other related
complications, such as ischemic stroke or death, as rate and rhythm control alone will not
decrease these risks. 44The rate control strategies often include management of the ventricular
rate without regard to efforts to maintain regular sinus rhythm. The goal of rhythm control
therapies is to restore or maintain sinus rhythm itself based on severity of symptoms.45
Regardless of strategy, pharmacologic therapies usually do not fully correct the
underlying rhythm disorder, but are intended to reduce the likelihood of adverse outcomes.46
Beyond these strategies, in managing AF, electrical cardioversion is often considered to attempt
to restore sinus rhythm by “reseting” the heart to a normal rhythm.44,75 Patient selection for
cardioversion depends on several factors including: type, severity and duration of AF,
concomitant cardiovascular and non-cardiovascular conditions, patient age, treatment goals, and
available treatment options.44 Ultimately, catheter ablations may be considered when
pharmacologic strategies or electrical cardioversion are either ineffective or contraindicated.76
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These other therapies and strategies used for AF are discussed because they will help
guide covariate selection for Chapter 3. These covariates will be used to control potential
confounders during the study of anticoagulation effectiveness and safety. Because rate control is
generally regarded first as a management option for AF, it is discussed first in this overview,
followed by a discussion of rate versus rhythm control and anticoagulation management. All of
these approaches in AF will be discussed more thoroughly in subsequent sections.

2.2.2. Rate control strategies
Initial treatment of atrial fibrillation is usually directed at controlling ventricular heart
rate. Evidence-based rate control strategies include the use of either digoxin, a beta-blocker, or a
calcium channel blocker (particularly a non-dihydropyridine such as diltiazem and verapamil).44
These therapies are recommended for patients with persistent or permanent AF.44 Digoxin can be
effective but is now considered a second-line agent, especially in patients with concomitant heart
failure, left ventricular dysfunction or sedentary individuals.44,77 Factors favoring rate control
strategy alone over rhythm control include patients with less symptomatic AF or concomitant
hypertension, while the presence of concomitant systolic dysfunction (heart failure) and potential
for adverse effects would hinder a preference for rate control.55, 44 Rate control strategies are
usually continued indefinitely or until cardioversion is successful.

2.2.3. Rate vs. rhythm control
Clinical guidelines recommend rate control as the first-line strategy especially in older
adults with concomitant heart conditions.45,46 However, published studies have found conflicting
results.55 The RACE (Rate Control vs. Electrical cardioversion for persistent atrial fibrillation)
study found no differences in rate control versus rhythm control for all adverse outcomes and
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mortality.75 The AFFIRM (Atrial Fibrillation Follow-up Investigation of Rhythm Management)
study also found no differences in the rate of ischemic stroke between patients assigned rate
versus rhythm control. However, overall mortality (26.7% vs. 25.9%, p=0.08) and frequency of
hospitalizations were higher among those assigned rhythm control.78 When stratifying on age,
older adults were found to have a significantly higher mortality burden in those using rhythm
control strategies compared with rate control strategies.78 However, a recent population-based
study found that rhythm control was associated with a lower rate of ischemic stroke compared
with rate control (Hazard Ratio [HR]: 0.80, 95% CI: 0.74-0.87).77 Considering patient quality of
life, patients have reported no differences in quality of life in rate versus rhythm control
strategies.75,79

2.2.4. Rhythm control strategies
Once the ventricular rate is controlled, restoration of an appropriate sinus rhythm is the
next AF management goal.44 In patients with newly-diagnosed atrial fibrillation, restoration of
sinus rhythm can be considered immediately in patients experiencing symptoms of AF, such as
shortness of breath or fatigue. However, rhythm control strategies have not demonstrated longterm benefits on reducing mortality or ischemic stroke risk. Furthermore, anticoagulation for
ischemic stroke prevention and rate control therapies are still generally required.

2.2.4.1 Electrical Cardioversion
Direct-current cardioversion can be considered a treatment choice to restore sinus
rhythm, especially if within 48 hours of onset of the AF episode. If the 48-hour window has
passed, a transesophageal echocardiography may be ordered to ensure no emboli formation and
then cardioversion can be performed. Regardless of specific strategy, anticoagulation is
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recommended for at least 4 weeks after cardioversion, depending on whether the causation of AF
is considered to be reversible or irreversible. Guidelines also recommend vigilance for
thromboemboli immediately following cardioversion. In addition to an increased risk of
embolism from the AF, cardioversion itself can also increase embolism risk, but occurrence is
almost always within the first 3-10 days following the procedure.44

2.2.4.2 Role of Anti-arrhythmic therapies
Pharmacologic rhythmic control therapies can be considered as chemical cardioversion,
especially in younger adults, those with paroxysmal lone AF, newly-detected AF and those
currently not preferred for electrical cardioversion.55 However, medication strategies are thought
to be less effective than electrical cardioversion. Ibutilide is the most commonly used
antiarrythmic drug to emergently restore heart rhythm. Once adequate heart rhythm has been
restored, pharmacologic therapies may also be used to maintain normal rhythm.46 These
therapies include flecanide, amiodarone, dronedarone, sotalol, propafenone and dofetilide, and
the choice of therapy typically depends on presence of concomitant heart conditions such as CHF
and coronary disease. Pharmacologic cardioversion is usually continued indefinitely until
clinical need for discontinuation due to adverse effects or clinical need subsides. As a secondline option in the event of antiarrhythmic drug failure, catheter ablation is often considered.

2.2.4.3 Ablation measures
Other ablation strategies are considered as possible curative measures. Radiofrequency
catheter ablation (RFCA) or pulmonary vein isolation are recommended as treatment options
particularly in patients with recurrent AF or patients not able to tolerate antiarrhythmic therapies.
Catheter ablation is thought to better reduce AF recurrence compared with antiarrhythmics with
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one meta-analysis finding a 23% recurrence after RFCA versus a 77% recurrence with
therapies.80 Another meta-analysis found that RCFA significantly inhibited recurrence of AF
(RR: 0.27; 95% CI: 0.18, 0.41) but with limited effect on reducing mortality (RR: 0.50, 95% CI:
0.04-5.65), complications (e.g., ischemic stroke) (RR: 1.01, 95% CI: 0.18-5.68), or death from
thromboembolic events (RR: 3.04, 95% CI: 0.13-73.43).76
Ablation of the AV node or accessory pathway to control heart rate appears to be
warranted when pharmacological therapy is insufficient or associated with undue adverse effects.
However, caution has been suggested in patients of advanced age (≥ 80 years).81 While discussed
more broadly in subsequent sections, anticoagulation may be used to manage patients either postelectrical conversion or post-ablation until successful restoration of sinus rhythm is
demonstrated.48 Two recent studies examined the comparative incidence of bleeding
complications in the first week following RFCA in patients using dabigatran and warfarin,
finding no differences in bleeding risk, ischemic strokes, TIAs or emboli.82,83 Future research is
warranted in this area.

2.2.5. Overview: Antithrombotic therapies
Regardless of rhythm or rate control strategy, guidelines recommend the use of an oral
antithrombotic agent in patients with AF to prevent ischemic stroke, except for patients with lone
AF or contraindications.48 Oral antithrombotic agents consist of two therapy classes: antiplatelets
(e.g., aspirin) and oral anticoagulants (OACs) (e.g., warfarin or dabigatran). When prescribing a
therapy, clinicians are largely recommended to weigh the benefit of preventing emboli versus the
risks of bleeding from the therapies using stroke and bleeding clinical prediction risk scores.1,45
More detail on these clinical prediction scores will be provided in subsequent sections.
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2.2.5.1. Antiplatelet therapy
Antiplatelet therapies examined for the prevention of ischemic stroke in atrial fibrillation
have primarily consisted of two medications: aspirin and clopidogrel. Evidence from a widelydisseminated meta-analysis suggested that aspirin reduces the risk of ischemic stroke by 22%
(95% CI: 2%-38%).84 The absolute risk reductions were 1.5% per year for primary prevention
and 2.5% per year for secondary prevention of ischemic stroke.84 Another meta-analysis found a
34% reduced likelihood of ischemic stroke in patients with atrial fibrillation using aspirin
compared with no therapy (RR: 0.66, 95% CI: 0.44-0.88).85 Dual antiplatelet therapy with
clopidogrel has seen mixed results.4,86-88 The ACTIVE W Trial (The Atrial Fibrillation
Clopidogrel Trial With Irbesartan for Prevention of Vascular Events) found that anticoagulant
therapy was statistically superior to dual antiplatelet therapy with aspirin and clopidogrel in
preventing ischemic stroke in patients with AF (RR: 0.56, 95% CI: 0.39-0.82).87 Among patients
deemed inappropriate for anticoagulation, another study found a decreased ischemic stroke risk
(RR: 0.72, 95% CI: 0.61-0.85) but increased bleeding risk (RR: 1.50, 95% CI: 1.18-1.89) among
dual platelet therapy users compared with aspirin alone. These findings suggest that risk for
ischemic stroke should determine use of antiplatelet therapy, if any, but be balanced with
bleeding risk.4
For patients at low risk of ischemic stroke, clinical guidelines recommend aspirin only or
combination therapy with aspirin and clopidogrel rather than anticoagulation to balance risks of
bleeding from anticoagulation.4 More discussion in the choice of antiplatelet versus
anticoagulant therapies will be discussed in upcoming sections.
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2.2.5.2. Anticoagulation
Prior to late 2010, the only FDA-approved anticoagulant for the prevention of ischemic
stroke in atrial fibrillation consisted of an oral vitamin K factor inhibitor (warfarin), which has
served as the cornerstone therapy for years.
More recently, oral direct thrombin inhibitors and oral Factor Xa inhibitors have been
studied and considered as possible alternatives.45,89,90 The first seemingly viable alternative to
warfarin was considered in the early 2000’s but was subsequently revoked: ximelagatran, the
first oral direct thrombin inhibitor, was studied into Phase III trials but was removed from
consideration for FDA approval in 2006.91,92 These Phase III RCTs suggested that ximelagatran
was similarly efficacious to alternatives in preventing deep vein thrombosis93,94 and non-inferior
to warfarin for ischemic stroke prevention.91,94 Ultimately, ximelagatran was withdrawn from the
FDA approval process in 2006 following reports of hepatotoxicity and elevated liver enzymes in
approximately 5-6% of patients.95 The next viable oral direct thrombin inhibitor alternative to
warfarin was FDA-approved in October 2010; dabigatran (PradaxaTM) will be discussed more
thoroughly in subsequent sections.
Oral Factor Xa inhibitors have also been developed to prevent ischemic stroke in atrial
fibrillation patients. Current FDA-approved therapies include rivaroxaban (approved Nov 2011)
and apixaban (approved Dec 2012).15,19 Edoxaban, a third Factor Xa inhibitor, is currently
undergoing FDA-approval, and betrixaban is currently undergoing Phase III clinical trials.96,97
RCTs and meta-analyses of RCTs have largely shown similar or better efficacy of these agents in
preventing ischemic stroke in patients with AF compared with warfarin, but the extent of
efficacy appears to differ somewhat across agents.15,18,89,90,98-102 These agents have also generally
been shown to lead to less or equal risk of bleeding compared with warfarin, but concerns have
been raised about a potentially increased risk of gastrointestinal bleeding compared with
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warfarin.18,89,90,98-100 It is anticipated that the literature will continue to robustly evolve in this
area. The evidence related to these therapies has currently been generally restricted to the
randomized-controlled trial setting or meta-analyses of these RCTs; broad observational studies
in real-world patients of these Factor Xa inhibitors have not yet been published
More discussion on warfarin and dabigatran will be provided in Section 2.2.6 “Specific
Anticoagulants and Atrial Fibrillation”. These therapies were the main focus of the dissertation
as more longitudinal data were available on them.

2.2.5.3 Bleeding risk from use of antithrombotic therapies
When prescribing antithrombotic therapies for patients with AF, practitioners must weigh
the risk of ischemic stroke with the risk of bleeding resulting from the therapies. Hemorrhagic
and gastrointestinal bleeding are notable adverse effects from using antithrombotic
pharmacotherapy for prevention of ischemic stroke.84,103 Without using anticoagulants, the
baseline risk of hemorrhagic stroke or bleeding in patients with atrial fibrillation has not been
shown to be independently elevated compared with those without atrial fibrillation.4 The risk of
hemorrhagic stroke or bleeding while using warfarin and dabigatran will be further discussed in
the following section examining pharmacotherapy in atrial fibrillation.

2.2.5.4 Tools to determine antithrombotic therapy
2.2.5.4.1 Stroke clinical prediction risk scores
In clinical practice, providers determine the need for anticoagulation for ischemic stroke
prevention in atrial fibrillation through the use of clinical risk prediction scores.4 The two most
common ischemic stroke risk scores used in clinical practice are CHADS2104 and CHAD2S2VASc105 and are described in Table 1.103
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Table 1. Stroke risk scores used in atrial fibrillation
Risk Score
CHADS2

Use
Stroke

CHA2DS2VASc

Stroke

Characteristics
C: Congestive Heart Failure
H: Hypertension above 140/90mmHg
A: Age ≥ 75 years
D: Diabetes Mellitus
S: Prior Stroke/TIA
C: Congestive Heart Failure
H: Hypertension above 140/90mmHg
A: Age ≥ 75 years
D: Diabetes Mellitus
S: Prior Stroke/TIA
V: Vascular disease
A: Age 65-74 years
Sc: Sex category (Gender)

Points Comment
1
Maximum 6 points
1
1
1
2
1
Maximum 9 points
1
2
1
2
1
1
1

Of these, clinicians have most frequently used the CHADS2 risk score to help select
anticoagulation or antiplatelet therapy.105,106 While the CHADS2 score has been around for much
longer, the CHA2DS2-VASc risk score is becoming more commonly used due to better
stratification of low-risk patients and better predictive ability for thromboembolism.105,107
European guidelines have recommended its use for the last few years, and the most recent US
clinical guidelines from the American Heart Association/American College of Cardiology/Heart
Rhythm Society (AHA/ACC/HRS) recommend the use of the CHA2DS2-VASc to estimate
ischemic stroke risk.5
However, the CHADS2 Score has been most frequently used in observational studies of
medical claims, but the CHA2DS2-VASc has been increasingly validated in observational
data.108-110 For either score, anticoagulation therapy is recommended in patients with patients
with a CHADS2 or CHA2DS2-VASc score of 1 or greater and strongly recommended in patients
with scores of 2 or greater. Of note, these clinical prediction scores have been validated in
warfarin users; however, to our knowledge, neither score to date has been explicitly validated in
users of newer anticoagulants.
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2.2.5.4.2

Bleeding clinical prediction risk scores

When prescribing antithrombotic therapies, providers also need to consider the risk of
bleeding in which clinical risk prediction scores are recommended.4 Three major bleeding risk
scores are used in for AF patients in clinical practice (HAS-BLED111, HEMORR2HAGES103, and
ATRIA112). These tools are described in Table 2 below.103
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Table 2. Bleeding risk scores used in atrial fibrillation
Risk Score
ATRIA

Use
Characteristics
Bleeding Anemia
Severe Renal Disease
Age ≥ 75 years
Any prior hemorrhage
Hypertension
HAS-BLED
Bleeding H: Hypertension
A: Abnormal Renal and liver function
S: Stroke
B: Bleeding
L: Labile INRs
E: Elderly (age > 65 yrs)
D: Drugs or alcohol
HEMORR2HAGES Bleeding H: Hepatic or renal disease
E: Ethanol abuse
M: Malignancy
O: Older age
R: Reduced platelet count or function
R: Re-bleeding risk (i.e., prior bleed)
A: Anemia
G: Genetic factors (CYP2C9 variant)
E: Excessive fall risk
S: Stroke

Points
3
3
2
1
1
1
1 or 2
1
1
1
1
1 or 2
1
1
1
1
1
2
1
1
1
1

Comment
Maximum 10 points

Maximum 9 points

Maximum 11 points

Of the validated bleeding risk scores, the HAS-BLED score has been the most
recommended in clinical guidelines; however, using the ATRIA score for observational studies
in medical claims has been thought to be the most accurate, because some of the criteria in the
HAS-BLED score cannot be directly or accurately measured in claims, such as labile INRs or
drug/alcohol use.107,113 Of note, these clinical prediction scores have been validated in a strictly
warfarin-taking population.
Published literature suggests that combining a bleeding risk score with a stroke clinical
prediction rule can help clinicians maximize the risk and benefit tradeoff of prescribing an
anticoagulant versus an antiplatelet therapy in patients with atrial fibrillation.103
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2.2.6. Specific Anticoagulants and Atrial Fibrillation
2.2.6.1. Warfarin: Uses, Efficacy, and Adverse Effects
2.2.6.1.1. Uses
Warfarin, an oral Vitamin K antagonist, is FDA-approved for prevention of ischemic
stroke and venous thromboembolism.73 Until very recently, ACC clinical guidelines favored the
use of chronic warfarin for patients without mechanical heart valves (non-valvular AF) at
moderate to high risk of stroke; however, more recent AHA/ACC/HRS clinical guidelines
released in March 2014 have offered no major preference between warfarin and the other novel
oral anticoagulants.1,4,70,73
To manage warfarin dosing, patients are monitored regularly in provider visits or selfmonitoring using international normalized ratio (INR) tests, because warfarin has a narrow
therapeutic index.45,46 In non-valvular AF, patients receive titrated warfarin doses to a target INR
of 2.0 to 3.0, monitored and adjusted through these INR tests.45 When first beginning warfarin,
patients generally start on doses of 5.0mg and increase or decrease doses as needed. INRs are
generally monitored at least weekly during the initiation of therapy and are recommended to be
conducted monthly once anticoagulation is stabilized.45,46 The use of laboratory tests has
historically been a drawback to using warfarin due to the added inconvenience to patients and
costs to the health system, but is recommended for chronic therapy.114

2.2.6.1.2. Efficacy and Effectiveness
A wide body of literature is available on warfarin and its use in prevention of stroke in
atrial fibrillation. Warfarin has a strong history of demonstrated effectiveness in ischemic stroke
prevention.115 Long-term anticoagulation therapy with warfarin has been shown to reduce the
risk of ischemic stroke in patients with non-valvular AF in RCTs by up to 68%.6,7,115,116 Meta27

analyses have suggested that the annual incidence of stroke or systemic embolism in AF patients
using warfarin is approximately 1.66% (95% CI: 1.41-1.91).9 However, the risk of ischemic
stroke on warfarin can also vary based on underlying risk factors. Ischemic stroke risk has been
shown to increase when taken in elderly patients, female patients, patients with a history of
stroke, and newly-initiated users (e.g., patients never having taken vitamin K antagonists
before).9 Renal impairment (OR: 1.54, 95% CI: 1.30-1.81), previous aspirin use (OR: 1.19, 95%
CI: 1.04-1.37), and higher CHADS2 score (1.64, 95% CI: 1.18-2.27) are also associated with a
higher risk of stroke on warfarin, even in more recent RCTs.117
Because warfarin has been available for decades, older RCTs were conducted when the
quality of care for AF patients was worse. 9,32,117 In addition, the time in therapeutic range (TTR)
has been shown to not only vary widely across clinical practice settings but also is strongly
related to warfarin’s effectiveness.118,119 More recently, home monitoring for INRs has become
available, further mudding the picture.120 Thus, the debate regarding the effectiveness of warfarin
continues and still remains relevant today.

2.2.6.1.3. Adverse Effects
Because of its narrow therapeutic index, warfarin has been linked with a number of
adverse effects, the most serious being a high risk of bleeding. 45,46 An observational cohort of
AF patients beginning warfarin found the rate of major hemorrhage was 7.2 years per 100
person-years (95% CI: 4.9-10.6) and rate of intracranial hemorrhage of 2.5% (95% CI: 1.1-4.7)
among those newly initiating warfarin.121 Anticoagulation therapy has been shown to increase
the annual risk for intracranial bleeding by 0.2% to 0.3% in RCTs.85 In particular, the first 90
days has been associated with a 3-fold increased risk of bleeding.85 However, the study reporting
this finding was conducted at a single site in specifically older adults, and the authors were
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concerned that the bleeding risk may even have been underestimated.121 Warfarin has also been
linked to osteoporosis, purple toe syndrome, and warfarin necrosis.73 Warfarin also has other
drug-drug and drug-lab interactions, which lead to many additional adjusted dosing
requirements.

2.2.6.2. Dabigatran: Uses, Efficacy, and Adverse Effects
2.2.6.2.1. Uses
Dabigatran, a direct thrombin inhibitor, has been FDA-approved since October 2010 for
prevention of stroke and embolism in non-valvular atrial fibrillation and for venous
thromboembolism prophylaxis.122 Dabigatran has not been approved for any mechanical valve
ischemic stroke prophylaxis. Importantly, patients with mechanical heart valves or significant
mitral stenosis were excluded from RCTs used for FDA-approval, and a more recent study
indicated dabigatran’s increased risk of bleeding compared with warfarin patients with valvular
AF.123 In the US, the FDA approved two doses of dabigatran for the prevention of stroke in atrial
fibrillation: 75mg twice daily and 150mg twice daily, while the 110mg dose was studied in
RCTs.19 The 75mg twice daily dose is specifically indicated for patients with renal impairment
(CrCl <30mL/min). Notably, no RCTs have been done to study the 75mg dose.

2.2.6.2.2. Efficacy and Effectiveness
The Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) trial has
provided most of the current evidence surrounding the efficacy of dabigatran for ischemic stroke
prevention in patients with AF. This study found a decreased risk of stroke or systemic embolism
in patients using dabigatran 110mg or 150mg twice daily versus INR adjusted-dose warfarin.13 In
this study, the rates of stroke or systemic embolism varied from 1.7% in the warfarin group to
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1.5% per year in the group receiving dabigatran 110mg (RR: 0.91, 95% CI: 0.74-1.11, p<0.001
for non-inferiority) and 1.1% per year in the group receiving 150mg dabigatran (RR: 0.66, 95%
CI: 0.53-0.82, p<0.001 for superiority).13
Some sub-analyses of the overall RE-LY trial have also been published. One sub-analysis
has found that the risk of ischemic stroke or systemic embolism was significantly higher in
patients from Asian countries than from non-Asian countries, though geographic treatment
variation is thought to have influenced these differences.124 Another RE-LY sub-analysis of
patients receiving concomitant anti-platelet therapy found that dabigatran was still non-inferior
to warfarin in reducing ischemic stroke or systemic embolism, regardless of receipt of antiplatelet therapy.88 Another third RE-LY sub-analysis following 5,851 patients who had not
discontinued dabigatran (with no warfarin comparator) found approximately 1.5% and 1.6%/year
rates of ischemic stroke or systemic embolism.125 These findings were largely similar to the
original RCT findings. Whether patients were adequately anticoagulated with warfarin
(measured by time in the therapeutic range) in the RE-LY trial was also found to slightly
influence the apparent efficacy of dabigatran.14 Additional post-hoc analyses have been
conducted on patients using anticoagulation for secondary prevention versus primary prevention
and found similar findings. Overall, these sub-analyses have been useful at elucidating potential
areas for further study, but are no substitution for large real-world studies. In addition, a number
of meta-analyses summarizing the clinical trials have been published – many of them combining
the novel oral anticoagulants together. These meta-analyses have largely found superiority of the
novel oral anticoagulants but also caution about possible increased risk of myocardial infarction
or gastrointestinal bleeding risk with dabigatran.18,126,127
To our knowledge, three observational studies to date have been published to begin to
examine the effectiveness of dabigatran in preventing ischemic stroke in AF patients.128 The
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first, a cross-sectional study, followed 103 patients treated with dabigatran for at least 3 months
at a single-center anticoagulation clinic without a comparator group. In this study, only 1
ischemic stroke was reported; the authors found no statistically significant difference between
treatment-naïve patients and patients previously treated with warfarin. Of the 99 patients they
had prescription fill records for, 12% of patients had inadequate adherence over the study period
(defined as <80% adherence). The second study, a registry-based study of patients in Denmark,
followed 4,978 dabigatran-treated patients against 8,936 propensity-score matched warfarin
patients using time-to-event analysis.129 This study found that while risk of stroke and systemic
embolism was not statistically different between the two groups, mortality and risk of AMI was
significantly lower in dabigatran patients. However, this study examined dabigatran at a dose of
110mg and 150mg, because the 75mg dose is not used in Europe. This study also exclusively
followed new users of anticoagulants. The third study examined the medication adherence and
the association between non-adherence to dabigatran and clinical outcomes in a cohort of 5,376
Veterans Affairs patients.130 They found high medication adherence among this VA population
(Mean proportion of days covered [PDC] 94%). Patients with low medication adherence (<80%
PDC) were associated with an increased risk for all-cause mortality and stroke (HR: 1.13, 95%
CI: 1.07-1.19) per 10% decrease in PDC, but adherence was not associated with increased risk of
non-fatal bleeding or myocardial infarction.
In summary, dabigatran has shown relative improved efficacy over warfarin in
randomized-controlled clinical trials, though the generalizability of the findings has been
questioned, because of the narrow inclusion criteria used in the trials. Specifically, the population
included in RE-LY tended to be younger and with fewer comorbidities than has been seen in
previous observational studies examining warfarin use.119,131 In addition, the RE-LY trial
excluded patients with renal impairment or hepatic disease, which could be important sub-groups
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to analyze in real-world settings. Lastly, patients who were non-adherent were excluded from
RE-LY analyses. Using our knowledge about low medication adherence in actual clinical
practice suggests that further observational research is continued to be needed.

2.2.6.2.3. Adverse Effects
While dabigatran has fewer monitoring requirements and easier dosing arrangements, its
use has also been suggested to lead to higher risk of dyspepsia, potentially higher risk of
bleeding, and myocardial infarction than warfarin.19 Uncertainty also remains about its relative
safety, because, unlike warfarin, dabigatran lacks a direct reversal agent in the event of bleeding
complications, even though some are under development.20
Major randomized-controlled trials have shown that dabigatran is associated with
decreased intracerebral hemorrhage (ICH) compared with warfarin whether or not patients have
prior stroke/TIA and are using anticoagulation for secondary prevention.13,132,133 The RE-LY trial
found that major bleeding was 3.36% per year in the warfarin group compared with 2.71% per
year in those receiving dabigatran 110mg (p=0.003) and 3.11% per year those receiving
dabigatran 150mg (p=0.31).13 In addition, the reported rate of hemorrhagic stroke was 0.38%,
0.12%, and 0.10% per year in the warfarin, dabigatran 110mg (p<0.001), and dabigatran 150mg
(p<0.001) groups, respectively.13 Mortality did not differ significantly between the groups.13
Other RE-LY sub-analyses and case reports have found an increased risk of bleeding in
dabigatran, mainly in older adults.19,42,134 Some RE-LY sub-analyses have found a slightly
increased risk of bleeding on dabigatran versus warfarin, while others did not.14,88,124,125 Case
studies suggest that the risk of bleeding in dabigatran may be among those that did not
appropriately receive renally-adjusted dosing or among older adults.27,117,135-137 The FDA has
reported a greater proportion of adverse events reported to their MEDWATCH program for
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dabigatran than warfarin since dabigatran market entry138; however, a Mini-Sentinel analysis
found in an unadjusted cohort of patients that the risk of bleeding was not significantly greater
than warfarin.26 Consensus opinion suggests that bleeding complications may be much more
difficult to manage, and that those that occur may also be much more severe.139 Another study
examined 2,391 atrial fibrillation patients admitted with intracranial bleeding and their
comparative risk of mortality among patients treated with dabigatran compared with warfarin
using the TruvenHealth MarketScan® database.140 They found similar in-hospital mortality and
no differences in propensity-score adjusted risk ratios. Overall, much less is known about the
comparative efficacy of dabigatran compared with warfarin in real-world use, and even more
questions regarding dabigatran’s comparative safety remain unanswered.20
Dabigatran used for the prevention of stroke in atrial fibrillation has also been thought to
lead to increased risk of myocardial infarction, but data examining this outcome have been
primarily aggregation of the large randomized, controlled trials.99,141,142 In addition, the RE-LY
trial also found significantly increased risk of dyspepsia-like symptoms compared with
warfarin.13 Sub-analyses have found that gastroesophageal reflux disease (GERD)-related nonbleeding adverse events occurred in 16.9% of those receiving dabigatran and 9.4% of those
receiving warfarin (RR: 1.81 [95% CI: 1.66-1.97], p<0.001).143 In this sub-analysis,
discontinuation occurred in 4% of patients receiving warfarin due to non-bleeding adverse
events.143

2.2.7. Guidelines for Anticoagulation in AF
Clinical guidelines recommend tailoring antithrombotic therapy to individual patient’s
risk of ischemic stroke and other side effects. The following sections discuss the recommended
treatment algorithms in patients with AF with regard to antithrombotic therapy. While either
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aspirin or warfarin have been shown to reduce stroke risk in patients with atrial fibrillation,
warfarin is considered to be significantly more effective than aspirin, but carries increased risk of
hemorrhage and other side effects.3,45
For either the CHADS2 or the CHA2DS2-VASc, a risk score of 0 indicates a low risk of
ischemic stroke, whereby no anticoagulation or aspirin use is suggested. A CHADS2 risk score of
1 suggests a moderate risk of ischemic stroke, whereby either aspirin or anticoagulation are
indicated based on patient preference.104,105 A CHADS2 risk score of 2 or greater suggests a
moderate or high risk of stroke, whereby anticoagulation is warranted. Anticoagulation with a
vitamin K antagonist is recommended for patients with at least 1 moderate risk factor, including
age > 75 years, hypertension, heart failure, impaired left ventricular systolic function, and
diabetes mellitus (e.g., CHADS2 Score – see previous discussion on this topic).104 Recently, the
guidelines have incorporated equivalencies of the new oral anticoagulant (e.g., dabigatran) or
well-controlled warfarin at INR 2.0-3.0 for risk scores of 1 or greater.3,19,45
As is discussed in the following sub-sections, the clinical guidelines by the various
associations appear to have reached some degree of consensus. Generally, dabigatran is
recommended as an alternative to warfarin for clinically-indicated patients, but these guidelines
caution against its use in patients with renal impairment and advanced age. As this is a rapidlygrowing area, other guidelines are possible, but the major relevant ones have been summarized
below.

2.2.7.1. American College of Chest Physicians (ACCP) 2012 Guidelines Update
The American College of Chest Physicians in February 2012 summarized antithrombotic
recommendations in a supplement to their 9th edition of clinical practice guidelines.4 These
recommendations for patients with non-valvular irreversible AF are summarized in Table 3.
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These guidelines use the GRADE approach which classifies recommendations as strong (Grade
1) or weak (Grade 2) based on expert consensus about the overall risks and benefits of
therapy.144,145 The quality of the evidence is also synthesized into high (Grade A), moderate
(Grade B), or low (Grade C) according to the overall validity and risk of bias inherent in the
available studies.144
Notable changes to the ACCP guidelines include an active suggestion towards dabigatran
150mg twice daily rather than adjusted-dose warfarin therapy in patients with CHADS2≥2, but
the evidence supporting this recommendation currently is considered to be “weak”. In addition,
at lower risk levels, other treatment decisions are considered on an individualized basis. All of
these include patients with paroxysmal AF.
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Table 3. American College of Chest Physicians 2012 Antithrombotic Guidelines Update
Recommendation
For patients with AF at low risk of stroke (CHADS2: 0), no antithrombotic therapy recommended
- If therapy chosen, aspirin 75mg or 325mg once daily recommended
For patients with AF at intermediate risk of stroke (CHADS2: 1), oral anticoagulation
recommended rather than no therapy
- Oral anticoagulation preferred over aspirin or aspirin + clopidogrel
- If precautions against oral anticoagulation, then aspirin + clopidogrel
For patients with AF at high risk of stroke (CHADS2: 2), oral anticoagulation recommended rather
than no therapy, or
- Aspirin (75mg or 325mg), or
- Aspirin + clopidogrel
- If precautions against oral anticoagulation, then aspirin + clopidogrel
For patients with AF with oral anticoagulation recommended, dabigatran 150mg twice daily
recommended rather than adjusted-dose warfarin
For patients with AF and stable coronary artery disease with oral anticoagulation recommended,
adjusted dose warfarin alone rather than adjusted-dose warfarin + aspirin

Grade
2B
2B
1B
2B
2B
1A
1B
1B
1B
2B
2C

2.2.7.2. 2012 Focused Update: Recommendations for Prevention of Thromboembolism in Nonvalvular AF3
The European Society of Cardiology (ESC) convened an update to practice guidelines for
atrial fibrillation published in August 2012. Their recommendations related to dabigatran are
summarized in Table 4 below. These guidelines incorporated ratings using the Class and Level
of Evidence (LOE) system. Class I indicates that good-quality RCTs are available. Lower levels
(up to III) suggest that poor quality evidence is available (such as case series or other studies
with no control group). The Level of Evidence ratings suggest how consistent the underlying
studies are. Overall, these guidelines provided similar recommendations as the ACCP guidelines,
based here on the CHA2DS2-VASc score. These guidelines seemed to suggest clinical equipoise
between dabigatran and warfarin depending on various risk factors, but that further evidence
would be needed to discern differences. These guidelines recommend that selection of therapy be
based on risk factors, cost, tolerability, patient preference, drug-drug interactions, TTR, and other
clinical risk factors.
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Table 4. 2012 European Society of Cardiology (ESC) Focused Update
Recommendation
Class Level of Evidence
Antithrombotic therapy to prevent thromboembolism is recommended for all
I
A
patients with AF, except in those patients (both male and female) who are at
low risk (aged < 65 years and lone AF) or with contraindications
In patients with a CHA2DS2-VASc score ≥2, OAC therapy with:
I
A
- Adjusted-dose VKA (INR 2-3); or
- A direct thrombin inhibitor (dabigatran); or
- An oral factor Xa inhibitor (e.g., rivaroxaban, apixaban)
… is recommended, unless contraindicated
In patients with a CHA2DS2-VASc score = 1, OAC therapy with:
IIa
A
- Adjusted-dose VKA (INR 2-3); or
- A direct thrombin inhibitor (dabigatran); or
- An oral factor Xa inhibitor (e.g., rivaroxaban, apixaban)
… should be considered, based upon an assessment of the risk of bleeding
complications and patient preferences
When patients refuse the use of any OAC, antiplatelet therapy should be
IIa
B
considered, using combination therapy with aspirin 75-100mg plus clopidogrel
75mg daily (where there is a low risk of bleeding), or, less effectively, aspirin
75-325mg daily
Abbreviations: AF, Atrial Fibrillation; OAC, Oral anticoagulant; VKA, Vitamin K Antagonist; INR, International
Normalized Ratio

2.2.7.3. American Heart Association (AHA)/American Stroke Association (ASA) Science
Advisory Committee 2012 recommendations
The AHA/ASA Science Advisory committee published recommendations even more
recently than the ACCP guidelines in December 2012 using expert consensus. These guidelines
suggested that selection of OACs should be individualized and based on risk factors, cost,
tolerability, patient preference, drug interaction potential and INR time in the therapeutic range.2
Notably, this committee also recommended that dabigatran 150mg twice daily is an efficacious
alternative to warfarin (Class I; Level of Evidence (LOE) B). Dabigatran 75mg twice daily may
be considered for patients with CrCl 15-30 ml/min but with a caution that safety and efficacy
have not been established in renal-insufficient patients (Class IIb; LOE C). The committee did
not, however, recommend dabigatran in patients with CrCl < 15ml/min (Class III; LOE C).
Their overall recommendations related to dabigatran are summarized in Table 5 below.
Prior to this update, these guidelines had previously separated out explicit recommendations
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based on whether antithrombotic therapy is being used for primary versus secondary prevention
of ischemic stroke. However, the committee has generally recommended dabigatran as an
efficacious alternative to warfarin for both primary and secondary prevention in patients with at
least a moderate risk of ischemic stroke but recommended caution in renal insufficiency.
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Table 5. American Heart Association/American Stroke Association 2012 Guidelines Update
Recommendation
For prevention of first and recurrent stroke in patients with non-valvular AF, one of the
following antithrombotic agents can be considered based on individualized factors:
- Warfarin
- Dabigatran
- Rivaroxaban
- Apixaban
Dabigatran 150mg twice daily is an efficacious alternative to warfarin for prevention of first
and recurrent stroke in patients with non-valvular AF and ≥1 other risk factor and CrCl
>30mL/min
Dabigatran 75mg twice daily may be considered for prevention of first and recurrent stroke in
patients with non-valvular AF and and ≥1 other risk factor and CrCl 15-30mL/min
Dabigatran is not recommended in patients with CrCl <15mL/min
Abbreviations: LOE, Level of Evidence; AF, Atrial Fibrillation; CrCl, Creatinine clearance

Class (LOE)
I (A)
I (B)
IIa (B)
I (B)
I (B)
IIb (C)
III (C)

2.2.7.4. American Heart Association (AHA)/American College of Cardiology (ACC)/Heart
Rhythm Society 2014 Guidelines
The AHA/ASA/HRS Science Advisory committee released recommendations in late
March 2014 regarding the management of atrial fibrillation.5 Similar to guidelines released in
2012, antithrombotic therapy is still recommended to be individualized based on shared decisionmaking and recommended for patients with high ischemic stroke risk. In this 2014 version,
patients with non-valvular AF are recommended to use warfarin, dabigatran, rivaroxaban or
apixaban, with no noted preference among the agents. However, again, patients with end-stage
chronic kidney disease or on hemodialysis are not recommended to use one of the novel oral
anticoagulants. The largest difference between these guidelines and previous guidelines are that
the oral anticoagulants are considered as equal options in newly-initiating patients.

2.2.8. Other adjunctive therapies used in atrial fibrillation
Angiotensin-converting-enzyme inhibitors (ACEIs), angiotensin receptor blockers
(ARBs), and HMG Co-A-reductase inhibitors (statins) are also under investigation as adjunctive
therapies to the 3-pronged approach in managing AF. ACEIs/ARBs have been thought to play a
39

potential role in decreasing both the incidence of AF and the rate of relapse following
cardioversion in patients with AF. These drugs are hypothesized to work by reducing P-wave
duration, but their overall primary use in AF is still being evaluated.146 A recent meta-analysis
found that ACEIs and ARBs significantly lowered the risk of incident AF compared with no use
(OR: 0.65, 95% CI: 0.55-0.76).146 Compared with non-users, users of ACEIs and ARBs were
also found to have a significantly reduced recurrence of sinus rhythm disturbances (OR: 0.45,
95% CI: 0.31-0.65).146 However, the included RCTs heavily relied on post-hoc analyses for their
conclusions. Statins have also been thought to play a role in maintaining sinus rhythm in patients
with persistent lone AF, but their role as a primary agent in AF is still being evaluated and only
hypothesized in commentaries.55 The literature examining the role of adjunctive therapies
beyond the 3-pronged approach currently recommended is still evolving, and no strong
recommendation for their uses in AF has been given.55

2.3. CLINICAL CONTROVERSIES
As previously discussed, dabigatran has shown similar efficacy in stroke prevention over
warfarin in treatment naïve patients with AF in randomized-controlled clinical trials.14-16 While
dabigatran requires less frequent monitoring and may lead to decreased intracerebral
hemorrhage, it may also lead to higher risk of dyspepsia, other types of bleeding, and myocardial
infarction than warfarin.19 In addition, dabigatran lacks a direct agent in the event of bleeding
complications, which may decrease its overall safety.20 This section explores the clinical
controversies surrounding the use of warfarin and dabigatran and identifies the literature
available in this area.
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2.3.1. Warfarin: Clinical controversies
Despite warfarin’s longevity on the market, some clinical controversies remain,
especially around patient-centered outcomes and effectiveness. Long-term therapy with warfarin
has been shown to decrease quality of life in patients with AF by as much as a mean 1.3%
decrease in utility.52,147 Other studies have also reported that some patients thought their quality
of life would be increased with the use of aspirin versus oral anticoagulants.52,148 In addition, the
extent to which warfarin’s effectiveness is affected by non-adherence and INR control is still not
fully established.119 INR control is directly related to the TTR for warfarin.119,149 This issue is
particularly important because patients’ TTR has been shown to vary widely among warfarin
users in not only observational studies but also Phase III RCTs examining the novel oral
anticoagulants (NOACs) (including dabigatran).14,15,118,150 Because TTR has been shown to be
related to clinical effectiveness of warfarin, the adequacy of the comparator groups in these
settings has been called into question.14
Research is also still examining rates and effects of warfarin initiation and
discontinuation, despite indications for chronic use, especially given perceived risks of bleeding.
Despite knowledge about its effectiveness, patients also have been shown to be fairly nonadherent with using warfarin.151,152 In addition, research is still assessing long-term outcomes of
warfarin use, even years after initiating therapy.11,153 9

2.3.2. Dabigatran: Clinical controversies
While the FDA-approved dabigatran at 75mg twice daily, this dose was not studied in
Phase III clinical trials.43 Instead, the RE-LY trial compared dose-adjusted warfarin against
dabigatran 110mg (along with the FDA-approved dose of dabigatran 150mg). Other countries
did, however, approve dabigatran at 110mg. The fact that dabigatran has not been studied at the
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75mg dose has implications for patients, as much further study is warranted to ensure
comparative effectiveness of dabigatran at that dose. The lack of current information about the
dabigatran110mg dose has raised considerable controversy, underlying the need for
observational studies to assess this dose.
There is also interest in the apparent effectiveness of dabigatran in patients with mildmoderate ischemic stroke – with a CHADS2 or CHA2DSs-VASc score of 1. Previously, these
patients would be treated with antiplatelet therapy. However, some commentaries suggest that
dabigatran may be useful in these marginal patients – ones where the decision to anticoagulate
had been primarily preference-driven prior to dabigatran’s availability.17,154 Thus, more research
will be needed to resolve whether dabigatran can be used in a wider degree of patients than
warfarin previously had been.
In addition, providers have raised some concerns regarding the apparent increased risk of
bleeding on dabigatran. A recent theheart.org analysis surveyed physicians regarding their
concerns of dabigatran use in AF patients.155 On a scale of 1-6 (6 being very concerned),
physicians were asked about intracranial hemorrhage, gastrointestinal (GI) bleeding and left
atrial enlargement, renal dysfunction, and recurrent stroke yielding average ratings of 4.11, 4.07,
3.45, 4.04, and 3.85, respectively.155 By comparison, physician asked about burden of INR
monitoring, difficulty maintaining INR, managing multiple medications, side effects, quality of
life and compliance in warfarin used yielded average ratings of 4.36, 4.22, 4.13, 4.13, 3.98, and
4.10, respectively.155
Management of dabigatran is simultaneously easier and more difficult. Currently, no
laboratory monitoring for chronic therapy is recommended; INR testing is neither useful nor
determinative.156 Thrombin time and ecarin clotting time, directly measuring thrombin activity
from the plasma, may be used to estimate anticoagulant effect in a concentration-dependent
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linear relationship.135,157 However, no studies have yet been conducted examining the real-world
utility of these tests. The fixed-dosing arrangements of dabigatran have also been widely
marketed as treatment advancement from INR dose-adjusted warfarin.
Moreover, in the event of over-anticoagulation (e.g., bleeding), no reversal agent exists to
stop the bleeding, unlike warfarin whereby phytonadione (vitamin K), among others such as
dialysis, factor, and fresh frozen plasma, can be used to reverse warfarin toxicity.156,157 This lack
of antidote for dabigatran has clinical implications, because while the drug is easier to take and
easier to dose, adverse outcomes may be more difficult to manage, and costs of managing
bleeding outcomes may be much higher than warfarin.158 Current recommendations for treatment
of bleeding include supportive care, activated prothrombin complex concentrate, activated factor
VIIs, or dialysis.19 A recent survey of 221 vascular neurologists found large variations in
recommended treatment modalities for bleeding events on dabigatran among these providers.157
Clearly, much more research is needed in this area as well.

2.3.3. Other controversies in choice of anticoagulation
While not the focus of this research, the use of dabigatran versus warfarin in the setting
of catheter ablation is also undergoing strenuous evaluations. Even when undergoing catheter
ablation, anticoagulation is still considered a recommended course of therapy as some patients
may still experience inconsistent sinus rhythms. Currently, it is still not clear whether dabigatran
is as safe and effective compared with warfarin during catheter ablation.159 One case-control
study examining the risk during radiofrequency catheter ablation found no significant difference
in perioperative acute risk in terms of major and minor bleeding events.160 Another study found a
decreased risk in rebleeding occurring from dabigatran patients compared with warfarin (20% vs.
44%, p =0.01).161
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Recent research has also uncovered the challenges of prescribing antithrombotic therapy
in patients with new-onset acute myocardial infarction and previous anticoagulation therapy to
prevent stroke. While long-term oral anticoagulation is important for the prevention of stroke in
atrial fibrillation, the combination of warfarin and antiplatelet medications following AMI
creates challenges for such patients. A sub-analysis of the RE-LY trial found that 38.4% of
included patients received clopidogrel and aspirin simultaneously along with warfarin or
dabigatran in the study.88 Both doses of dabigatran studied (110mg and 150mg) were found to be
non-inferior to warfarin in terms of stroke or systemic embolism risk regardless of platelet use.88
Major bleeding was also similar to warfarin among those using concomitant antiplatelet therapies
(HR: 0.80, 95% CI: 0.70-1.25). Dual antiplatelet therapy (clopidogrel + aspirin) increased the
risk of bleeding as well (HR: 1.60, 95% CI: 1.42-1.82). Fewer than 50% of these patients have
been shown to use warfarin at discharge, even with CHADS2 greater than 2, and triple therapy
(with antiplatelet medications) is used in only 14.6% of patients.70 Literature has suggested a
further research need in this area.
Because of the difficulty in attaining and maintaining an INR in the recommended
therapeutic ranges in treatment with warfarin, pharmacogenetic testing for variants in the
cytochrome P450 2C9 gene has been developed. Interindividual dose variability has been shown
to derive from coding variations and polymorphisms on this gene.10,162,163 While the uptake of
the testing is still limited to some health settings, warfarin dosing can be affected by the results
of the test.164 The cost-effectiveness of the test in determining warfarin dosing has affected its
uptake in clinical practice despite recommendations.163 This potential for better identification of
genetic differences in response to warfarin has relevance for comparisons to dabigatran, as
researchers better understand idiosyncratic differences in response to warfarin dosing.
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2.4. ISSUES IN USE OF ANTICOAGULATION IN REAL-WORLD PRACTICE
The previous section summarizes the published research examining clinical differences
between anticoagulants under optimal clinical conditions. However, selection between available
treatment options may also be influenced by additional factors frequently studied in health
services research related to health behavior, patient/provider preferences, and willingness and
ability to pay. Examining how these factors affect anticoagulant use and outcomes in the realworld is just as important as under optimal clinical conditions and settings to help improve
evidence-based clinical practice. This section explores the research related to use of
anticoagulants in the management of AF and related contexts.

2.4.1. Andersen’s Behavioral Model of Health Services Use
The Andersen’s Behavioral Model of Health Services Uses can be used to help illustrate
factors associated with the use of anticoagulants in patients with atrial fibrillation. Briefly, the
Andersen’s Model describes multiple levels of factors that have been historically associated with
use of health care services – individual, provider and health-system factors.165 The first model,
created in the 1960s, described that the use of health services is primarily driven by individual
predisposition, factors that affect use, and need for the services.166 More recent models have
incorporated system factors that all influence health services, including processes of care and
provider interactions as part of health behavior affecting service use.165-167 More discussion on
the Andersen’s model and its application to this proposed research will be provided in Chapter 3.
The most recent version of the Andersen model is displayed below in Figure 1.
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Figure 1. Andersen's Behavioral Model of Health Services Use166

In Figure 1 above, predisposing, enabling and need characteristics are illustrated on
multiple levels, including contextual and individual. These factors influence health behaviors and
ultimately outcomes, such as perceived health, evaluated (clinical) health, and satisfaction.165-167
Predisposing demographic characteristics (e.g., age, gender) and social characteristics (e.g.,
education, race/ethnicity) occur on multiple levels as well. Enabling characteristics (e.g.,
financial, access to care) may also occur on multiple levels. Need characteristics often
encompass both an individual’s perceived and evaluated (clinical) need for services. In the
setting of this dissertation, evaluated need will serve as the primary measurement for need
factors. Because much contextual information is not available in the data source for the study,
the dissertation focuses on those variables primarily describing the individual level. The
Andersen’s Model has also been successfully used in a number of settings examining factors
associated with pharmaceutical use.165 Chapter 3 illustrates the proposed adaption of the model
for the dissertation, given the available data and ultimate study questions.
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2.4.2. Real-world uptake of anticoagulation in AF
To examine factors associated with the use of anticoagulants, the overall uptake of
anticoagulants also needs to be examined. Historically, utilization of anticoagulants in the setting
of atrial fibrillation has been shown to be remarkably low, largely because of concerns over
perceived risk of bleeding.121,168,169 Before the introduction of direct thrombin inhibitors and
Factor Xa antagonists, the use of warfarin in AF patients has ranged widely in observational
studies (9.1%-79.8% across 28 studies; median=49.1%).168 Other reviews suggest that of eligible
patients without contraindications (as indicated by CHADS2 score), only 15-44% are prescribed
warfarin.7 While over time utilization has increased, without alternatives to warfarin in patients
with high CHADS2 scores, patients with contraindications to warfarin may have gone
undertreated.95,168 One study found a strong correlation between proportion of patients using
warfarin and the year the study was conducted, suggesting some increased initiation of warfarin
over time (r=0.60; p=0.002).168
Despite being chronic therapy, discontinuation and medication non-adherence has also
been high in patients treated with warfarin. In a population-based cohort of AF patients starting
warfarin, 8.9% of patients did not fill a second prescription, 31.8% discontinued therapy within 1
year, and 61.3% discontinued therapy within 5 years with a median time to discontinuation of 2.9
years.11
The real-world uptake of dabigatran has been examined in a few, small studies. A study
by Kirley et al in 2012 examining the proportion of office visits in the US in IMS Health data
from 2007-2011 for AF resulting in anticoagulation prescriptions found that visits attributed to
warfarin declined from 2.1 million in 2007 to 1.6 million in 2011.170 The number of office visits
resulting in a dabigatran prescription increased from 0.062 million in quarter 4 of 2010 to 0.363
million visits in quarter 4 of 2011 (3.1% to 18.9% share of visits resulting in oral anticoagulants).
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However, the proportion of office visits resulting in warfarin decreased from 60.5% to 44.4%
over the same interval. Pharmacy sales for dabigatran also increased from 0.8% to 8.1%. Despite
the uptake of dabigatran, the treatment rates of high-risk patients still ranged from 20-80%,
depending on the population under study.170 A very recent study of Medco claims of 41,805 nonvalvular patients indicated that patients using dabigatran were less likely to have comorbidities
and higher ischemic stroke risk between patients initiating anticoagulation from Feb 2011 to
April 2012.40

2.4.3. Factors associated with anticoagulant use
Factors associated with real-world use of dabigatran for the prevention of stroke in atrial
fibrillation patients are still being elucidated. Characteristics of users of warfarin by comparison
have been studied, but primarily in cohorts prior to the introduction of these novel oral
anticoagulants though additional research is being released.171 The Andersen’s Behavioral Model
of Health Services Use was used to help guide the factors examined for inclusion in the study, as
will be described in Chapter 3. Because fewer health-system level factors can be directly
measured in the insurance claims data used for the dissertation, the focus of this section is
primarily on individual-level factors.
While the use of warfarin is part of the 3-pronged approach for ischemic stroke
prevention in atrial fibrillation and overall use has been shown to be less than adequate, some
contraindications to therapy do exist.148,172 The initiation of anticoagulants often depends on
precautions or relative contraindications to therapy (e.g., history of bleeding, alcohol use,
dementia, falls, cancer or use of nonsteroidal anti-inflammatory medications).116,172 The need
predicted by the stroke prediction scale (e.g., CHADS2 score) can also influence the decision of
prescribing anticoagulation.116,172 Of these factors in the CHADS2 score, advanced age has been
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repeatedly cited as one of the largest barriers to anticoagulation.7,116 History of stroke has also
been shown to better predict more aggressive and consistent anticoagulation.173
Previous research has also uncovered individual factors associated with the use of
warfarin. A widely-cited chart review of 707 patients found that use of warfarin was significantly
higher among patients who were younger, had prior stroke or TIA, and concomitantly used betablockers, ACEIs, or diuretics.116 Those with lower activities of daily living or used aspirin were
associated with a lower rate of warfarin use.116 Other studies have corroborated the association of
these factors with use of warfarin.7,116,169,173 Patients with coronary artery disease also trended
towards higher use of warfarin.174 Patient geographic location has also been shown to influence
anticoagulation, with patients in the South being shown to be less likely to receive warfarin than
other geographic regions, even after adjusting for other measured covariates.169,173
Discontinuation after initiation has also been shown to depend on several factors.
Younger adult men with lower stroke risk have also been shown to be more likely to discontinue
warfarin therapy.11 However, this study was conducted in Canada with a strictly older adultbased cohort where all patients had comprehensive drug coverage.
The type of physician has also been found to affect initiation of warfarin for
anticoagulation.169,175 Cardiologists or internists were more likely to prescribe anticoagulation
compared with antiplatelet therapy (e.g., aspirin) for stroke prevention in atrial fibrillation
compared with general and family practitioners.173
Only one study using IMS health physician-level data has examined provider-level
factors in the use of dabigatran (or any other new anticoagulant since 2010). In the study by
Kirley et al examining the proportion of office visits attributable to warfarin versus dabigatran,
cardiologists were found to contribute to most of the uptake.170 Additional literature on the
provider-level factors associated with the use of the new anticoagulants is warranted.
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2.4.4. Medication switching
2.4.4.1. Switching between generic and brand warfarin products
Because of warfarin’s narrow therapeutic index, substitution of generic warfarin for
brand warfarin (Coumadin®) clinically has been discouraged in clinical practice guidelines.4,176
Previous research has largely found minimal effects of switching, but caution that additional
monitoring is warranted. In particular, switching between warfarin products has been thought to
lead to increased risk of bleeding and other adverse outcomes. Out of 265 patients, Milligan et al
saw no statistically significant differences in adverse effects or bleeding between those who
switched to generic warfarin from brand over a 1-year period.177 In a multiple n-of-1 study
between generic warfarin and Coumadin and vice versa over 30 weeks, Pereira et al saw no
differences in mean INR or number of dosage adjustments required between groups.33 In an
observational study of 2,299 patients, the INR control changed by <10% in 28.0% of patients,
where 33.1% experienced a 10% improvement in INR and 38.9% experienced INR control that
worsened by greater than 10%. The study authors found these differences to be statistically
significant but not clinically significant. A major meta-analysis found strong evidence of clinical
equivalence between brand and generic warfarin formulations (5 of 5 RCTs) but did not
comment on safety of switching.25 Overall, switching between warfarin formulations is
discouraged but still remains an area of study.

2.4.4.2. Switching between anticoagulants
Compared with switching between warfarin products, the published literature examining
switching between warfarin and dabigatran (or any other new anticoagulant) is thin. Most of the
literature in non-naïve patients exists solely in the setting of randomized-controlled trials. In the
clinical trial RE-LY trial, 50% of the patients enrolled were “warfarin-experienced” resulting in a
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0.40 reduction in ICH (p≤0.001).13 However, the exact outcomes immediately following the
switch to dabigatran were not elucidated.
Some recent literature is emerging via primary data collection methods. A recent study
using patient-administered written surveys from Sept to Dec 2010 in one warfarin clinic in 155
chronically warfarin-treated patients studied willingness to switch from warfarin to
dabigatran.178 Of the examined factors, this study found that women were less willing to switch
than men (44% vs. 69%, p=0.003) and that patients ≥ 70 years versus ≤ 70 years were less
willing to switch (71% v. 51%, p=0.017).178 Overall, the actual rate of switching and factors
associated with switching have yet to be thoroughly examined empirically.

2.4.5. Concerns associated with newly-approved products
One final issue in examining factors associated with the use of dabigatran versus warfarin
lies in the nature of dabigatran being a newly-approved product. Research has suggested that
examining the effectiveness of newly-approved products may be difficult for a number of
reasons. Some theorize that it may take up to 5-10 years for significant adverse effects to be
identified in new drugs until a sufficient number of patients have encountered new medicines.179
Phase II and III studies often do not have sufficient patients included with comorbidities and
complexity of drug regimens that patients in real-world settings typically have; such patients are
frequently excluded in clinical trials.180 It is also difficult to mimic routine clinical care and study
every relevant sub-group in head-to-head RCTs.181 In addition, newly-diagnosed new users of
medications may experience different harms and benefits than patients who have been previous
users of alternative therapy options.182
Related to dabigatran specifically, commentaries examining the generalizability of the
RE-LY trial have suggested that dabigatran may be less useful in patients previously stabilized
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on warfarin (defined by a high TTR for the INRs).182,183 Thus, examining the factors associated
with patients who are switching from warfarin and the types of outcomes these patients may be
experiencing has particular usefulness.
In addition, new pharmaceuticals are usually not adopted equally and universally.
Diffusion of innovations theory suggests that a bell-curve distribution of users of a new
medication may exist, whereby the innovators/early adopters, using the newer therapies first,
may differ innately from those adopting later.184,185 Moreover, new users of newly-approved
products may also not be treatment naïve to other alternative therapies. These users may be those
that previously failed these therapies and thus may be different than the ultimate users of
medications.122,186
Lastly, the apparent comparative effectiveness has also been thought to be influenced by
whether a pharmaceutical is newly-approved or not. Some patients with greater need for the new
therapy may be treated preferentially upon release of a new pharmaceutical.21,22 Said another
way, sicker patients may be more likely to initiate therapy than healthier patients. Thus,
observational studies of factors associated with uptake of dabigatran versus warfarin are needed.
Examining the factors associated with the use of new therapies and how these change over time
can help to inform future research in this area. This study seeks to advance knowledge in this
area by incorporating these concerns about newly-approved products by examining outcomes
among new users and switchers alike.
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CHAPTER 3: RESEARCH METHODS

3.1. OVERVIEW OF RESEARCH DESIGN AND AIMS

The goal of this research is to investigate the factors associated with use and switching
between anticoagulants, the comparative effectiveness and safety of initiating different
anticoagulants, and the real-world clinical effects of switching anticoagulants in the setting of
new market entry of dabigatran in practice. This chapter provides an overview of the analytic
approaches that was used in this dissertation and a rationale for their uses. Details are provided
for the conceptual and analytic frameworks used for the study, data sources, study design,
measurements of variables, and statistical analyses to support the dissertation aims.
Analytically, Aim 1 consists of two sub-aims (hereafter labeled as Aim 1a and Aim 1b to
distinguish the study designs). Aim 1a examined factors associated with new users of either
warfarin or dabigatran post-dabigatran market entry (10/19/2010), and Aim 1b examined factors
associated with use of dabigatran among new and previous users of warfarin after dabigatran
entered the market. Aim 2 examined comparative clinical and safety outcomes among new users
of warfarin and dabigatran post-dabigatran market entry. Aim 3 examined effectiveness and
safety outcomes of switching therapy classes.
The proposed study employed a retrospective cohort design using health insurance
claims. While randomized-controlled trials (RCTs) are considered to provide the highest-level of
evidence, robust to many biases, employing an observational approach allows for the study of
real-world use patterns and clinical effects. Due to costs associated with RCTs, sample sizes in
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RCTs are often smaller. RCTs are typically more selective with a more homogenous patient
population that may not well represent the patient population in clinical practice. Observational
studies generally allow for the inclusion of more clinical comorbidities and diverse patient
characteristics than RCTs.

3.2. RESEARCH FRAMEWORK
3.2.1. Conceptual Framework

A theoretical framework can be used to explain factors associated with patient outcomes
in anticoagulation use for stroke prevention in atrial fibrillation. The Andersen’s Behavioral
Model of Health Services Use was used as the basis for the conceptual framework.166 The
Andersen’s Behavioral Model identifies a 3-stage model where predisposing, enabling, and need
characteristics underlie a patient’s predisposition and use of health services, including
medications.165,166 The Andersen’s Model has been frequently applied in the study of medication
use and outcomes in other settings.167,187,188 Applying the Andersen’s Model in this setting helps
to identify potential factors associated with anticoagulant use for atrial fibrillation. An
application of the Andersen’s model can be found in Figure 2. In this figure, factors were
identified and classified into whether they are predisposing, enabling, or need characteristics
affecting the type of medication used and their effects on outcomes. The factors and outcomes
pictured in Figure 1 are available within the data source for the study.
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Figure 2. Conceptual Framework

3.2.2. Analytic Diagram
Beyond the conceptual framework, an analytic diagram was used to categorize the factors
from the conceptual framework into how they was analyzed as variables in the specific aims. The
literature review from Chapter 2 was used to identify these covariates for the analytic diagram.
The analytic diagram in Figure 3 classifies factors identified in the literature review into those
associated with: 1) the exposure (anticoagulation therapy), 2) the outcomes (e.g., ischemic
stroke), and 3) both the exposure and outcomes (confounders). Some of these factors are
measurable using the data source; other factors cannot be measured.
The purpose of the analytic diagram is to help distinguish true confounders from other
factors. Confounders by definition are associated with both the exposure and the outcome and
are not mediators between exposure and outcome but can lead to biased estimates when not
controlled for. The X1 variables are possible instrumental variables, which could be a potential
method to address confounding in the study, but may not be able to be measured within the
data189-191. In this situation, the X3 variable would not be adjusted for in regression analyses, as
adjustment for these could lead to bias but may influence precision of the estimates, but are not
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available within the given data source of the Truven Health MarketScan Research Databases®
anyway.192 The X2 variables are considered confounders and would be adjusted for in regression
analyses.
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Figure 3. Analytic Diagram

X1: Exposure Only
- Treatment preference
- Calendar Time (diffusion
of technology)

X2: Exposure and Outcome
- Age
- Gender
- Clinical comorbidities
- Concomitant medications
- Ischemic stroke and
bleeding risk scores
- Geographic residence (small
area variation in treatment
preference)
- Type of health insurance
- Prescription benefits

Exposure: Anticoagulant
- Warfarin
- Dabigatran

X3: Outcome Only
- Genetic factors

Outcomes
- Clinical effectiveness
- Risk of harm
- Acute myocardial infarction

3.3. DATA SOURCE
The study used the TruvenHealth MarketScan® Commercial Claims and Encounters
(CCAE) and Medicare Supplemental Databases from January 1, 2009 through December 31,
2012. These databases include annual information on approximately 30 million commerciallyinsured individuals and Medicare beneficiaries (with supplement coverage) in the US from over
100 nationwide insurers. These databases are considered to be nationally representative of
commercially-insured patients in the United States.193,194 Those Medicare Supplement enrollees
in the database are those who receive employer-sponsored health insurance benefits and may be
less generalizable to Medicare Part D beneficiaries on stand-alone plans. These data are also not
generalizable to Medicaid patients, as those patients generally differ from those in commercially
insured plans.
This proposed dissertation research used inpatient services files, outpatient services files,
prescription claims files, laboratory files, and annual enrollment summary files. All files are
linked by a unique but encrypted identifier for individual enrollees. The database also includes
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the REDBOOKTM supplement, which provides drug name, therapeutic classification, pricing and
product strength and dosage forms to identify drugs in the outpatient pharmaceutical claims files
by national drug code (NDC). Inpatient services files include dates of admission and discharge,
diagnoses and procedures, admission source, length of stay, and discharge destination for each
individual. Outpatient services files include dates of service, procedures and diagnoses, and cost
information for each individual patient encounter. Pharmaceutical claims files include each
prescription filled by the patient, including dates of fill, type of medication, strength, dose,
dosage form, quantity copay and coinsurance, and cost to the third-party payer. As with similar
databases, no inpatient pharmaceutical claims history is available. Laboratory files are available
on approximately 10% of patients in the MarketScan® datafiles. These tests are from the
outpatient setting from one large national testing laboratory including dates of the tests,
diagnosis, test result, and reference values.
All analyses and cohort selection were performed using SAS 9.3.

3.4. COHORT SELECTION
To address the aims of this project, two cohorts of samples were assembled: a new-user
cohort since dabigatran market entry (10/19/2010) and a prevalent user cohort that also includes
enrollees using warfarin prior to dabigatran market entry, with some additional restrictions.
Published studies11,30,151,173,195,196 and STrengthening the Reporting of Observational studies in
Epidemiology (STROBE) guideline recommendations from an international collaborative of
epidemiologists, statisticians, and researchers were used to guide the study design. 197,198 More
information on the inclusion and exclusion criteria is provided in the next section.
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3.4.1. Aims 1a and 2: Cohort design and identification
This section describes the specifications for the new user cohort that was used for Aims
1a, 2, and 3. By definition, new user designs for medication studies identify patients in the study
population who are newly initiating therapy.199 Generally, a wash-out period in retrospective
studies is used to ensure that patients are in fact first beginning therapy after a specific date.
Studying new users helps to control for other disease risk factors that may be altered by previous
use of the study drugs and fully capture any adverse events that would occur early in therapy
use.199

3.4.1.1 Inclusion criteria
For all the aims of the project, we selected a cohort of patients meeting the following
inclusion criteria: 1) filling ≥ 1 prescription for warfarin or dabigatran after 10/19/2010
(dabigatran FDA approval date), hereafter referred to as the “index prescription” with the date of
fill as the index prescription fill date; 2) ≥ 18 years of age at index prescription fill date; 3)
receiving at least 1 inpatient or 2 outpatient International Classification of Diseases, 9th edition
(ICD-9) codes for atrial fibrillation (AF) (ICD-9: 427.31) occurring on separate days in the 12
months on or prior to the index prescription fill date; and 4) maintained continuous enrollment
for at least 12 months prior to the index prescription fill date. Of note, 1 outpatient ICD-9 AF
code could occur after the index prescription fill date. We also required that the 2 ICD-9 codes
occur on separate days to eliminate the possibility of using the code as a rule-out condition.
For Aims 1a, 2 and 3, a new user cohort of patients with AF was assembled. By
definition of a new user cohort, participants were not included if they have had a warfarin or
dabigatran fill in the previous 12 months prior to their index prescription fill date. Patients were
also identified as “newly-diagnosed” new users if their first ICD-9 AF code occurred within 30
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days prior to the index prescription fill date. For Aim 1b, a prevalent user cohort of AF patients
was assembled from this larger cohort meeting the above inclusion criteria, but who are also
previous users of warfarin. For Aim 1b, an additional restriction of continuous eligibility was
also applied for this prevalent user cohort and for the new user cohort to examine switching the
12-month period following initiation. In addition, Aim 3 utilized the cohort from Aim 1a.
For both cohorts, patients were also required to be enrolled continuously in their
insurance plan for at least 12 months prior to their index diagnosis date and up until the index
prescription fill date in order to adequately capture baseline clinical characteristics and
medication use history. As context, commercial insurance databases have an approximately 2530% annual turnover in enrollees, with an average enrollment time of approximately 2 years.200
We have found this statistic to be similar with Truven MarketScan® database.201 Requiring 12
months of continuous enrollment, while common in these types of studies, may limit the patient
sample.200 However, the internal validity of the study is increased when using an adequate run-in
period – both to ascertain that patients are new users and to better capture baseline
characteristics.200 New user study designs and similar inclusion criteria have been used
previously when evaluating prescription claims data.199,202

3.4.1.2 Exclusion criteria
For the new user cohort used in Aims 1a, 2, and 3, patients were excluded from the study
if they received any prior prescription for warfarin or dabigatran within the 12-month baseline
period prior to the index date. Excluding these individuals by requiring a 12-month “clean”
period of treatment-naïve individuals lowers the potential for including prevalent users.199
Including a prevalent user population could lead to a potential induction of survivor bias,
especially as the likelihood of switching between medications and adverse effects from switching
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may vary over time.199 However, events that occur before the 12-month inclusion period may be
missing, because the 12-month look back period is not all-inclusive. For instance, patients with a
warfarin prescription fill more than 12 months prior to the index diagnosis date would still be
included in the inception cohort. This limitation, however, is common to other observational
studies using a new user design.
Because dabigatran is only indicated in non-valvular AF, patients with ICD-9 codes
corresponding to valvular and transient AF in the 12-month baseline period were excluded from
the analysis to ensure that appropriate comparator groups were maintained.13,203 These exclusions
are similar to those applied in the RE-LY trial and have been applied previously.13,201 These
codes include ICD-9 codes for mitral valve replacement (35, 37, 35.1, 35.2, 35.9, 35.12, 35.23,
35.24, 35.9, 35.96, 35.97, 37.4, 37.35, 37.4, 37.41), heart valve replacement (V42.2, V43.3),
mitral valve stenosis (394.0, 394.2, 396.0, 396.1, 396.8), atrial flutter (427.32), hyperthyroidism
(242, 242.0, 242.1, 242.2, 242.3, 242.9), hepatic-related diagnosis (571.1, 571.3, 571.5, 571.8,
571.9, 572.8, 573.3, 573.9), vitamin K deficiency (269.0) and coagulation or antiphospholipid
deficiencies (286.0-286.8, 286.52, 286.53, 286.59).

3.4.2. Aim 1b: Cohort design and identification
To examine the factors associated with switching between anticoagulants and clinical
effects following switching, Aim 1b examined the 12-month period following the index
prescription date (or the first prescription post-10/19/2010). As previously discussed, it is
possible that the reasons for new users to initiate one therapy versus another may differ from
those who have been previously using warfarin therapy, so first, a cohort of newly-initiating
patients who were continuously enrolled for 12-months after the index prescription fill date was
constructed for Aim 1b. Secondly, a prevalent user cohort was also created, whereby patients
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were prevalent users of warfarin, having received at least prescription in the 12-month baseline
period. Using this prevalent user design additionally allowed the inclusion of individuals who
have previously used warfarin and examine whether certain characteristics over the 12-month
baseline are more associated with switching to dabigatran.
Thus, for Aim 1b, with one exception, the same inclusion and exclusion criteria from the
new user cohort for Aim 1a applied, including age ≥ 18 years, ≥1 inpatient or 2 outpatient AF
diagnoses within the previous 12 months, no reversible AF condition, no warfarin prescription
fill, and ≥12 months of continuous eligibility and prescription drug benefits in the previous 12
months. For the new user cohort for Aim 1b, patients were additionally excluded if they did not
have continuous eligibility and prescription drug benefits through 12 months after the index
anticoagulation date. For the prevalent user cohort, all of the aforementioned inclusion criteria
applied, but patients were not excluded if they had a warfarin prescription fill in the 12-month
baseline but they were excluded if they were not continuously enrolled through 12 months after
their first anticoagulation date after 10/19/10.

3.4.3. Aim 3: Cohort design and identification
For Aim 3, two subcohorts were constructed from non-valvular AF patients using
anticoagulation after 10/19/2010. The first primary cohort was constructed from newly-initiating
patients who switched anticoagulation following the index prescription fill date using a timevarying method of anticoagulant switching to avoid immortal time bias.204-206 In this main
cohort, patients were selected if they met the Aim 1a cohort criteria (≥18 years of age, newlyinitiating anticoagulation after 10/19/2010, having continuous eligibility and ≥1 inpatient or ≥2
outpatient diagnoses within the previous 12 months, at least one of which occurring before the
index prescription fill date) and were followed to see if they switched anticoagulation.
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In this time-varying analysis, all patients were considered non-switchers from the time of
study entry until they lost continuous eligibility, experienced the study outcomes of interest (e.g.,
clinical effectiveness outcome, as described later), switched anticoagulants, or were censored
administratively on 12/31/2012. This time was captured as “non-switcher” time; notably, if
patients switched after they experienced a study outcome, they were censored and not included
as “switchers”. Patients who switched anticoagulants were measured for follow-up time as
“switchers” then from the time of the switched until loss of continuous eligibility, administrative
censoring, or experiencing the study outcome of interest. This time-varying exposure method
(compared with time-fixed methodology) is designed to limit both confounding by indication and
immortal time bias by adequately categorizing follow-up time from treatment initiation. As
described later, patients who experienced a clinical effectiveness outcome were not censored in
the analyses for either the harm outcome composite or acute myocardial infarction outcome,
either before or after an anticoagulant switch.

3.4.4. Study Schematic
Figure 4 below illustrates the proposed study schematic for the cohorts. Aims 1a and 1b
utilized a retrospective cohort study design to determine factors associated with the
anticoagulants’ use. Aims 2 and 3 examined comparative clinical and safety outcomes among
users of warfarin and dabigatran post-dabigatran market entry using the cohorts assembled for
Aim 1a and 1b with the few differences in cohort construction noted above. For Aims 2, patients
were followed from the index medication date until either: 1) outcome; 2) loss of continuous
eligibility; or 3) end of the administrative period. Aim 3 examined effectiveness and safety
outcomes of switching anticoagulants compared with non-switchers using two different methods.
For the primary analysis, patients were followed from the index prescription fill date until either:
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1) switch; 2) outcome of interest; 3) loss of continuous eligibility; or 4) end of the administrative
period. Patients who switched were then followed until one of the following: 1) outcome of
interest; 2) loss of continuous eligibility; or 3) end of the administrative period.
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Figure 4. Study Schematic: New User Cohort
a. Aim 1a and 1b: New User and Switcher Cohorts
Study Period
10/19/2009

10/19/2010

12/31/2012

Cohort Definitions

b.

Aim 1b: Prevalent
user cohort

Aim 1a: New user
cohort

- ≥ 18 years of age
- ≥ 1 inpatient or 2 unique outpatient
diagnoses on separate days (1 can be
after index fill)
- No reversible AF condition
- ≥ 12 months continuous eligibility
and prescription benefits
- No anticoagulation fill in previous
12 months

- ≥ 12 months continuous eligibility
and prescription benefits

Aim 1b: New user
cohort

Aim 1a: Newlydiagnosed new user
cohort

- ≥ 12 months continuous eligibility
and prescription benefits

- ≥ First AF diagnosis within 30 days
Index prescription
(anytime after
10/19/2010)
Measurement of baseline factors (12 months)

Note: New User and Newly-diagnosed New User Cohorts did not require 12-months of
continuous eligibility after index prescription date
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b. Aim 1b. Switching definition for prevalent user cohort
Study Period
10/19/2009

10/19/2010

12/31/2012

Prevalent user definition

≥1 warfarin prescription in 12
months

Index prescription
(anytime after 10/19/2010)

If prescription
is warfarin

If prescription
is dabigatran
If prescription
is rivaroxaban
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No dabigatran or rivaroxaban
fill in 12-month follow-up

Nonswitcher

≥1 dabigatran or rivaroxaban
fill in 12-month follow-up

Warfarin
Switcher

c. Aim 2: New User Cohort: CER
Study Period
10/19/2009

10/19/2010

- ≥ 18 years of age
- ≥ 1 inpatient or 2 unique outpatient
diagnoses on separate days (1 can be
after index fill)
- No reversible AF condition
- ≥ 12 months continuous eligibility
and prescription benefits
- No warfarin fill in previous 12
months

12/31/2012

Patients followed until either: 1)
outcome; 2) loss of continuous
eligibility; or 3) administrative
censoring

Index prescription
(anytime after
10/19/2010)

Measurement of baseline factors (12 months)

d. Aim 3: Anticoagulant switchers versus non-switchers (primary analysis)
Cohort entry as
“non-switcher”

Cohort entry as
“switcher”

12/31/2012

“Non-switcher” until different
anticoagulant Rx; then “switcher”
until outcome (X)

Case 1
Case 2

“Non-switcher” until
administrative censoring

Case 3

“Non-switcher” until outcome (X)

Case 4

“Non-switcher” until outcome (X)

Follow from initial entry until anticoagulant switching, outcome of
interest, loss of continuous eligibility, or 12/31/2012
Note: Patients were not censored for the clinical effectiveness
outcome if experiencing one of the harm outcomes, etc.

= Anticoagulant 1 Rx
= Anticoagulant 2 Rx
= Outcome
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3.4.4. Sample size
The TruvenHealth MarketScan® research database provides information on more than 30
million individuals.193,194 Sample size calculations were based on the narrowly-defined new user
cohort used for Aim 1a and Aim 2. Based on preliminary sample size selection in the 1% sample,
the database was anticipated to provide sufficient power for studying the aims. We anticipated
the ability to reach this level based on the dataset. From Oct 2010 until Dec 2012, 64,935 new
users of warfarin and dabigatran meeting the inclusion criteria were identified in the 100%
sample. Given parameters (80% power, 2-tail 0.05 significance level) and event rates from
published RCTs, the relationship between the effect size and sample size was estimated using
Proc Power in SAS and displayed in Table 6.
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Table 6. Sample size calculations

Outcomes

Stroke (TIA or
ischemic)
VTE
Effectiveness
Composite
Intracranial
hemorrhage
Gastrointestinal
hemorrhage
Other bleeding
events
Harm Composite

Power = 80% and alpha = 0.05 (two-tailed)
Reference
Hazard Ratio
12-month
1.35
1.30
1.25
1.20
1.15
event-free Total N 1.40
needed
rate
0.957 N
4,516 5,774 7,688 10,822 16,526 28,694

AMI

1.10

1.05

63,022

245,934

45,060
26,350

175,792
102,732

0.936
0.886

N
N

3,234
1,898

0.99207

N

22,480 28,748 38,292 53,936 82,392 143,130 314,516 1,227,960

0.95131

N

4,516

5,774

7,688 10,822 16,526 28,694

63,022

245,934

0.96208

N

5,640

7,210

9,600 13,518 20,642 35,846

78,740

307,310

0.78131

N

1,048

1,338

1,778

2,498

3,806

6,594

14,450

56,254

0.8672

N

1,600

2,082

2,770

3,896

5,942

10,306

22,610

88,122

4,132
2,424

5,502
3,226

7,744
4,536

11,822 20,520
6,922 12,008

Abbreviation: TIA: transient ischemic attack; VTE, venuous thromboembolism; AMI, Acute Myocardial Infarction

The possible hazard ratios comparing warfarin versus dabigatran are displayed in Table 6
with corresponding sample sizes required to note a statistically significant difference. These
power calculations also assume approximately equal sample sizes in each of the new user
groups. As the table illustrates, this total sample size should have had the power to detect at least
a 10% relative risk difference for the clinical effectiveness and harm outcomes composites and
the acute myocardial infarction endpoints between warfarin and dabigatran. This relative risk
difference is generally considered to be clinically significant.

3.5. MEASUREMENTS
3.5.1. Treatments
Treatment was determined using National Drug Codes (NDC) codes from the outpatient
pharmaceutical files. Patients were classified by the type of medication used initially following
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the diagnosis date, with either warfarin or Coumadin® use classified as ‘warfarin’ and fills for
dabigatran being classified as dabigatran users. Prescription refill records are often considered
the ‘gold-standard’ for measuring medication use and have demonstrated similar sensitivity and
specificity as other observational adherence methods, including pill counts, self-report and
electronic records.209,210 Prescription fill information was also measured, including anticoagulant
strength/dose, quantity and days’ supply information. Other medications were measured as
indicated in the Covariates section, including copay costs.

3.5.2. Outcomes
3.5.2.1 Medication Switching
For Aim 1b, as indicated in Figure 4, a medication switch was defined as the first
prescription claim for a different anticoagulant (e.g., warfarin, dabigatran or rivaroxaban) in the
outpatient pharmaceutical claims file within the 12 months following the index prescription fill
date. This date was referred to as the medication switch date. The anticoagulant that the index
medication was switched to was also reported. Prescription claims for warfarin and Coumadin®
were classified as the same pharmaceutical product for this research. Individuals without a
medication switch throughout the entire follow-up period were classified as non-switchers.
For Aim 3, as indicated in Figure 4, a medication switch was defined as the first
prescription claim for a different anticoagulant (e.g., warfarin or dabigatran) in the outpatient
pharmaceutical claims files. If patients were not previously administratively censored, lost
continuous eligibility, or experienced a study outcome and then received a prescription for a
different anticoagulant, this date is heretofore referred to as the medication switch date. Patients
switching from warfarin or dabigatran to rivaroxaban were not included in the main analysis.
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3.5.2.2 Clinical Effectiveness
Clinical effectiveness was defined as a composite of the occurrence of ischemic stroke,
TIA, and other thromboembolic events in the follow-up period. The presence of either a primary
or secondary diagnosis using ICD-9 coding in the inpatient or outpatient medical claims was
used. Validated ICD-9 coding algorithms were used to measure the outcome events for clinical
effectiveness, which are based on published studies found in the literature.104,211-214 Table 7
displays the ICD-9 coding schema used to identify clinical effectiveness outcomes; these
algorithms are discussed further in the following sections. Patients with previous ischemic stroke
were not excluded from the analysis; of note, previous stroke history was adjusted for in the
regression analyses.
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Table 7. International Classification of Disease, 9th Edition (ICD-9) codes
for clinical effectiveness outcome definitions in inpatient and outpatient service claims files
Outcome
Stroke
Ischemic stroke
Transient ischemic attack

Other thromboembolic event (deep
vein thrombosis, pulmonary
embolism)

ICD-9 Codes
433.01, 433.11, 433.21, 433.31,
433.81, 433.91, 434 (excluding
434.x0), 436
435
415, 451, 453

Diagnosis position*
Primary or Secondary
Primary*

Primary or Secondary

* Inpatient service claims files only

3.5.2.3 Risk of Harm
The risk of harm is defined as a composite of the occurrence of severe adverse side
effects from the use of anticoagulant therapies. The severe adverse side effects was the presence
of a primary or secondary diagnosis of intracranial hemorrhage/hemorrhagic stroke,
gastrointestinal hemorrhage, other bleeding events, and inpatient hospitalization in the inpatient
or outpatient medical files in the follow-up period. Validated ICD-9 coding algorithms from the
published literature were used to measure these outcomes. Table 8 displays the ICD-9 codes
used for the risk of harm outcomes; these algorithms are discussed further in the following
sections.
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Table 8. International Classification of Disease, 9th Edition (ICD-9) codes
for risk of harm outcome definitions in outpatient or inpatient service claims files
Outcome
Intracranial hemorrhage or
hemorrhagic stroke
Gastrointestinal hemorrhage
Other bleeding events

Hospitalization in the follow-up

ICD-9 Codes
430, 431, 432

Diagnosis field position
Primary or Secondary

455.2, 455.5, 455.8, 456.0,
456.20, 459.0, 578
423.0 (hemopericardium),
593.81 (vascular disorders of
kidney), 599.7 (hematuria),
719.11 (hemarthrosis), 784.7
(epistaxis), 784.8 (hemorrhage
from throat), 786.3
(hemoptysis)
-

Any

Measured separately for Aims 2 and 3
Myocardial infarction§
410.x1

Any

Any encounter in inpatient
services files
Primary or Secondary*

* Inpatient service claims files only
§
Not included in risk of harm composite outcome
3.5.2.4. Myocardial Infarction
Notably, AMI was measured as an outcome for the study. However, because of how the
RE-LY trial collated its outcomes, was not included in either the individual risk of effectiveness
or risk of harm composites, but is listed in Table 8. AMI has been thought to be both a “harm”
outcome, in that the RE-LY trial showed a slight increase in the risk of AMI compared with
warfarin (with an unknown pathophysiology); however, ischemic stroke and AMI frequently cooccur in patients, and warfarin has been used to anticoagulant in patients with AMI.

3.5.2.5. Algorithms to identify outcomes
Tables 7 and 8 illustrate the ICD-9 codes used for the clinical effectiveness outcome and
harm outcome definitions in Aims 2 and 3. Each of these clinical effectiveness outcomes was
identified using ICD-9 codes in the inpatient or outpatient service claims files unless otherwise
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specified; specific diagnosis field position requirements are listed in the table. Outcomes were
assessed based on the presence of medical or inpatient claims with either a primary or secondary
diagnosis. For Aim 1b, these outcomes were measured as independent variables to be tested for
an association with a medication switch. For Aims 2 and 3, these outcomes were considered
dependent variables in the comparative effectiveness and safety analyses among new users.
All these ICD-9 codes have been validated and/or used frequently in the published
literature (when validation studies not available). Each of these outcomes was identified in
inpatient or outpatient service claims files; specific diagnosis field position requirements are
listed in Tables 7 and 8.
While a variety of algorithms have been studied to identify these outcomes using ICD-9
codes, some have better reported correlation with clinical records. Usually ICD-9 diagnostic
measures are compared using positive predictive value (PPV), which is the proportion of positive
tests that are true positives; the higher the PPV, the higher the probability that a positive test
indicates the underlying disease condition. Validated algorithms identifying ischemic stroke have
generally performed well, resulting in positive predictive values of 85% of higher.211,215-218 Some
algorithms in a recent systematic review recommended also including transient ischemic attack
(TIAs) as part of the composite endpoint, shorter ischemic strokes of less severe nature, as long
as they were identified in the inpatient file only in the principal position.211,219 TIA tended to
have lower PPV than ischemic stroke algorithms.211 Studies comparing algorithms using the
primary diagnosis code versus the secondary code found slightly higher PPV for algorithms
using primary versus secondary, but others have recommended both positions.211,216 In studying
thromboembolic events, the highest PPV has been reported for the combined use of ICD-9 codes
415 (pulmonary embolism), 451, and 453 (deep vein thrombosis) for identifying a VTE event,
with a PPV of 65 to 95% in either the primary or secondary diagnostic field.64,214 Studies have
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also recommended studying VTE events in tandem in ICD-9 algorithms compared with either
DVT or PE alone.64,214
Compared with the clinical effectiveness outcomes, comparably fewer validation studies
have been conducted on risk of harm outcomes.211,215,220 Validation studies examining the
identification of intracranial hemorrhage (including intracerebral hemorrhage and subarachnoid
hemorrhage) through ICD-9 codes have reported PPVs of 77% or higher compared with
abstraction of medical charts, in both the inpatient and outpatient setting.211,215 The reported
PPVs ranged from 80% to 94% for patients with a primary or secondary discharge diagnosis; one
study examining codes in any position of the inpatient file still reported a high PPV for
intracranial bleeds.211,215,221 Other bleeding events validation studies are even less frequently
studied in the literature.211 Because these conditions are less likely to present as the primary or
secondary diagnoses (and more likely to be less severe), these conditions were identified by
diagnosis codes used from previous studies using any diagnosis field position in either the
outpatient or inpatient service claims files. In addition, because of limitations with how the
coding schemes for intracranial hemorrhage and hemorrhagic stroke overlap in clinical practice,
these outcomes were combined together.
Acute myocardial infarction, by comparison, is generally considered to be a relatively
well-validated outcome. Previously-validated algorithms for identifying AMI have yielded PPV
of 89% to 97% when using 410.x1 in the primary or secondary discharge field.220,222
Sensitivity analyses were also conducted on this outcome definition, specifically
restricting to only outcomes that occurred in the inpatient setting, which would help examine the
comparative effectiveness of the agents on clinically-significant events.
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3.5.3. Covariates
Several covariates have been identified from the predisposing characteristics, enabling
resources, and need characteristics from the previously-described analytic model. The Truven
Health MarketScan® database dictionary and user guide were used to identify the variables
which were available. The covariates used in the analysis are frequently used in the published
literature in this field of research.11,13,174,202,223,224 These covariates thought to be predictive of the
outcomes in this study were included in the analytic models, described in later sections. These
covariates were measured in the 12-month baseline period prior to the medication fill under
study for that aim using published algorithms. For Aims 1a, 1b, 2, and the primary analysis for
Aim 3, these covariates were measured in the 12 months prior to the index prescription fill date.
These definitions are summarized in Table 9 below.
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Table 9. Covariate descriptions and coding strategies for patient
characteristics in 12-month baseline period
Patient Characteristics
Predisposing Characteristics
Age at Diagnosis
Sex
Geographic Region

Covariate Coding
Continuous; Categorical (<55
years, 55-64 years, 65-74 years,
>74 years)
1=Male, 2=Female
Northeast, North central, West,
South

Covariate Definition
Age in years at time of prescription
fill
Sex from enrollment file
Region from enrollment file

Enabling Resources
Insurance Type

Comprehensive, HMO, POS, PPO,
CDHP

Prescription benefits generosity

None, Poor, Fair, Good

Index prescription generosity
(measured descriptively not as
covariate)

None, Poor, Fair, Good

Type of insurance from enrollment
file
Ratio of patient cost-sharing for
prescription payments relative to
total payments for prescriptions
Ratio of patient cost-sharing for
index anticoagulation
prescription(s), relative to total
payments

Need Characteristics
Comorbidities
Previous ischemic stroke

0=Absent, 1=Present

Renal Impairment

0=Absent, 1=Present

Congestive Heart Failure
Previous venous thromboembolism
(VTE)
Hyperlipidemia
Hypertension
Diabetes Mellitus
Previous myocardial infarction
Coronary artery disease

0=Absent, 1=Present

Ischemic stroke diagnosis
Chronic kidney disease or End
Stage Renal Disease diagnosis
Congestive heart failure diagnosis

0=Absent, 1=Present

VTE diagnosis

0=Absent, 1=Present
0=Absent, 1=Present
0=Absent, 1=Present
0=Absent, 1=Present
0=Absent, 1=Present

Previous major bleeding

0=Absent, 1=Present

Anemia
Peptic Ulcer disease

0=Absent, 1=Present
0=Absent, 1=Present

Peripheral vascular disease

0=Absent, 1=Present

Sleep apnea

0=Absent, 1=Present

Cognitive impairment

0=Absent, 1=Present

Hyperlipidemia diagnosis
Hypertension diagnosis
Diabetes Mellitus diagnosis
Myocardial infarction diagnosis
Coronary artery disease diagnosis
Diagnosis of hemorrhagic or
gastrointestinal bleeding
Diagnosis of anemia
Diagnosis of peptic ulcer disease
Diagnosis of peripheral vascular
disease
Diagnosis of sleep apnea
Diagnosis of dementia,
Alzheimer’s

Patient Disease Severity
Charlson Comorbidity Index (CCI)
CHADS2
CHA2DS2-VASc
ATRIA
HAS-BLED

Continuous, Categorical (0, 1-2, 35, 6-8, ≥9)
Continuous, Categorical (0, 1, ≥2)
Continuous, Categorical (0, 1, ≥2)
Continuous, Categorical (0-3, 4,
≥5)
Continuous, Categorical (0-2, ≥3)
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Patient disease severity
Ischemic Stroke Risk score
Ischemic Stroke Risk score
Bleeding Risk score
Bleeding Risk score

Number of hospitalizations

Continuous, Categorical (0, ≥1)

Number of hospitalizations in
baseline

Concomitant treatments and
therapies
Antiplatelet therapy

0=Non-use, 1=Use

Gastroprotective agents

0=Non-use, 1=Use

Antiarrhythmics

0=Non-use, 1=Use

Rate control therapy

0=Non-use, 1=Use

Catheter ablation

0=No CA, 1=CA

Hormone use

0=Non-use, 1=Use

ACEI/ARB therapy

0=Non-use, 1=Use

Statin therapy

0=Non-use, 1=Use

Prescription fill for clopidogrel,
Aggrenox or aspirin
Prescription fill for PPIs, H2RAs,
GI protectants (e.g., sucralfate)
Prescription fill for flecainide,
amiodarone, dronedarone, sotalol,
propafenone and dofetilide
Prescription fill for beta-blockers,
digoxin, or calcium channel
blocker
Procedure for catheter ablation
Prescription fill for oral
contraceptive or hormone
replacement therapy
Prescription fill for ACEI/ARB
Prescription fill for HMG Co-Areductase (statin)

Abbreviations: HMO, Health Maintenance Organization, POS, Point-of-service; PPO, Preferred provider organization; CDHP,
consumer-driven health plan , PPI, proton pump inhibitor; H2RA, H2 receptor antagonist; GI, gastrointestinal; CA, catheter
ablation; ACEI, angiotensin-converting-enzyme inhibitor; ARB, angiotensin receptor blocker

3.5.3.1 Patient characteristics
Clinical and demographic characteristics and their coding strategies can be found in
Table 9 based on whether they can be classified as predisposing, enabling or need characteristics.
Based on the literature, all of these clinical and demographic characteristics were considered to
be X2 covariate variables (identified by the analytic framework) and are displayed by type of
characteristic from the conceptual model.

3.5.3.1.1 Predisposing characteristics
Available predisposing characteristics, such as age, gender, type of health plan, and
geographic location was included as covariates in the 12-month baseline period prior to the index
prescription fill date. Sex was coded as “male” or “female”. Geographic region was coded from
the “Region” variable in the database, which is based on the employee residence at the time of
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the index prescription fill. Previous research in a variety of disease has indicated that patient
geographic residence is associated with varying quality of health care received. Controlling for
broad geographic regions can help adjust for these variations in care received prior to AF
diagnosis to help identify true clinical differences between anticoagulants. Northeast was used as
the reference category. Per the TruvenHealth MarketScan® user guide, as of 2011, the 3-digit zip
code field throughout the enrollment, inpatient and outpatient files, and pharmaceutical files is
no longer supported and has been removed due to data quality issues. Thus, the most granular
geographic variable available is the variable indicating the patient’s state.

3.5.3.1.2 Enabling characteristics
Enabling factors were measured based on information available in the databases. Type of
insurance was classified based on the “Plan Indicator” variable in the database, as follows:
comprehensive, health maintenance organization (HMO), non-capitated point-of-service (POS),
preferred provider organization (PPO), and other (basic/major medical, exclusive provider
organization, capitated or partially-capitated point-of-service and consumer-driven health plans).
Prescription benefits generosity was calculated from the method described by Artz et al225, which
sums the enrollee’s cost-sharing contributions for all prescription drugs divided by the total net
prescription drug payments (including brand and generic products), because the overall
copayment burden may influence medication preferences and a patient’s predisposition towards
a certain therapy. This prescription benefits generosity measure would not include the study
anticoagulant. If a patient has no record of any prescription fill prior to the anticoagulation in the
12-month baseline period, they were coded with a ‘missing’ value. The ratio was initially
categorized into four levels: None (ratio > 0.99), Poor (ratio > 0.80 and ≤ 0.99), Fair (ratio > 0.20
and ≤ 0.80) and Good (ratio ≥ 0 and ≤ 0.20).
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The patient’s index anticoagulation copay cost and relative cost-sharing proportion
compared with the amount paid by the insurer was also measured and categorized using the
method by Artz et al described above.225 Multiple anticoagulation fills may have occurred on the
same day (e.g., multiple strengths of warfarin), and these were summed together. These two
covariates were examined descriptively and not included in regression analyses.

3.5.3.1.3 Need characteristics
Need characteristics included patient baseline comorbidities, patient disease severity, risk
of ischemic stroke and bleeding from disease severity measures, and concomitant medications
thought to be associated with prognosis in atrial fibrillation. These factors were previously
described in Chapter 2. Patient disease severity coding schemes have been published previously,
along with diagnosis field code positions.103,105,111,202
The Charlson Comorbidity Index (CCI) is a commonly-used composite measure of
disease burden which serves as a proxy for patient health status; the higher the score, the greater
the comorbidity burden.226,227 The CCI algorithm using ICD-9 codes has been previously
published in a variety of settings and was employed to garner patient baseline disease
burden.28,226,227 The CCI was measured from the 12-month baseline period. In addition, all
factors related to adverse outcomes from the medication use were also measured following the
index prescription fill date until the medication switch date. These were classified as covariates
for Aims 1b and 3 for adjustment in the switcher analysis as previously discussed.
Risk of ischemic stroke was measured using both the CHADS2 and CHA2DS2-VASc risk
scores while risk of bleeding was measured using the ATRIA and HAS-BLED risk scores. As
previously discussed in Chapter 2, ATRIA risk factors are currently considered to be more
reliably measured in medical claims compared with other severity indices. As of March 2014,
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CHA2DS2-VASc score has been recommended for use in the United States over the CHADS2
score.5 In addition, the HAS-BLED risk score was measured as a sensitivity analysis as it
includes additional risk factors beyond the ATRIA and has been more commonly used in
observational studies using secondary claims. All of these risk scores were also assessed
descriptively.

3.6. ANALYSES
This is a retrospective observational cohort study studying factors associated with use,
clinical effectiveness and safety following anticoagulation with either warfarin or dabigatran. For
these analyses for all aims, commercially-insured patients were also analyzed separately from the
Medicare Supplement patients as a sensitivity analysis, because these patients could have
different clinical and demographic backgrounds.37,193 The following sections detailed the
analyses plan for each specific aim.

3.6.2. Aim 1
Specific Aim #1: Assess and investigate patient factors associated with new use of either
warfarin or dabigatran and switching between anticoagulants in patients with atrial fibrillation.
Hypothesis 1: Clinical prediction risk scores (e.g., ischemic stroke and bleeding risk) will
not differ between new users of warfarin compared with dabigatran.
Hypothesis 2: Clinical prediction risk scores (e.g., ischemic stroke and bleeding risk) will
not differ between new users who switch anticoagulants within 12 months compared with
those who do not switch.
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Analytic model:

Equation 1
Anticoagulant treatment = α + β1(X1) + βx(Xl) + ε
α = Intercept
βx = Regression coefficient for X1
Xl = Independent variable (a risk score)
βx = Vector of all measured variable coefficients for the X
Xl = Vector of all other measured baseline covariates
ε = Error term

3.6.2.2 Statistical analysis and model diagnostics
As previously described, Aim 1 was analytically structured into two sub-aims: Aim 1a
and Aim 1b. Aim 1a assessed factors associated with new use of either warfarin or dabigatran;
Aim 1b assessed factors associated with switching from the index anticoagulant following
dabigatran market entry. Both sub-aims used the ischemic stroke and bleeding risk scores as
primary independent variables for the analysis. Even though these sub-aims involved the
separation of cohorts (new user and prevalent user), the statistical analysis of the factors
associated with the anticoagulant use is the same.
The number and proportion of patients initiating each medication was described.
Descriptive statistics of initiation by medication (Aim 1a) and switches (Aim 1b), including
direction (Aim 1b) were presented for each major demographic and clinical characteristic across
the entire study period, including the absolute standardized differences between the proportions.
The time between the index medication and the medication switch date was measured and
reported descriptively
For Aim 1a, the anticoagulation doses and patient cost-sharing (e.g., copayments) at the
time of the index prescription were also presented for the doses used in clinical practice and
assessed descriptively. Time trends in initiation of the index anticoagulation medication were
also examined.
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Each covariate was tested separately to determine the bivariate relationship between the
predictor and the outcome, without controlling for the other covariates. Multivariable modified
Poisson regression models were also applied to investigate the initiation and switch of warfarin
and dabigatran for new AF patients with each variable added to the model simultaneously to
examine the independent effects of each covariate.
While binary outcomes (e.g., warfarin vs. dabigatran) are often analyzed using logistic
regression models to obtain odds ratios for characteristics between two treatment groups,
estimating relative risks (RRs) can be more preferable.228 RRs tend to be more interpretable than
odds ratios, especially in commonly-occurring events (such as the anticoagulants each being
used frequently in new users, which is suggested by the 100% sample).229 Relative risk
estimation via a modified Poisson approach (using robust error variances) was used to compare
characteristics of the comparator groups (using Proc Genmod and a repeated statement in SAS),
which lead to direct RRs.230 By contrast, log-binomial models assume that the probability of an
outcome increases linearly on the log scale, while logistic regression models assume that the
probability of an outcome increases linearly on the logit scale, which can lead to differences in
the predicted probabilities between the two models, especially when the outcome is common.228
Even compared with the log-binomial model (also yields relative risks using a log scale), the
modified Poisson approach avoids the possibility of too narrow confidence intervals and
convergence issues and may be a better fit for these data for this aim.
For Aim 1a, the association between new use of each medication and the baseline
characteristics was tested using bivariate and multivariate regression to estimate the likelihood of
receipt of warfarin versus dabigatran, studying ischemic stroke and bleeding risk clinical
prediction scores as the main independent variables. For Aim 1b, the association between
switching from the index anticoagulant compared with not switching was assessed using
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bivariate and multivariate regression to estimate the likelihood of switching using the clinical
prediction scores as the main independent variables. The multivariable regression models
included each of the predictors previously described, except for those already included in the risk
scores. The general form of the model for Aims 1a and 1b is provided in Equation 1 above. For
Aim 1a, sensitivity analyses were conducted on each of the ischemic stroke and bleeding risk
clinical prediction scores (e.g., ATRIA versus HAS-BLED).
For Aim 1a, the Quasilikelihood under the Independence model Criterion (QIC) was also
used for model comparisons and model selection. Interaction terms were also examined for
potential inclusion in the multivariate model to determine any variation in a priori determined
possible relationships, including age and sex. Upon examining for this effect measure
modification, if the interactions are not significant, then they are deemed unnecessary as they
would add no additional explanatory power to the model. These tests were conducted to help
choose the overall model.

3.6.3. Aim 2
Specific Aim #2: Investigate the comparative clinical outcomes (risk of harm and clinical
effectiveness) following new use of either warfarin or dabigatran, adjusting for baseline patient
factors.
3.6.3.1 Hypothesis
Hypothesis 3: There are no significant differences in the risk of clinical effectiveness
outcomes or harm outcomes in new users of warfarin compared with users of dabigatran.
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Statistical model:

Equation 2
hl(tlxl) = h0(t)*exp(βTTl+βxXi),
t = survival time (in days) from the index date to event or censoring
Ti = Treatment (1=dabigatran; 0=warfarin)
Xi = Vector of all measured baseline covariate confounders
βT= Coefficient of X1, the change in survival time
βx = Vector of coefficients of Xi

3.6.3.2 Statistical analysis and model diagnostics
As previously summarized, Aim 2 tests the comparative effectiveness and safety of
warfarin versus dabigatran in AF patients initiating anticoagulation in an intention-to-treat
analysis. Aim 2 used the same cohort specified in Aim 1a and followed individuals until either
one of the composite outcomes was observed or loss of continuous eligibility or the end of the
administrative period at 12/31/2012 occurred, using an intention to treat (ITT) perspective.231 In
ITT analysis, every individual beginning warfarin or dabigatran therapy is assigned to that
therapy for the analysis, regardless of potential non-adherence, withdrawal or anything else that
occurs following the first prescription fill.231
Descriptive statistics were generated including the outcome rates per 1,000 person years
in each anticoagulant group, the time to the composite outcome events, and the proportion of
patients censored. Cox proportional hazard models were also used to estimate the relationship
between anticoagulant use and being event-free after controlling for confounders.232 Cox
proportional hazards methods use a semi-parametric model that accounts for multiple predictor
variables and provide partial likelihood estimation of experiencing an event by factoring out the
baseline hazard of experiencing an event from the covariates. The general form of the model is
provided in Equation 2 above. In this equation, β represents the effect of the exposure on the
hazard of experiencing the outcome.232,233
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Cox models assume that covariates are independent of time and that hazards are
proportional across strata of the variable and constant over time, in the event of time-varying
covariates. Nested and non-nested models were tested for the AIC to select covariates for the
final models. Deviance residuals were used to plot model fit and assess functional form. Ties
were assessed using Efron’s method, where ties are those instances where two or more patients
have the same study time. Additionally, the proportional hazard assumption (in that covariates
are multiplicatively related to the baseline hazard and that time does not change this relationship)
was assessed using Schoenfeld residuals, supremum tests, Kaplan-Meier plots, and interaction
terms with time. Outcomes of anticoagulation were first regressed in the Cox models as the only
independent variable (unadjusted model) to examine the effect of the additionally measured
covariates added to the multivariable models.
These Cox methods all assume that the patients are independently grouped and that the
data do not derive from the same unit or cluster (e.g., are not grouped hierarchically under
providers). Other studies using these databases have assumed independence of observations and
given the vastness of the database and high prevalence of the condition, we assume that
clustering is not common and negligible.
Separate multivariable Cox proportional hazards models were also constructed for a
composite of measures of risk (e.g., hemorrhagic bleeding, major bleeding, etc.) and a composite
of measures of effectiveness (e.g., ischemic stroke, etc.).233,234 Cause-specific Cox proportional
hazards models were also conducted on each of the clinical effectiveness and risk of harm
outcomes, whereby patients were censored at the time one of the other events occurred.
Typically, composite measures are used as primary analysis to avoid issues of competing risk.235
However, as a secondary analysis, cause-specific models were used. As with Aims 1a and 1b,
interaction terms were evaluated for inclusion in the final regression models.
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3.6.3.3. Propensity Score Risk Adjustment
Risk adjustment methods through multivariate regression, while useful, may not be
sufficient when the potential for unmeasured confounding or confounding by indication exists.236
Because individuals are not randomly selected to receive a specific treatment in this study,
endogeneity (selection bias) between treatment and outcomes may exist. In addition, risk
adjustment methods assume that all confounders are either measured or that unmeasured
confounders are “ignorable” if other measured confounders are controlled.
Propensity score (PS) methods attempt to control for lack of randomization in
observational studies by balancing covariate distributions between treatment groups.237,238
Estimates of the average treatment effect in the treated group can be obtained by PS matching
between two comparable groups, such that pairs are formed and these matched individuals have
similar values of the PS. Other options involving propensity scores are including the PS as a
covariate in multivariable regression models, stratification, or using weighting through inverseprobability treatment weighting (IPTW) or standardized mortality ratios (SMR) weighting from
an estimated propensity score in a regression model.
In particular, the PS method proposed in this research employed IPTW as a primary
analysis. Specifically, IPTW uses propensity score weights to create a study sample whereby the
distribution of measured baseline characteristics does not depend on treatment. In IPTW, each
subject’s weight is equal to the inverse of the probability of receiving that particular treatment.
Regression models can be weighted by the inverse probability of treatment to estimate the
average treatment effect of receiving the treatment. Because weights may be unstable for
individuals with very low probabilities of receiving treatment, stabilizing weights and ‘trimming’
subjects are methods often used and were examined here.
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For Aim 2, propensity score-adjusted hazard ratios were presented for the Cox
proportional hazard models. For this study, IPTW was used as the primary analysis rather than
matching on subjects, so as to preserve sample size. These propensity scores were fit by a
logistic regression model to predict treatment with the use of the measured covariates. These
propensity score models included confounder variables.237,238 Stabilizing weights and trimming
of subjects were used depending on the need when the weights are created.239 SMR weighting
was also used as a secondary analysis, which provides estimates of the treatment effect in the
treated group.
These propensity scores were first used to investigate the balance in the treatment groups
of patients initiating treatment since market entry. Propensity scores were constructed comparing
the baseline characteristics of the new anticoagulant initiators. These propensity scores were
used to examine overlap in the distribution of baseline and clinical covariates of users initiating
warfarin and dabigatran occurs. The absolute standardized difference was also used to compare
the baseline characteristics between warfarin and dabigatran users, whereby significant
imbalance of baseline characteristics between groups is usually characterized by an absolute
standardized difference > 10.240 Secondly, the models used IPTW from the propensity scores as a
weight in the Cox proportional hazards models to estimate the comparative effect of warfarin
versus dabigatran, adjusting for any covariate imbalances. The IPTW propensity score deciles
were examined for any underlying heterogeneity of treatment effect in a sensitivity analysis.

3.6.4. Aim 3
Specific Aim #3: Explore the comparative clinical outcomes (risk of harm and clinical
effectiveness) of switching from warfarin to dabigatran or dabigatran to warfarin compared with
non-switchers, adjusting for patient clinical and demographic factors.
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3.6.4.1 Hypotheses
Hypothesis 4: Switching from warfarin to dabigatran will not be associated with increased risk of
harm or clinical effectiveness outcomes compared with those who switch remain on warfarin.
Hypothesis 5: Switching from dabigatran to warfarin will not be associated with an increased
risk of harm or clinical effectiveness outcomes compared with those who remain on dabigatran.
3.6.4.2 Statistical analysis and model
Statistical model:

Equation 3
hl(tlxl) = h0(t)*exp(βTTl+βxXi),
t = survival time (in days) from the switch date to event or censoring
Ti = Treatment (1=switcher; 0=non-switcher)
Xi = Vector of all measured baseline covariate confounders
βT= Coefficient of X1, the change in survival time
βx = Vector of coefficients of Xi

Equation 3 illustrates the statistical model for this aim. For the primary analysis,
warfarin switchers were compared with non-switchers, and dabigatran switchers were compared
with non-switchers. Descriptive statistics were generated including the outcome rates per 1,000
patient years, the proportion of patients censored, and the time to each event. For both analyses,
Cox proportional hazards regression was used to assess the association with treatment and
outcomes. Equation 3 and Aim 2 describe the general model and the diagnostic approach for
assessing Cox proportional hazards models. These models were adjusted using the covariates
identified in Table 9 using the previously-described diagnostic steps. The dependent variable for
each model was time to outcome event. In the primary analysis, patient days of follow-up were
classified as “non-switcher” time until the anticoagulant switch date occurred (or until
experiencing the outcome of interest or censoring due to loss-to-follow-up or administratively on
12/31/2012). This time-varying exposure approach has been previously described in settings
examining users versus non-users of medications.206
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3.7. SENSITIVITY AND EXPLORATORY ANALYSES
Certain sensitivity analyses and exploratory analyses were conducted throughout the
study. These additional analyses were classified as sensitivity analyses when the analyses were
primarily intended to examine the robustness of the study conclusion, such as the lack of
mortality data. Other descriptive exploratory analyses were also conducted because of known
limitations in the data (such as limited laboratory data), but because of the primary intention-totreat approach of this dissertation, were descriptive in nature. These approaches included
assessments of warfarin patients’ monitoring values and medication adherence in the follow-up
period.

3.7.1. Mortality
Because the TruvenHealth MarketScan® databases do not measure mortality,
censoring/dropout could be attributable to unmeasured death. To test the robustness of the results
for Aim 2 and Aim 3, we tested whether significantly more ‘censoring’ occurs in one
anticoagulant group versus another. In addition, the robustness of the results was tested again in
the Cox proportional hazards models, whereby all those dropping out were assumed to have
experienced the outcome in the anticoagulant group. For patients with a hospitalization in the
follow-up period, the discharge variable was examined descriptively to see whether in-hospital
mortality had occurred.

3.7.2. Outcomes: Transient Ischemic Attack and Hemorrhagic Stroke
While some algorithms recommended also including transient ischemic attack (TIAs) as
part of the composite endpoint, TIAs tend to have lower PPVs than ischemic stroke algorithms
and the other clinical effectiveness endpoints.211,219 To test the robustness of the results for Aim
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2, we tested whether removing TIA as part of the composite clinical effectiveness endpoint
affects the results. Because TIAs are difficult to identify diagnostically, including TIAs as part of
the endpoint could possibly adversely influence the results.
In addition, the parent RE-LY trial measured hemorrhagic stroke both as a clinical
effectiveness and a harm outcome, effectively double-counting the outcomes. In this study, the
number of hemorrhagic events in the warfarin group far outweighed the number in the dabigatran
group, which was a primary driver of the efficacy endpoint in the study. Because the primary
results of this study included hemorrhagic stroke as a risk of harm outcome solely (but still
included it in the full composite), a sensitivity analysis for Aim 2 was also conducted including
the hemorrhagic stroke/intracranial hemorrhagic endpoint in the clinical effectiveness outcomes.

3.7.3. Stratification by dabigatran strengths
Because the RE-LY trial showed different efficacy in prevention of stroke and systemic
embolism during separate analyses of dabigatran strengths (110mg and 150mg in the trial), this
present study also stratified initiators of dabigatran 75mg and dabigatran 150mg in Aim 2. For
this study, the comparative effectiveness and safety of the two dabigatran strengths were also
studied in stratified analyses using all doses warfarin as the referent group (as was done in the
RE-LY trial). Multivariable and propensity-score adjustment was used for these separate survival
analyses and Cox proportional hazards regression in the methods discussed above.

3.7.4. Clinical and demographic subgroups
To explore any underlying heterogeneity in treatment effects, clinical and demographic
subgroups were also examined in Aim 2. We stratified patients with certain characteristics that
were identified as contributing to non-overlap of the propensity scores and among characteristics
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known to affect treatment effects, such as age and clinical prediction risk scores. For these
analyses, the composite outcomes of the clinical effectiveness and safety were examined using
Cox proportional hazards regression and the application of stratum-specific inverse probability
treatment weighted propensity scores.

3.7.5. International Normalized Ratio (INR) laboratory values
As previously described, the TruvenHealth MarketScan® databases contain some
laboratory values on approximately 10% of enrollees. INRs, used to measure the effectiveness of
warfarin, can be captured through laboratory tests but may also be point of care measurements,
done without extensive laboratory examination.10,135,164 Because the TTR for users of warfarin
has been thought to affect clinical outcomes, INRs were captured for those users of warfarin with
available laboratory data.118 These INRs were averaged during the follow-up period descriptively
for Aim 2, because the TTR has been seen to drastically affect apparent efficacy in the RCTs
examining the new OACs.

3.7.6. Medication adherence
For Aim 2, patient medication adherence in the follow-up period was also measured
descriptively comparing between warfarin and dabigatran. We used the proportion of days
covered by the prescription supply calculated from the prescription refill records in the outpatient
pharmaceutical claims in the follow-up period. Conforming to current literature, a patient was
defined as adherent if the patient had ≥80% of days covered with prescription supply. Patient
medication refill rates were also measured descriptively, defined as the proportion of patients
filling the index medication again in the follow-up period. These analyses were performed
descriptively because of the intention-to-treat approach of this dissertation.
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3.8. LIMITATIONS
As with other studies using observational data, unmeasured confounding may affect the
overall study conclusions. However, the proposed approaches have been shown to limit the
effects of unmeasured confounding and heterogeneity in treatment effects. As with other
observational designs, causality is often difficult to ascertain, but these approaches may limit this
concern. Other limitations due to various study design configurations and assumptions have been
previously described in these chapters or are outlined in Chapter 5.

3.9. SUMMARY
The approaches described in Chapter 3 assess the factors associated with new use of
anticoagulants, switching between anticoagulants, comparative effectiveness of new use of
anticoagulants, and effects following switching between anticoagulants using Poisson and
logistic regression, survival analysis, and the application of propensity scores.
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CHAPTER 4: RESULTS
AIM 1: ANTICOAGULANT USE AND SWITCHING

4.1. AIM 1A. RISK SCORES AND ANTICOAGULANT USE
4.1.1. Descriptive statistics
4.1.1.1. Cohort identification
Over 400,000 unique patients were identified as receiving at least one prescription for
warfarin or dabigatran after 10/19/2010 until 12/31/2012. Of these, there were 64,935 treatmentnaïve AF patients included in the final cohort (Figure 5). In total, 33,843 (52.1%) patients were
newly-diagnosed with AF, having received their first ICD-9 code for AF within the 30 days prior
to the index anticoagulation prescription fill. Of these, 43,865 (67.6%) used warfarin and 21,070
(32.5%) used dabigatran. There were 93,335 patients who were classified as prevalent users of
warfarin – i.e., having received warfarin within 12 months prior to the index prescription fill date
or the first prescription fill after 10/19/2010.
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Figure 5. New User Cohort Flow Diagram
Inclusion

Exclusion


Include: ≥ 1 prescription fill for warfarin or
dabigatran following 10/19/2010



Include: ≥18 years of age at index prescription
fill date



Include: ≥ 1 inpatient or 2 unique outpatient
diagnoses on separate days (ICD-9: 427.31) in 12
months prior to index prescription fill date

N=401,913

N=401,834

N=79

N=292,663

N=109,171

N=223,013

N=69,650

-

Exclude: Reversible AF conditions (such as
hyperthyroidism) or valvular AF at time of index
diagnosis or in previous 12 months

N=158,270

N=64,743



Include: Maintained ≥ 12 months of continuous
eligibility and prescription benefits prior to index
prescription fill date

N=64,935
New User
Cohort

N=93,335

–

Exclude: Warfarin prescription fill in 12 months
prior to index prescription fill date

N=31,092



Include: Newly-diagnosed with AF within 30
days prior to index prescription fill date

N=33,843
Newly-diagnosed
New User Cohort

4.1.1.2. Baseline demographic characteristics
Patient sociodemographic characteristics among new users of warfarin and dabigatran are
shown in Table 10, including the absolute standardized differences for each characteristic
category between the two anticoagulants. As previously described in Chapter 3, absolute
standardized differences are indexes which measure the effect size between two groups to assess
imbalance between groups, with differences greater than 10% in absolute value generally
indicating imbalance. New users of dabigatran were more likely to be younger, male, from the
South region, use high-deductible health or preferred provider organization insurance health
plans, and have good prescription benefits coverage (ratio ≥ 0 and ≤ 0.20) for all of their
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medications filled within the previous 12 months. The proportion of newly-diagnosed AF
patients with these sociodemographic characteristics was similar across all these baseline
demographic categories.
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Table 10. Demographic characteristics of new users and newly-diagnosed
new users of warfarin and dabigatran

Baseline Characteristic
Age
< 55 years
55-64 years
65-74 years
≥ 75 years
Male Gender
Region
Northeast
North Central
South
West
Insurance plan
Comprehensive
HMO
POS
PPO
CDHP
Prescription generosity
No coverage (> 0.99)
Poor coverage(> 0.80
and ≤ 0.99)
Fair coverage (> 0.20
and ≤ 0.80)
Good coverage (≥ 0 and
≤ 0.20)

Warfarin,
N (%)

New users
Dabigatran, Absolute
N (%)
SD

Newly-diagnosed new users
Warfarin,
Dabigatran, Absolute
N (%)
N (%)
SD

3,886 (8.9)
10,146 (23.1)
9,792 (22.3)
20,041 (45.7)
25,562 (58.3)

2,963 (14.1)
6,443 (30.6)
4,838 (23.0)
6,826 (32.4)
13,363 (63.4)

20.2
20.5
2.1
34.3
11.6

2,107 (9.5)
5,317 (24.1)
5,063 (22.9)
9,591 (43.4)
12,867 (58.3)

1,727 (14.7)
3,626 (30.8)
2,672 (22.7)
3,740 (31.8)
7,481 (63.6)

23.5
19.6
0.6
28.1
12.2

7,589 (17.3)
15,408 (35.1)
12,181 (27.8)
7,732 (17.6)

3,513 (16.7)
6,107 (29.0)
7,864 (37.3)
3,259 (15.5)

2.1
15.7
26.1
7.2

3,777 (17.1)
7,767 (35.2)
6,131 (27.8)
4,189 (19.0)

1,999 (17.0)
3,458 (29.4)
4,477 (38.1)
1,659 (14.1)

0.3
14.9
28.2
16.5

15,701 (35.8)
6,368 (14.5)
1,973 (4.5)
16,889 (38.5)
707 (1.6)

6,812 (32.3)
1,723 (8.2)
1,226 (5.8)
9,766 (46.4)
464 (2.2)

8.9
24.3
8.6
19.4
6.7

7,760 (35.1)
3,475 (15.7)
1,037 (4.7)
8,510 (38.5)
385 (1.7)

3,893 (33.1)
907 (7.7)
693 (5.9)
5,411 (46.0)
276 (2.4)

5.1
29.9
7.8
18.4
7.6

716 (1.6)

35 (0.2)

15.8

296 (1.3)

22 (0.2)

13.7

909 (2.1)

26 (0.1)

468 (2.1)

18 (0.2)

18.7

21,410 (48.8)

9,769 (46.4)

10,762 (48.7)

5,458 (46.4)

5.3

20,830 (47.5)

11,240 (53.3)

10,552 (47.8)

6,267 (53.3)

12.8

9.8
5.6
13.5

Abbreviations: SD, Standardized difference; HMO, Health maintenance organization; POS, Point-of-service; PPO, Preferred
provider organization; CDHP, consumer-driven health plan

4.1.1.3. Baseline clinical characteristics
Clinical characteristics of the new users of warfarin and dabigatran are shown in Table
11. Patients using warfarin for the first time were more likely to have experienced relevant
comorbidities, particularly ischemic stroke, congestive heart failure, and venous
thromboembolism. Across both new users and newly-diagnosed new users, the proportion of
patients receiving warfarin was more likely to have comorbidities, and higher ischemic stroke
risk and bleeding risk scores. The absolute standardized differences were somewhat lower
among patients who were newly-diagnosed with the exception of hyperlipidemia, peptic ulcer
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disease, and cognitive deficiency, although the underlying proportion of patients with those
comorbidities altogether influenced these differences. For example, at most, 1.0% of patients
were diagnosed with cognitive deficiency, which led to small cell sizes for both new users and
newly-diagnosed new users. Patients were also more likely to have had a previous hospitalization
if they received warfarin. However, AF patients were more likely to receive dabigatran if they
had a catheter ablation in the previous 12 months. Examining the ischemic stroke clinical
prediction risk scores, as predicted, the CHADS2 score classified more individuals as low or
intermediate risk of ischemic stroke compared with the CHA2DS2VASc score.
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Table 11. Clinical characteristics of new users and newly-diagnosed
new users of warfarin and dabigatran

Baseline Characteristic
Ischemic Stroke
Congestive Heart Failure
VTE
Hyperlipidemia
Hypertension
Myocardial infarction
Coronary artery disease
Peripheral vascular disease
Renal impairment
Diabetes
Major bleeding
Anemia
Peptic Ulcer disease
Sleep Apnea
Cognitive deficiency
CCI
0
1-2
3-5
6-8
≥9
CHADS2
0
1
≥2
CHA2DS2-VASc
0
1
≥2
ATRIA
0-3
4
≥5
HAS-BLED
0-2
≥3
Hospitalizations
≥1
Catheter ablation

Warfarin, N
(%)
4,710 (10.7)
12,414 (28.3)
5,385 (12.3)
21,710 (49.5)
32,043 (73.0)
2,001 (4.6)
15,000 (34.2)
3,892 (8.9)
5,517 (12.6)
13,957 (31.8)
5,975 (13.6)
8,736 (19.9)
320 (0.7)
4,546 (10.4)
438 (1.0)

New users
Dabigatran,
N (%)
1,495 (7.1)
3,851 (18.3)
538 (2.6)
10,456 (49.6)
14,578 (69.2)
500 (2.4)
5,942 (28.2)
1,150 (5.5)
1,210 (5.7)
5,610 (26.6)
1,983 (9.4)
2,241 (10.6)
93 (0.4)
2,526 (12.0)
126 (0.6)

Newly-diagnosed new users
Absolute Warfarin,
Dabigatran, Absolute
SD
N (%)
N (%)
SD
18.9
1,984 (9.0)
709 (6.0)
14.4
32.7
5,793 (26.2)
2,022 (17.2)
26.5
81.8
2,025 (9.2)
232 (2.0)
34.9
0.2
10,730 (48.6) 5,777 (49.1)
1.2
9.1
15,900 (72.0) 8,068 (68.6)
8.1
19.9
1,106 (5.0)
312 (2.7)
14.7
16.5
6,951 (31.5)
3,076 (26.1)
14.5
20.2
1,628 (7.4)
571 (4.9)
13.2
39.8
2,481 (11.2)
618 (5.3)
25.7
14.6
6,824 (30.9)
3,264 (27.7)
8.6
19.1
2,385 (10.8)
916 (7.8)
13.1
39.4
3,853 (17.5)
1,102 (9.4)
28.7
6.7
136 (0.6)
44 (0.4)
45.6
6.6
1937 (8.8)
1,187 (10.1)
6.2
7.3
157 (0.7)
45 (0.4)
69.0

10,051 (22.9)
17,657 (40.3)
11,871 (27.1)
3,165 (7.2)
1,121 (2.6)

7,091 (33.7)
9,058 (43.0)
4,001 (19.0)
686 (3.3)
234 (1.1)

28.7
6.5
26.2
29.9
20.1

5,350 (24.2)
9,345 (42.3)
5,608 (25.4)
1,322 (6.0)
453 (2.1)

4,008 (34.1)
5,215 (44.3)
2,104 (17.9)
323 (2.8)
115 (1.0)

28.7
4.8
22.3
18.8
10.8

4,432 (10.1)
11,319 (25.8)
28,114 (64.1)

3,342 (15.9)
7,044 (33.4)
10,684 (50.7)

21.3
20.1
31.3

2,381 (10.8)
5,937 (26.9)
13,760 (62.3)

1,874 (15.9)
3,932 (33.4)
5,959 (50.7)

21.7
18.2
26.2

2,935 (6.7)
6,339 (14.5)
34,591 (78.9)

2,444 (11.6)
4,665 (22.1)
13,961 (66.3)

20.9
24.1
30.8

1,531 (6.9)
3,387 (15.3)
17,160 (77.7)

1,366 (11.6)
2,626 (22.3)
7,773 (66.1)

24.9
25.1
27.8

30,667 (69.9)
4,158 (9.5)
9,040 (20.6)

17,602 (83.5)
1,501 (7.1)
1,967 (9.3)

65.8
12.6
50.6

16,124 (73.0)
2,047 (9.3)
3,907 (17.7)

10,018 (85.2)
808 (6.9)
939 (8.0)

32.1
11.3
34.4

38,249 (87.2)
5,616 (12.8)

19,608 (93.1)
1,462 (6.9)

20.3
31.1

19,764 (89.5)
2,314 (10.5)

11,128 (94.6)
637 (5.4)

19.3
22.9

25,231 (57.5)
391 (0.9)

9,431 (44.8)
459 (2.2)

30.1
12.5

13,809 (62.5)
55 (0.3)

5,726 (48.7)
44 (0.4)

31.2
2.6

Abbreviations: SD, Standardized difference; CCI, Charlson comorbidity index
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4.1.1.4. Baseline medication use characteristics
The distributions of patients receiving relevant concomitant medications within the 12
months prior to or including the index prescription fill date are shown in Table 12. The absolute
standardized differences indicate that the medication use characteristics are relatively balanced
between both groups of anticoagulant users. However, patients receiving warfarin were
somewhat more likely to receive antiplatelet therapy, a gastroprotective agent (e.g., PPI), rate
control therapy with digoxin, beta-blockers or calcium channel blockers, and ACEI/ARBs.
Newly diagnosed new user patients were more likely to receive an antiarrhythmic while overall
new user warfarin patients were less likely to receive one.
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Table 12. Medication use characteristics of new users and newly-diagnosed
new users of warfarin and dabigatran

Baseline Characteristic
Antiplatelet therapy
Gastroprotective agent
Antiarrhythmic
Digoxin
Beta-blocker
Calcium channel blocker
ACEI/ARB
Statin
Hormone

Warfarin,
N (%)
5,726 (13.1)
5,558 (12.7)
9,991 (22.8)
7,435 (16.9)
29,513 (67.3)
18,501 (42.2)
25,001 (57.0)
23,964 (54.6)
1,626 (3.7)

New users
Dabigatran,
N (%)
2,684 (12.7)
2,267 (10.8)
5,344 (25.4)
2,973 (14.1)
14,132 (67.1)
8,602 (40.8)
11,891 (56.4)
11,205 (53.2)
959 (4.6)

Absolute
SD
1.6
8.2
7.6
10.5
0.5
3.4
1.4
3.2
6.0

Newly-diagnosed new users
Warfarin,
Dabigatran, Absolute
N (%)
N (%)
SD
2,962 (13.4)
1,360 (11.6)
7.1
2,740 (12.4)
1,186 (10.1)
9.4
4,329 (19.6)
2,217 (18.8)
2.6
3,365 (15.2)
1,479 (12.6)
9.6
15,753 (71.4) 8,089 (68.8)
6.1
10,013 (45.4) 4,939 (42.0)
8.0
13,478 (61.0) 6,977 (59.3)
3.9
12,488 (56.6) 6,308 (53.6)
6.8
894 (4.1)
536 (4.6)
3.5

Abbreviations: SD, Standardized difference; ACEI, angiotensin-converting-enzyme inhibitor; ARB, angiotensin receptor blocker

4.1.1.5. Baseline characteristics: Means and standard deviations
The means and standard deviations for the sociodemographic and clinical characteristics
which were also measured continuously are displayed in Table 13. The mean age, CCI, stroke
risk and bleeding risk prediction scores, and the average number of hospitalizations were all
higher in those AF patients filling warfarin as their first anticoagulation prescription. The patient
ages in the cohort ranged from 18 to 103 years of age.
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Table 13. Means of baseline characteristics of new users and newly-diagnosed
new users of warfarin and dabigatran

Baseline Characteristic
Age
CCI
CHADS2
CHA2DS2-VASc
ATRIA
HAS-BLED
Number of hospitalizations

New users
Warfarin,
Dabigatran,
Mean (SD)
Mean (SD)
71.4 (12.2)
67.5 (12.4)
2.3 (2.3)
1.6 (1.9)
2.1 (1.3)
1.7 (1.2)
2.9 (1.7)
2.3 (1.6)
2.9 (2.4)
2.0 (1.9)
1.4 (1.0)
1.3 (0.9)
0.8 (0.9)
0.5 (0.7)

Newly-diagnosed new users
Warfarin,
Dabigatran,
Mean (SD)
Mean (SD)
70.7 (12.0)
67.2 (12.4)
2.1 (2.2)
1.5 (1.8)
2.0 (1.2)
1.6 (1.2)
2.8 (1.6)
2.3 (1.5)
2.7 (2.3)
1.9 (1.8)
1.3 (1.0)
1.1 (0.8)
0.8 (0.8)
0.6 (0.7)

Abbreviations: SD, standard deviation; CCI, Charlson comorbidity index

4.1.1.6. Index anticoagulant prescription characteristics
For the anticoagulation prescriptions filled on each patient’s index prescription date, the
index prescription benefits generosity and distribution of dosage strengths are shown in Table
14. Approximately 90% of dabigatran users received the 150mg dose. Of the 1,448 patients
receiving the 75mg dose indicated for patients with renal insufficiency, only 21.7% had
diagnosed renal insufficiency. By contrast, 9.7% of patients receiving the 150mg had diagnosed
chronic kidney disease, for whom the 150mg dose is neither FDA-approved nor recommended in
clinical guidelines. More than half of warfarin patients received 5mg as their index prescription
strength, which is generally the guideline-recommended warfarin starting dose. Lastly, of the
43,865 patients newly using warfarin, 1,817 (4.1%) patients filled more than one dosage strength
on the same day.
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Table 14. Characteristics of the initial warfarin and dabigatran prescriptions

Baseline Characteristic
Prescription generosity
No coverage
Poor coverage
Fair coverage
Good coverage
Dosage strength
1mg
2mg
2.5mg
3mg
4mg
5mg
6mg
7.5mg
10mg
75mg
150mg

New users
Warfarin,
Dabigatran,
N (%)
N (%)

Newly-diagnosed new users
Warfarin,
Dabigatran,
N (%)
N (%)

17,321 (39.5)
3,938 (8.98)
10,339 (23.6)
12,267 (28.0)

63 (0.3)
20 (0.1)
4,760 (22.6)
16,227 (77.0)

8,732 (39.6)
2,141 (9.7)
5,310 (24.1)
5,895 (26.7)

30 (0.3)
9 (0.1)
2,550 (21.7)
9,176 (78.0)

2,858 (6.5)
4,953 (11.3)
5,279 (12.0)
2,977 (6.8)
2,754 (6.3)
24,452 (55.7)
725 (1.7)
1,108 (2.5)
676 (1.5)
N/A
N/A

N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
1846 (8.8)
19,234 (91.3)

1,149 (5.2)
2,287 (10.4)
2,555 (11.6)
1,258 (5.7)
1,142 (5.2)
13,315 (60.3)
236 (1.1)
542 (2.5)
263 (1.2)
N/A
N/A

N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
950 (8.1)
10,818 (92.0)

In addition, the mean warfarin copay ($5.95, 6.54 SD) was lower than the mean
dabigatran copay ($37.34, 33.11 SD), as was the proportion of the index prescription paid by the
patient relative to insurance benefits. The highest warfarin copay was $233.57 (for brand) while
the lowest warfarin copay was $0, with 25th, 50th, and 75th percentiles at $1.54, $5.00, and $8.84,
respectively. The highest dabigatran copay was $784.51 while the lowest dabigatran copay was
$0, with 25th, 50th, and 75th percentiles at $20.00, $30.00, and $75.00, respectively.
Table 14 also indicates that patients with dabigatran had a lower cost-sharing burden than
patients receiving warfarin. Less than 1% of dabigatran patients paid more than 80% of the
overall index prescription cost, while more than 75% of dabigatran patients paid less than 20% of
the overall index prescription cost. By comparison, almost 50% of warfarin patients paid more
than 80% of the overall index prescription cost.
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4.1.1.7. Trends in initiation of anticoagulation
Trends in the index date of anticoagulant for each patient initiating therapy were also
examined via calendar months and calendar quarters. These calendar months and quarters are
displayed in Figure 6 and were determined in the time interval whereby each new user AF
patient’s index prescription was filled. New prescriptions for warfarin spiked in January 2011
(and somewhat in January 2012), but generally decreased over time. New prescriptions for
newly-diagnosed AF patients receiving warfarin were fairly stable over time but dipped
somewhat within the 2011 calendar year and then again in the 2012 calendar year. By contrast,
new prescriptions for dabigatran increased from the 4th quarter of 2010 through the 2nd quarter of
2011 but then appeared to decrease beginning in the 1st quarter of 2012 – in line with the FDAapproval of rivaroxaban, another NOAC. Notably, this introduction of rivaroxaban may explain
why the proportion of new users initiating anticoagulation in each month appears to decrease
overall in 2012.
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Figure 6. Trends in initiation of warfarin and dabigatran, 2010-2012
Figure 6a. Initiation of anticoagulation for each patient with atrial fibrillation by calendar
month
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Figure 6b. Initiation of anticoagulation for each patient with atrial fibrillation by calendar
quarter
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4.1.2. Bivariate analyses of anticoagulant selection
The bivariate association between each clinical and sociodemographic covariate level and
anticoagulation use was also assessed, by definition without controlling for the other covariates.
These associations were assessed using relative risk estimation by modified Poisson regression
with robust error variance. These associations are presented in Table 15 with warfarin as the
referent group. Categories of covariates with fewer than 2% of patients (or n=500, whichever
was smaller) with that characteristic were combined with another relevant level (e.g., “No” and
“Poor” prescription benefits generosity), when possible. The other identified small cell
categories included peptic ulcer disease, cognitive deficiency, and catheter ablation. These
associations were conducted on both new users and newly-diagnosed new user cohorts.
In these bivariate associations, because of the large sample size, almost all of the baseline
sociodemographic and clinical characteristics were statistically significantly associated with
anticoagulant selection, as seen in Table 15. The sole exceptions included: hyperlipidemia,
antiplatelet therapy (new user only), antiarrhythmic therapy (newly-diagnosed new user only),
beta-blocker therapy (new user only), and ACEI/ARB therapy (new user only). These suggested
that the new users and newly-diagnosed new users of dabigatran and warfarin are significantly
different from each other at baseline.
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Table 15. Bivariate association between warfarin and dabigatran use and baseline
sociodemographic and clinical characteristics in the 12-month baseline period
Baseline Characteristic
Demographic
Age (ref: <55 years)
55-64 years
65-74 years
≥ 75 years
Gender (ref: Female)
Region (ref: Northeast)
North Central
South
West
Insurance plan (ref:
Comprehensive)
HMO
POS
PPO
CDHP
Prescription generosity
(ref: None/Poor)
Fair coverage
Good coverage
Clinical (ref: 0/None
unless specified)
Ischemic Stroke
Congestive Heart Failure
VTE
Hyperlipidemia
Hypertension
Myocardial infarction
Coronary artery disease
Peripheral vascular
disease
Renal impairment
Diabetes
Major bleeding
Anemia
Peptic Ulcer disease
Sleep Apnea
Cognitive deficiency
CCI (ref: 0)
1-2
3-5
6-8
≥9
CHADS2 (ref: 0)
1

New Users
RR
95% CI

Newly-diagnosed new users
RR
95% CI

0.90
0.76
0.59
1.16

0.87-0.93**
0.74-0.79**
0.57-0.61**
1.13-1.19**

0.90
0.77
0.62
1.16

0.86-0.94**
0.73-0.80**
0.60-0.65**
1.12-1.19**

0.92
1.27
0.96

0.89-0.95**
1.23-1.31**
0.92-0.99*

0.87
1.20
0.81

0.84-0.91**
1.15-1.25**
0.76-0.85**

0.70
1.25
1.20
1.30

0.67-0.73**
1.20-1.32**
1.17-1.23**
1.21-1.39**

0.61
1.18
1.14
1.23

0.57-0.65**
1.11-1.25**
1.11-1.18**
1.12-1.35**

8.66
9.69

6.77-11.09**
7.57-12.40**

6.76
7.49

4.99-9.16**
5.53-10.14**

0.72
0.67
0.26
1.00
0.88
0.61
0.83

0.69-0.76**
0.65-0.69**
0.24-0.28**
0.98-1.03
0.86-0.90**
0.56-0.66**
0.80-0.85**

0.74
0.69
0.28
1.01
0.90
0.62
0.84

0.70-0.80**
0.65-0.69**
0.25-0.32**
0.98-1.04
0.87-0.93**
0.56-0.69**
0.81-0.87**

0.69
0.53
0.84
0.74
0.59
0.69
1.11
0.69

0.58-0.83**
0.50-0.56**
0.82-0.86**
0.71-0.77**
0.56-0.61**
0.58-0.83**
1.08-1.15**
0.59-0.80**

0.73
0.55
0.90
0.78
0.60
0.70
1.10
0.64

0.68-0.79**
0.52-0.59**
0.87-0.93**
0.74-0.83**
0.57-0.64**
0.54-0.91*
1.05-1.16**
0.49-0.83**

0.82
0.61
0.43
0.42

0.80-0.84**
0.59-0.63**
0.40-0.46**
0.37-0.47**

0.84
0.64
0.46
0.47

0.81-0.86**
0.61-0.67**
0.41-0.51**
0.40-0.56**

0.89

0.86-0.92**

0.90

0.87-0.94**
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≥2
CHA2DS2-VASc (ref: 0)
1
≥2
ATRIA (ref: 0-3)
4
≥5
HAS-BLED (ref: 0-2)
≥3
Hospitalizations
≥1
Catheter ablation
Medication use
Antiplatelet therapy
Gastroprotective agent
Antiarrhythmic
Digoxin
Beta-blocker
Calcium channel blocker
ACEI/ARB
Statin
Hormone

0.64

0.62-0.66**

0.69

0.66-0.71**

0.93
0.63

0.90-0.97**
0.61-0.65**

0.93
0.66

0.88-0.97**
0.64-0.69**

0.73
0.49

0.70-0.76**
0.47-0.51**

0.74
0.51

0.70-0.78**
0.48-0.54**

0.61

0.58-0.64**

0.60

0.56-0.64**

0.71
1.68

0.69-0.72**
1.58-1.79**

0.69
1.28

0.67-0.71**
1.03-1.60*

0.98
0.88
1.10
0.86
0.99
0.96
0.98
0.96
1.15

0.95-1.01
0.85-0.91**
1.07-1.13**
0.83-0.89**
0.97-1.02
0.94-0.99*
0.96-1.01
0.94-0.98**
1.09-1.21**

0.89
0.85
0.97
0.86
0.92
0.91
0.95
0.93
1.08

0.85-0.94**
0.81-0.90**
0.93-1.01
0.82-0.90**
0.89-0.95**
0.89-0.94**
0.93-0.98*
0.90-0.95**
1.01-1.16*

*p<0.05
**p<0.001
Abbreviations: RR, Relative risk; ref, referent group; CI, confidence interval; HMO, health maintenance organization; POS,
point of service; PPO, preferred provider organization; CDHP, consumer driven health plan; VTE, venous thromboembolism;
CCI, Charlson comorbidity index; ACEI/ARB, angiotensin converting enzyme inhibitor/angiotensin receptor blocker

Other bivariate analyses were also conducted among characteristics not included in the
multivariate analyses (discussed in the next section). Among all new users, AF patients who
were newly-diagnosed were 15% more likely to receive dabigatran versus warfarin compared
with those who were not newly-diagnosed (RR: 1.15, 95% CI: 1.12-1.18). New user AF patients
were much more likely to receive dabigatran if they had also received dronedarone, a newer
antiarrhythmic, specifically in the previous 12 months (RR: 1.61, 95% CI: 1.56-1.67). There was
a similar likelihood among newly-diagnosed new users with regard to dronedarone receipt (RR:
1.66, 95% CI: 1.66-1.58).
The scores for the ischemic stroke, bleeding risk and overall clinical severity were also
compared using those variables as continuous in bivariate analyses for both new users and
newly-diagnosed new users as sensitivity analyses. These analyses are shown in the Appendix in
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Appendix table 1. For example, for each additional year of age, new users were 1% less likely
to receive dabigatran versus warfarin (RR: 0.99, 95% CI: 0.98-0.99). Overall, these bivariate
associations were very similar as those assessed categorically in Table 15 for both new users and
newly-diagnosed new users.

4.1.3. Multivariate analyses of anticoagulant selection
4.1.3.1 Main analyses
The associations between ischemic stroke and bleeding risk scores and anticoagulant
selection were also assessed using multivariable relative risk estimation by modified Poisson
regression with robust error variance (Table 16). In this model, the independent variables were
CHA2DS2-VASc and ATRIA risk scores, with the dependent variable being selection for a
particular anticoagulant. Warfarin was used as the referent group for all analyses. These models
adjusted for all other baseline clinical characteristics which were not already included in the risk
scores to avoid collinearity issues to ensure appropriate interpretation of the association of
ischemic stroke and bleeding risk scores with anticoagulant selection. The associations with the
other baseline characteristics are shown in Appendix table 2.
We found that high ischemic stroke risk was significantly associated with anticoagulant
selection. Compared with warfarin, new users of dabigatran were significantly less likely to have
CHA2DS2-VASc ≥ 2 or ATRIA score ≥4, even after adjusting for other clinical and demographic
characteristics. These results indicate that AF patients using dabigatran were less likely to be at
high ischemic stroke or bleeding risk when newly initiating therapy. However, intermediate
ischemic stroke risk was not associated with any differential anticoagulant selection. AF patients
newly initiating anticoagulation were also less likely to have other clinical comorbidities. These
results were also seen consistently in the sensitivity analysis of newly-diagnosed new users.
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Table 16. Multivariable association between ischemic stroke and bleeding
risk prediction scores and warfarin and dabigatran selection
Baseline Characteristic
Demographic
CHA2DS2-VASc (ref: 0)
1
≥2
ATRIA (ref: 0-3)
4
≥5

New Users
RR
95% CI

Newly-diagnosed new users
RR
95% CI

0.97
0.91

0.94-1.01
0.87-0.95**

0.97
0.92

0.92-1.02
0.87-0.98*

0.86
0.72

0.82-0.89**
0.69-0.76**

0.85
0.71

0.80-0.91**
0.67-0.76**

*p<0.05
**p<0.001
Abbreviations: RR, Relative risk; ref, referent group; CI, confidence interval
NOTE: Adjusted for all other measured baseline covariates, except for those already included in risk scores, as shown in
Appendix table 2

4.1.3.2. Model fit diagnostics
The Quasilikelihood under the Independence model Criterion (QIC) was used to compare
the insertion of CHADS2 and the HAS-BLED score as possible predictors instead of the
CHA2DS2-VASc and ATRIA risk scores. The QIC is analogous to the Akaike’s Information
Criterion (AIC) but is instead used for models fitting generalized estimating equation, such as the
regression model used in this case. The QIC can be used for model selection, whereby the
optimal model would have the lowest possible QIC. The model possibilities and resultant QICs
are shown in Appendix table 3 and indicate that indeed the CHA2DS2-VASc and ATRIA risk
scores lead to a better model fit for both new users and newly-diagnosed new users, as that
model possibility has the lowest QIC.
Notably, hyperlipidemia and the other medication use characteristics in the bivariate
analyses not shown to be significantly significant were still included in the multivariable model
as they were specified a priori, have been thought to be confounders in other research settings,
and may still modify the relationship between predictor and anticoagulant use. The relative risks
and 95% confidence intervals for the baseline covariates included in the model are shown in the
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Appendix (Appendix table 2). Key interactions (e.g., age and gender) were also examined. As
discussed in the previous section, age was examined via restriction to the commercially-insured
and Medicare supplement patients, and some slight differences were noted. In addition, gender
was also examined as an interaction term, and it was not found to have a significant interaction
with either the ATRIA score or the CHA2DS2-VASc score.

4.1.3.3. Sensitivity analyses
The cohorts were also stratified based on the data sources into commercially-insured and
Medicare supplemental claims (Appendix table 4). In these analyses, we observed similar
associations between bleeding prediction risk scores and anticoagulant selection in the 12-month
follow-up period similar to the original results presented in Table 16. The sole difference from
the full combined cohort was that neither intermediate nor high ischemic stroke risk was
associated with anticoagulation selection among the sub-cohort of Medicare Supplement
beneficiaries.
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4.2. AIM 1B: RISK SCORES AND ANTICOAGULANT SWITCHING
4.2.1. Descriptive statistics
4.2.1.1. Cohort identification
In total, 64,935 AF patients were treatment-naïve. Of these, 33,712 patients were
continuously enrolled for at least 12 months after the index anticoagulant fill date. Figure 7
shows the switcher cohort selection, as an extension from the new user cohort flow diagram in
Figure 5. Of note, these are individuals who are eligible for switching anticoagulants, not that
they did within the 12-months post anticoagulation fill. The new users were examined as the
primary analysis, with the prevalent users as a secondary analysis. Of the new users, 21,989
(65.2%) and 11,723 (34.8%) filled warfarin and dabigatran as their index prescriptions,
respectively. Of note, a similar proportion filled each anticoagulation of the newly-diagnosed
new users, with 10,776 (63.0%) and 6,343 (37.1%) filling warfarin and dabigatran, respectively.
By contrast, 78,937 (98.1%) of the prevalent users of warfarin had warfarin as their first
prescription fill post 10/19/2010. The remaining 1.9% of patients were, in fact, previous users of
warfarin who used dabigatran as their first prescription post 10/19/2010.
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Figure 7. Switcher Flow Diagram
Inclusion

Exclusion

N=158,270

N=64,743



Include: ≥1 prescription fill for warfarin or dabigatran
after 10/19/2010, ≥18 years of age, ≥1 inpatient or ≥2
outpatient AF diagnoses, no reversible AF condition,
≥12 months continuous eligibility prior to index fill

N=114,201

N=44,069



Include: Maintained ≥ 12 months of continuous
eligibility and prescription benefits after the index
prescription fill date

N=80,489
Prevalent users

–

Exclude: Warfarin prescription fill in 12 months
prior to index prescription fill date

N=33,712
New users

N=21,989
Warfarin new users

N=11,723
Dabigatran new users

4.2.1.2. New users: Anticoagulant switching characteristics
In total, 4,216 new user patients switched therapy within 12 months of treatment
initiation (12.5%). Of the total new users, 2,800 (12.7%) of warfarin patients and 1,416 (12.1%)
of dabigatran patients switched. The demographic, clinical, and medication use characteristics of
the AF patients switching from warfarin and dabigatran are provided in Table 17. Examining the
absolute standardized differences, switchers of warfarin compared with non-switchers were less
likely to be aged ≥ 75 years, have an HMO health plan, have CHF, renal impairment, VTE, or
anemia, or have high ischemic stroke risk or bleeding risk scores. Switchers from warfarin were,
however, more likely to have a PPO health plan and previous hormone use. Switchers of
dabigatran compared with non-switchers were more likely to be ≥75 years of age, have higher
ischemic stroke risk, and use beta-blockers. However, switchers of dabigatran were less likely to
be younger, male, have previously experienced an ischemic stroke, and have a previous catheter
ablation. Overall, the characteristics descriptively appear more balanced between dabigatran
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switchers and non-switchers compared with warfarin users. Upon further analysis, of the
warfarin switchers, 11.7% switched to dabigatran while 1.3% switched to rivaroxaban. By
contrast, of the dabigatran switchers, 8.9% switched to warfarin while 3.6% switched to
rivaroxaban.
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Table 17. Characteristics of switchers and non-switchers of new users
of warfarin and dabigatran within 12-months following treatment
Warfarin New Users (N=21,989)
NonSwitcher,
Absolute
Baseline Characteristic
Switcher,
N (%)
SD
N (%)
Switching, N (%)
2,800 (12.7) 19,189 (87.3)
Demographic
Age
< 55 years
246 (8.8)
1,695 (8.8)
0.0
55-64 years
771 (27.5) 4,195 (21.9)
16.0
65-74 years
705 (25.2) 4,421 (23.0)
6.4
≥ 75 years
1,078 (38.5) 8,878 (46.3)
19.1
Male Gender
1,654 (59.1) 11,232 (58.5)
1.4
Region
Northeast
398 (14.2) 3,279 (17.1)
10.9
North Central
876 (31.3) 6,618 (34.5)
8.5
South
938 (33.5) 5,379 (28.0)
14.4
West
493 (17.6) 3,395 (17.7)
0.3
Insurance plan
Comprehensive
1,082 (38.6) 7,504 (39.1)
1.2
HMO
212 (7.6) 2,760 (14.4)
34.1
POS
165 (5.9)
911 (4.8)
6.4
PPO
1,161 (41.5) 6,729 (35.1)
15.6
CDHP
54 (1.9)
299 (1.6)
3.1
Benefits generosity
No coverage
40 (1.4)
291 (1.5)
1.2
Poor coverage
42 (1.5)
361 (1.9)
4.6
Fair coverage
1,267 (45.3) 9,419 (49.1)
8.9
Good coverage
1,451 (51.8) 9,118 (47.5)
9.9
Clinical
Ischemic Stroke
260 (9.3)
1,801 (9.4)
0.5
Congestive Heart Failure 611 (21.8) 4,993 (26.0)
12.9
VTE
159 (5.7) 2,189 (11.4)
33.0
Hyperlipidemia
1,253 (44.8) 8,809 (45.9)
2.6
Hypertension
1,971 (70.4) 13,526 (70.5)
0.2
Myocardial infarction
86 (3.1)
747 (3.9)
6.4
Coronary artery disease
865 (30.9) 6,319 (32.9)
5.3
Peripheral vascular
disease
193 (6.9)
1,510 (7.9)
5.4
Renal impairment
184 (6.6) 2,092 (10.9)
23.3
Diabetes
845 (30.2) 5,915 (30.8)
1.6
Major bleeding
318 (11.4) 2,465 (12.8)
5.9
Anemia
338 (12.1) 3,424 (17.8)
22.9
Peptic Ulcer disease
12 (0.4)
130 (0.7)
6.7
Sleep Apnea
343 (12.3) 1,914 (10.0)
9.4
Cognitive deficiency
15 (0.5)
137 (0.7)
4.0
CCI
0
760 (27.1) 4,810 (25.1)
5.7
1-2
1,278 (45.6) 7,923 (41.3)
10.2
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Dabigatran New Users (N=11,723)
Switcher, N Non-Switcher, Absolute
(%)
N (%)
SD
1,416 (12.1)

10,307 (87.9)

142 (10.0)
361 (25.5)
333 (23.5)
580 (41.0)
826 (58.3)

1,452 (14.1)
2,934 (28.5)
2,428 (23.6)
3,493 (33.9)
6,548 (63.5)

18.1
8.6
0.3
17.4
12.0

219 (15.5)
369 (26.1)
571 (40.3)
239 (16.9)

1,685 (16.3)
2,872 (27.9)
4,016 (39.0)
1,579 (15.3)

2.9
5.1
3.2
5.6

552 (39.0)
100 (7.1)
72 (5.1)
611 (43.1)
27 (1.9)

3,669 (35.6)
744 (7.2)
646 (6.3)
4,610 (44.7)
215 (2.1)

8.4
0.5
7.5
3.8
2.1

2 (0.1)
0 (0.0)
671 (47.4)
743 (52.5)

15 (0.2)
11 (0.1)
4,762 (46.2)
5,519 (53.5)

4.5
N/A
2.8
2.3

75 (5.3)
242 (17.1)
42 (3.0)
694 (49.0)
988 (69.8)
30 (2.1)
440 (31.1)

741 (7.2)
1,765 (17.1)
267 (2.6)
4,880 (47.3)
6,943 (67.4)
240 (2.3)
2,905 (28.2)

11.6
0.0
3.3
3.9
5.6
2.0
7.8

91 (6.4)
83 (5.9)
375 (26.5)
137 (9.7)
151 (10.7)
3 (0.2)
176 (12.4)
8 (0.6)

569 (5.5)
527 (5.1)
2,650 (25.7)
997 (9.7)
990 (9.6)
44 (0.4)
1,175 (11.4)
55 (0.5)

5.1
4.7
2.3
0.0
4.8
6.3
4.1
1.8

447 (31.6)
630 (44.5)

3,573 (34.7)
4,488 (43.5)

8.2
2.4

3-5
6-8
≥9
CHADS2
0
1
≥2
CHA2DS2-VASc
0
1
≥2
ATRIA
0-3
4
≥5
HAS-BLED
0-2
≥3
Hospitalizations
≥1
Catheter ablation
Medication Use
Antiplatelet therapy
Gastroprotective agent
Antiarrhythmic
Digoxin
Beta-blocker
Calcium channel blocker
ACEI/ARB
Statin
Hormone

624 (22.3)
105 (3.8)
33 (1.2)

4,978 (25.9)
1,151 (6.0)
327 (1.7)

11.0
15.8
6.4

286 (20.2)
43 (3.0)
10 (0.7)

1,856 (18.0)
297 (2.9)
93 (0.9)

7.1
0.8
3.4

352 (12.6) 2,075 (10.8)
820 (29.3) 5,197 (27.1)
1,628 (58.1) 11,917 (62.1)

7.3
6.0
9.2

190 (13.4)
446 (31.5)
780 (55.1)

1,663 (16.1)
3,512 (34.1)
5,132 (49.8)

10.4
6.9
12.1

224 (8.0)
1,340 (7.0)
505 (18.0) 2,808 (14.6)
2,071 (74.0) 15,041 (78.4)

5.0
11.7
11.0

125 (8.8)
253 (17.9)
1,038 (73.3)

1,189 (11.5)
2,239 (21.7)
6,879 (66.7)

12.8
12.8
15.6

2,249 (80.3) 13,963 (72.8)
238 (8.5)
1,683 (8.8)
313 (11.2) 3,543 (18.5)

18.8
1.5
30.3

1,181 (83.4)
91 (6.4)
144 (10.2)

8,734 (84.7)
714 (6.9)
859 (8.3)

3.7
2.8
8.5

2,122 (75.8) 13,717 (71.5)
678 (24.2) 5,472 (28.5)

10.5
12.6

1,117 (78.9)
299 (21.1)

8,202 (79.6)
2,105 (20.4)

1.8
2.2

1,456 (52.0) 10,588 (55.2)
26 (0.9)
188 (1.0)

7.4
1.5

580 (41.0)
7 (0.5)

4,512 (43.8)
230 (2.2)

6.8
33.7

363 (13.0)
330 (11.8)
707 (25.3)
482 (17.2)
1,868 (66.7)
1,201 (42.9)
1,671 (59.7)
1,551 (55.4)
150 (5.4)

2.8
0.4
9.7
0.3
0.9
3.8
7.3
3.9
10.4

186 (13.1)
155 (10.9)
361 (25.5)
205 (14.5)
1,010 (71.3)
598 (42.2)
803 (56.7)
766 (54.1)
75 (5.3)

1,388 (13.5)
1,083 (10.5)
2,567 (24.9)
1,497 (14.5)
6,853 (66.5)
4,197 (40.7)
5,835 (56.6)
5,622 (54.5)
499 (4.8)

1.6
1.7
1.7
0.0
11.3
3.6
0.2
0.9
3.1

2,365 (12.3)
2,293 (11.9)
4,214 (22.0)
3,282 (17.1)
12,714 (66.3)
7,923 (41.3)
10,842 (56.5)
10,308 (53.7)
704 (3.7)

Abbreviations: SD, Standardized difference; HMO, Health maintenance organization; POS, Point-of-service; PPO, Preferred
provider organization; CDHP, consumer-driven health plan; CCI, Charlson Comorbidity Index; ACEI, angiotensin-convertingenzyme inhibitor; ARB, angiotensin receptor blocker

4.2.1.2. Prevalent users of warfarin: Anticoagulant switching characteristics
Of the 80,489 prevalent users of warfarin, 10,561 (13.1%) switched therapies within 12months. The demographic, clinical and medication use characteristics of these prevalent users are
provided in Table 18. Prevalent users were less likely to switch (more likely to be classified as
“Non-Switchers”) if they were >75 years of age, resided in the North Central Region, had HMO
health insurance, had poor or fair benefits generosity, VTE, renal impairment, high ischemic
stroke risk (CHA2DS2-VASc or CHADS2 ≥ 2), or high bleeding risk (ATRIA ≥ 5). Prevalent
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users were more likely to switch (more likely to be classified as “Switchers”) if they were 55-64
or 65-74 years of age, resided in the South Region, had PPO health insurance, had good benefits
generosity, sleep apnea, catheter ablation, intermediate ischemic stroke risk (CHA2DS2-VASc =
1), low bleeding risk (ATRIA < 4) or anti-arrhythmic therapies.

117

Table 18. Characteristics of switchers and non-switchers of prevalent
users of warfarin within 12-months following treatment

Baseline Characteristic
Switching, N (%)
Demographic
Age
< 55 years
55-64 years
65-74 years
≥ 75 years
Male Gender
Region
Northeast
North Central
South
West
Insurance plan
Comprehensive
HMO
POS
PPO
CDHP
Benefits generosity
No coverage
Poor coverage
Fair coverage
Good coverage
Clinical
Ischemic Stroke
Congestive Heart Failure
VTE
Hyperlipidemia
Hypertension
Myocardial infarction
Coronary artery disease
Peripheral vascular
disease
Renal impairment
Diabetes
Major bleeding
Anemia
Peptic Ulcer disease
Sleep Apnea
Cognitive deficiency
CCI
0
1-2
3-5

Prevalent Users (N=80,489)
Switcher,
Non-Switcher,
Absolute
N (%)
N (%)
SD
10,561 (13.1)
69,928 (86.9)

588 (5.6)
2,169 (20.5)
2,847 (27.0)
4,957 (46.9)
6,392 (60.5)

3,378 (4.8)
10,828 (15.5)
15,360 (22.0)
40,362 (57.7)
40,640 (58.1)

4.8
16.2
14.3
25.3
5.5

1,885 (17.8)
2,579 (24.4)
4,171 (39.5)
1,908 (18.1)

13,468 (19.3)
22,973 (32.9)
20,856 (29.8)
12,537 (17.9)

5.1
24.6
24.2
0.7

4,851 (45.9)
626 (5.9)
627 (5.9)
4,054 (38.4)
135 (1.3)

32,049 (45.8)
11,352 (16.2)
3130 (4.5)
20,921 (29.9)
782 (1.1)

0.2
57.8
8.2
21.3
2.5

38 (0.4)
75 (0.7)
5,016 (47.5)
5,432 (51.4)

362 (0.5)
1,040 (1.5)
37,587 (53.8)
30,939 (44.2)

2.2
13.5
14.7
16.6

698 (6.6)
2,265 (21.4)
473 (4.5)
4,691 (44.4)
6,984 (66.1)
120 (1.1)
3,501 (33.2)

4,644 (6.6)
16,856 (24.1)
5352 (7.7)
29,040 (41.5)
45,529 (65.1)
879 (1.3)
22,296 (31.9)

0.0
8.4
21.1
6.9
2.3
2.7
3.4

726 (6.9)
714 (6.8)
3,022 (28.6)
1,544 (14.6)
1,284 (12.2)
51 (0.5)
1,433 (13.6)
69 (0.7)

5295 (7.6)
6302 (9.0)
20,511 (29.3)
9,953 (14.2)
9,937 (14.2)
331 (0.5)
6,887 (9.9)
492 (0.7)

3.8
11.8
1.9
1.5
8.1
0.0
14.5
0.0

3,098 (29.3)
4,692 (44.4)
2,308 (21.9)

19,416 (27.8)
30,041 (43.0)
16,579 (23.7)

4.1
3.3
5.5
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6-8
≥9
CHADS2
0
1
≥2
CHA2DS2-VASc
0
1
≥2
ATRIA
0-3
4
≥5
HAS-BLED
0-2
≥3
Hospitalizations
≥1
Catheter ablation
Medication Use
Antiplatelet therapy
Gastroprotective agent
Antiarrhythmic
Digoxin
Beta-blocker
Calcium channel blocker
ACEI/ARB
Statin
Hormone

373 (3.5)
90 (0.9)

3,159 (4.5)
733 (1.1)

7.5
3.0

1,203 (11.4)
3,258 (30.8)
6,100 (57.8)

6,804 (9.7)
19,218 (27.5)
43,906 (62.8)

7.2
8.9
11.5

595 (5.6)
1,660 (15.7)
8,306 (78.6)

3,593 (5.1)
8,226 (11.8)
58,109 (83.1)

3.0
14.3
12.1

8,459 (80.1)
799 (7.6)
1,303 (12.3)

53,274 (76.2)
5,300 (7.6)
11,354 (16.2)

10.0
0.0
15.6

8,208 (77.7)
2,353 (22.3)

53,504 (76.5)
16,424 (23.5)

3.0
3.7

3,173 (30.0)
216 (2.1)

20,538 (29.4)
721 (1.0)

1.6
10.8

810 (7.7)
1,247 (11.8)
2,845 (26.9)
2,878 (27.3)
7,278 (68.9)
4,614 (43.7)
6,676 (63.2)
6,792 (64.3)
458 (4.3)

4,420 (6.3)
7,752 (11.1)
14,578 (20.8)
19,566 (28.0)
47,226 (67.5)
28,109 (40.2)
42,125 (60.2)
42,677 (61.0)
2513 (3.6)

7.2
2.9
17.6
2.0
3.3
8.4
6.8
7.5
4.8

Abbreviations: SD, Standardized difference; HMO, Health maintenance organization; POS, Point-of-service; PPO, Preferred
provider organization; CDHP, consumer-driven health plan; CCI, Charlson Comorbidity Index; ACEI, angiotensin-convertingenzyme inhibitor; ARB, angiotensin receptor blocker

4.2.1.3. Anticoagulant switching time periods
The time to switching anticoagulants were also descriptively assessed for both the new
user and prevalent user cohorts. Of the 4,216 AF patients newly-initiating an anticoagulant and
switching within 12-months, the mean time from initiation until discontinuation was 136.6 days
(106.4 SD). Among patients who switched, the switch from warfarin was shorter than the switch
to dabigatran. Specifically, the mean switch time from warfarin was 127.4 days (102.1 SD) while
the mean switch time from dabigatran was 155.0 days (112.3 SD). Of the prevalent users, the
mean switch time was 168.4 days (97.3 SD). Of the patients newly-initiating warfarin and
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switching within 12 months, 568 (20.3%) and 1,002 (35.8%) switched therapies within 30 and 60
days since initiation, respectively. These proportions represent 1.7% and 3.0% of the total
warfarin new-initiators. The proportion of patients newly-initiating dabigatran and switching
within 30 and 60 days was somewhat lower (30 days: 16.7%, N=236; 60 days: 29.0%, N=411).
As many as 151 (5.4%) and 51 patients (3.6%) of the warfarin and dabigatran patients who
switched to another anticoagulant did so within 7 days of newly-initiating the respective
therapies.

4.2.1.4. Anticoagulant switching prescription copayments
The distributions of the proportion of the index prescription copayments paid by the new
user and prevalent user AF patients are shown in Appendix table 5.

4.2.2. Bivariate analyses
The bivariate association between each clinical and sociodemographic covariate level and
anticoagulation switching for each type of anticoagulant was also assessed, by definition without
controlling for the other covariates. These associations were assessed using relative risk
estimation by modified Poisson regression with robust error variance. These associations are
presented in Table 19 with “non-switching” as the referent group for each anticoagulant
comparison. These associations were conducted on both the new user and prevalent user cohorts
using the same methodology as Aim 1a.
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Table 19. Bivariate association between anticoagulant switching and baseline
sociodemographic and clinical characteristics in the 12-month baseline period
Baseline Characteristic
Demographic
Age (ref: <55 years)
55-64 years
65-74 years
≥ 75 years
Gender (ref: Female)
Region (ref: Northeast)
North Central
South
West
Insurance plan (ref:
Comprehensive)
HMO
POS
PPO
CDHP
Prescription generosity (ref:
None/Poor)
Fair coverage
Good coverage
Clinical (ref: 0/None unless
specified)
Ischemic Stroke
Congestive Heart Failure
VTE
Hyperlipidemia
Hypertension
Myocardial infarction
Coronary artery disease
Peripheral vascular disease
Renal impairment
Diabetes
Major bleeding
Anemia
Peptic Ulcer disease
Sleep Apnea
Cognitive deficiency
CCI (ref: 0)
1-2
3-5
6-8
≥9
CHADS2 (ref: 0)
1
≥2

Warfarin New Users
RR
95% CI

Dabigatran New Users
RR
95% CI

Prevalent Users
RR
95% CI

1.23
1.09
0.85
1.02

1.07-1.40*
0.95-1.24
0.75-0.97*
0.95-1.09

1.23
1.35
1.60
0.83

1.02-1.48*
1.12-1.63*
1.34-1.90**
0.75-0.91**

1.13
1.05
0.74
1.09

1.04-1.22*
0.97-1.14
0.68-0.80**
1.05-1.13**

1.02
1.29
1.10

0.92-1.13
1.17-1.43**
0.98-1.24

1.00
1.09
1.15

0.86-1.16
0.95-1.26
0.97-1.36

0.82
1.35
1.07

0.78-0.87**
1.29-1.42**
1.01-1.14*

0.57
1.23
1.18
1.23

0.50-0.67**
1.06-1.43*
1.10-1.27**
0.96-1.58

0.92
0.78
0.91
0.86

0.75-1.12
0.62-0.98*
0.82-1.01
0.60-1.24

0.40
1.27
1.23
1.12

0.37-0.43**
1.17-1.37**
1.19-1.28**
0.95-1.31

1.06
1.23

0.86-1.31
1.00-1.52

1.73
1.66

0.45-6.59
0.44-6.33

1.58
2.00

1.32-1.89**
1.67-2.40**

0.99
0.82
0.50
0.96
1.00
0.80
0.92
0.88
0.61
0.97
0.88
0.67
0.66
1.22
0.77

0.88-1.12
0.75-0.89**
0.43-0.59**
0.90-1.03
0.92-1.07
0.66-0.99*
0.85-0.99*
0.77-1.02
0.52-0.70**
0.90-1.05
0.79-0.99*
0.60-0.74**
0.38-1.14
1.10-1.35**
0.48-1.25

0.75
1.00
1.13
1.06
1.10
0.92
1.13
1.15
1.13
1.04
1.00
1.11
0.53
1.09
1.05

0.60-0.93*
0.88-1.13
0.85-1.50
0.96-1.17
0.99-1.23
0.65-1.29
1.02-1.25*
0.95-1.40
0.92-1.39
0.93-1.16
0.85-1.18
0.95-1.30
0.18-1.58
0.94-1.26
0.55-2.01

1.00
0.88
0.60
1.11
1.04
0.91
1.05
0.91
0.76
0.97
1.03
0.85
1.02
1.36
0.94

0.93-1.07
0.84-0.92**
0.55-0.66**
1.07-1.15**
1.00-1.08*
0.77-1.08
1.01-1.09*
0.85-0.98*
0.71-0.82**
0.93-1.01
0.98-1.09
0.81-0.90**
0.79-1.31
1.29-1.43**
0.75-1.17

1.02
0.82
0.61
0.67

0.94-1.11
0.74-0.90**
0.50-0.74**
0.48-0.94*

1.11
1.20
1.14
0.87

0.99-1.24
1.05-1.38*
0.85-1.52
0.48-1.58

0.98
0.89
0.77
0.79

0.94-1.02
0.85-0.93**
0.69-0.85**
0.65-0.97*

0.94
0.83

0.84-1.05
0.74-0.92**

1.10
1.29

0.94-1.29
1.11-1.49*

0.96
0.81

0.91-1.03
0.77-0.86**
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CHA2DS2-VASc (ref: 0)
1
≥2
ATRIA (ref: 0-3)
4
≥5
HAS-BLED (ref: 0-2)
≥3
Hospitalizations
≥1
Catheter ablation
Medication use
Antiplatelet therapy
Gastroprotective agent
Antiarrhythmic
Digoxin
Beta-blocker
Calcium channel blocker
ACEI/ARB
Statin
Hormone

1.06
0.85

0.92-1.23
0.74-0.96*

1.07
1.38

0.87-1.31
1.16-1.64**

1.19
0.88

1.08-1.29**
0.82-0.95*

0.89
0.59

0.79-1.01
0.52-0.66**

0.95
1.21

0.78-1.16
1.03-1.42*

0.96
0.75

0.89-1.02
0.71-0.79**

0.83

0.76-0.89**

1.04

0.92-1.17

0.94

0.90-0.98*

0.89
0.95

0.83-0.96*
0.66-1.34

0.90
0.24

0.82-1.00*
0.12-0.50**

1.03
1.77

0.99-1.07
1.57-2.00**

1.05
0.99
1.17
1.01
1.02
1.06
1.12
1.06
1.40

0.95-1.17
0.89-1.10
1.08-1.26**
0.92-1.10
0.95-1.10
0.99-1.14
1.04-1.20*
0.99-1.14
1.21-1.63**

0.98
1.04
1.03
1.00
1.22
1.06
1.00
0.98
1.09

0.84-1.13
0.89-1.22
0.92-1.15
0.87-1.15
1.10-1.36**
0.96-1.17
0.91-1.11
0.89-1.09
0.87-1.35

1.02
1.06
1.33
0.97
1.06
1.13
1.12
1.13
1.18

0.94-1.11
1.01-1.12*
1.28-1.39**
0.93-1.09
1.02-1.10*
1.09-1.17**
1.08-1.16**
1.09-1.17**
1.09-1.29**

*p<0.05
**p<0.001
Abbreviations: RR, Relative risk; ref, referent group; CI, confidence interval; HMO, health maintenance organization; POS,
point of service; PPO, preferred provider organization; CDHP, consumer driven health plan; VTE, venous thromboembolism;
CCI, Charlson comorbidity index; ACEI/ARB, angiotensin converting enzyme inhibitor/angiotensin receptor blockers

In these bivariate associations, many of the baseline sociodemographic and clinical
characteristics were statistically significantly associated with anticoagulant selection, as seen in
Table 19. These suggested that the switchers and non-switchers for each type of anticoagulant
may significantly differ from each other in the 12-month baseline period. When examining the
warfarin new user cohort, being from the South region and being 55-64 years of age, having a
PPO plan, sleep apnea and using antiarrhythmics, ACEI/ARB or hormone therapies were
significantly associated with switching from warfarin in the 12-month follow-up period. Patients
were less likely to switch if they were ≥ 75 years of age, had an HMO plan, had CHF, VTE,
anemia or renal impairment, had higher comorbidity burden, higher risk of ischemic stroke or
bleeding, and had a previous hospitalization.
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When examining the patients initiating dabigatran, patients greater than 55 years of age,
with coronary artery disease, moderate comorbidity burden, higher ischemic stroke risk or
bleeding risk and using beta-blocker therapies were more likely to switch from dabigatran.
Patients were less likely to switch from dabigatran if they were male, had a POS plan, had
previous ischemic stroke, were previously hospitalized or had a catheter ablation procedure. By
comparison, patients with bleeding risk or ischemic stroke risk or congestive heart failure, VTE,
renal impairment, anemia or PVD were less likely to switch if they were prevalent users.
However, prevalent user patients with hypertension, hyperlipidemia and sleep apnea were more
likely to switch. There was a significant amount of geographic variation between the regions,
particularly among the prevalent users.
Lastly, among new users, newly-diagnosed AF was significantly associated with
switching for warfarin in the 12-month follow-up period (warfarin RR: 1.32, 95% CI: 1.24-1.42;
dabigatran RR: 1.03, 95% CI: 0.94-1.14), and a new diagnosis of AF was also adjusted for in the
multivariate analyses discussed in the next section.

4.2.3. Multivariate analyses
4.2.3.1. Main analyses
The associations between ischemic stroke and bleeding risk scores and anticoagulant
switching were also assessed using multivariable relative risk estimation by modified Poisson
regression with robust error variance (Table 20). In this model, the independent variables were
CHA2DS2-VASc and ATRIA risk scores, with the dependent variable being selection for a
particular anticoagulant. Non-switchers were used as the referent group for all analyses using
both the new user and the prevalent user cohorts and the methods described in Aim 1a. The
associations with the other baseline characteristics are shown in Appendix table 6.
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Compared with non-switchers, patients initiating warfarin were significantly less likely to
switch therapies with high bleeding risk (RR: 0.69, 95% CI: 0.61-0.79). By comparison, patients
initiating dabigatran were significantly more likely to switch with high ischemic stroke risk (RR:
1.35, 95% CI: 1.09-1.66) compared with non-switchers. Comparatively, patients who are newlyinitiating dabigatran are more likely to switch with high baseline ischemic stroke risk, which
appears to be driven by advanced age.
By contrast, in the prevalent users of warfarin, having a high ischemic stroke risk was
associated with an 8% reduction in the likelihood of switching anticoagulants, while intermediate
ischemic stroke risk was paradoxically associated with a 12% increase in switching. Similar to
the new users of warfarin, however, high bleeding risk in the 12-month baseline was associated
with a lower risk of switching (RR: 0.82, 95% CI: 0.77-0.87).
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Table 20. Multivariable association between ischemic stroke and bleeding
risk prediction scores and anticoagulant switching
Risk Score
Demographic
CHA2DS2-VASc (ref: 0)
1
≥2
ATRIA (ref: 0-3)
4
≥5

All Warfarin New Users
RR
95% CI

All Dabigatran New Users
RR
95% CI

Prevalent Users
RR
95% CI

1.01
0.88

0.87-1.17
0.76-1.02

1.06
1.35

0.86-1.31
1.09-1.66*

1.12
0.91

1.03-1.22*
0.84-0.99*

0.95
0.69

0.83-1.08
0.61-0.79**

0.91
1.12

0.74-1.12
0.94-1.33

0.96
0.82

0.90-1.03
0.77-0.87**

*p<0.05
**p<0.001
Abbreviations: RR, Relative risk; ref, referent group; CI, confidence interval
NOTE: Adjusted for all other measured baseline covariates, except for those already included in risk scores, as shown in
Appendix table 2

4.2.3.2. Model fit diagnostics
Just as in Aim 1a, the Quasilikelihood under the Independence model Criterion (QIC)
was used to compare the insertion of CHADS2 and the HAS-BLED score as possible predictors
instead of the CHA2DS2-VASc and ATRIA risk scores. The model possibilities and resultant
QICs are shown in Appendix table 8 and again indicate that indeed the inclusion of the ATRIA
risk score leads to a better model fit across both the warfarin and prevalent user models, as that
model possibility had lower QICs than HAS-BLED. However, the models incorporating
CHADS2 and ATRIA (instead of CHA2DS2-VASc) had slightly lower QICs. The QICs were,
indeed, marginally higher for the model including CHA2DS2-VASc and ATRIA, but the
directionality and significance of the findings were similar. Moreover, intermediate ischemic
stroke risk was associated with a reduction in the likelihood of switching – not just high ischemic
stroke risk, but this difference was seen more strongly in the CHADS2 models compared with the
CHA2DS2-VASc models. These slight differences are likely due to differentiation differences in
patients at intermediate risk between the two scores. Despite this slight difference, CHA2DS2VASc and ATRIA were determined appropriate to be used in further analyses, because current
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clinical guidelines are emphasizing the use of the CHA2DS2-VASc score instead of the CHADS2
and the ATRIA score is better measured in this data source.
The relative risks and 95% confidence intervals for the baseline covariates included in the
model are shown in the Appendix (Appendix table 6). Key interactions (e.g., age and gender)
were also examined. As discussed in the previous section, age was examined via restriction to
the commercially-insured and Medicare supplement patients, and some slight differences were
noted. As with Aim 1a, gender was also investigated as an interaction term, and the term was not
found to significantly interact with either score.

4.2.3.3. Sensitivity analyses
Just as in Aim 1a, the cohorts were also stratified based on the data sources into
commercially-insured and Medicare supplemental claims (Appendix table 7). In the analysis of
the new user cohort, the directions and significance of the associations between bleeding
prediction risk scores and anticoagulant switching were largely similar to the original results for
both warfarin and dabigatran. However, the strength of the associations did differ somewhat
between the groups, with a stronger association between bleeding risk and switching seen in the
CCAE group. Some differences with regard to ischemic stroke risk were also seen between the
CCAE and Medicare supplement, however. Specifically, for warfarin initiators, no difference
was seen between ischemic stroke risk and switching in the CCAE population, but higher
ischemic stroke risk was associated with a slightly lower likelihood of switching in the Medicare
Supplement group. These differences could possibly be due to age influencing switching. There
were no differences in ischemic stroke risk and switching in the dabigatran initiators, however.
When examining the prevalent user cohort, there was one difference from the primary
results when stratifying on insurance status. Intermediate and high ischemic stroke risk was, in
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fact, associated with a reduction in the risk of switching within the 12-month follow-up period
among Medicare beneficiaries, but not in the commercially-insured patients. However, there
were few major differences in bleeding risk associations with switching between both the CCAE
and Medicare supplement population – bleeding risk just had a slightly stronger association with
not switching in the CCAE arm. Overall, the direction of the estimates was similar even when
examining the two groups separately.

127

AIM 2: COMPARATIVE EFFECTIVENESS

4.3. AIM 2: COMPARATIVE EFFECTIVENESS OF ANTICOAGULANTS
4.3.1. Descriptive statistics
4.3.1.1. Cohort identification
A total of 64,935 patients were included in the new user cohort, which was the primary
analysis. Newly-diagnosed new users were also examined as a secondary analysis. The clinical
and demographic characteristics of the cohort were previously shown in Aim 1a. In Aim 2,
patients were followed from anticoagulant initiation until they experienced an outcome of
interest, lost continuous eligibility, or were censored administratively on 12/31/2012 (the end of
available data). The mean patient follow-up time from initiation was 323 days with an
interquartile range of 113 days to 513 days. For the warfarin new users, the mean follow-up time
was 311 days; for dabigatran new users, the mean follow-up time was 349 days.

4.3.1.2. Crude outcome rates
The unadjusted rates of outcomes in the new user cohort were also examined. The
identification of clinical effectiveness and harm outcomes were previously discussed in Chapter
3 (Methods). Table 21 shows the observed rate of the clinical effectiveness and harm outcomes
by the type of anticoagulant initiated, standardized by 1,000 person-years of anticoagulant
exposure. The overall incidence of ischemic stroke, TIA, and VTE was 177.36 per 1,000 personyears (PYs). As shown below in Table 21, the overall unadjusted outcome rates were higher
among warfarin users compared with dabigatran users across both the new users and newlydiagnosed new users. For the effectiveness outcome endpoints, 54,667 (84.3%) of the patients
were censored either administratively on 12/31/2012 at the end of the data collection period or
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because of loss of continuous eligibility. For the harm outcome composites, 42,473 of the
patients were censored (65.4%) for these same reasons (administratively on 12/31/2012 or loss of
continuous eligibility).
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Table 21. Outcome rates per 1,000 person-years by anticoagulant initiated
New Users
Newly-diagnosed new users
Outcome Type
Warfarin
Dabigatran
Warfarin
Dabigatran
Clinical Effectiveness
Ischemic stroke
108.6
66.0
95.8
60.5
TIA
12.9
9.7
11.6
7.7
VTE
131.0
30.7
111.8
30.7
Composite
222.7
93.3
195.3
88.2
Harm
Hemorrhagic stroke/
intracranial hemorrhage
16.3
7.1
14.4
6.2
Gastrointestinal
hemorrhage
90.8
70.8
84.9
69.7
Other bleeding event
121.5
90.0
119.0
87.1
Hospitalization
391.7
310.8
375.3
309.6
Composite
419.1
338.6
401.6
337.4
21.8
13.1
22.9
13.4
Myocardial infarction
Abbreviations: TIA, Transient Ischemic Attack; VTE, Venous thromboembolism

4.3.2. Preliminary assessment of model specifications
As described in Chapter 3, the association between anticoagulant and the hazard of
experiencing an outcome was examined using Cox proportional hazards regression via bivariate
models, multivariable models, and propensity-score adjusted models. First, the baseline
characteristics and their associations with anticoagulant exposure and outcomes were assessed
for whether they are confounders and should be included (or not included) in the models. This
process was previously shown in the Analytic Diagram (Chapter 3, Figure 3) and the Cox
proportional hazards model (Chapter 3, Equation 2).
These baseline characteristics and their associations with exposure and the composite
outcomes are shown in Appendix table 9. These tests were done in order to determine which
covariates should be considered confounder variables (X3) for the analysis and thus included in
statistical adjustments. Overall, these tests indicated that there was only one variable (i.e.,
hormone use) that statistically should be considered an X1 variable, a variable statistically
associated solely with exposure that should not be included in propensity score analysis.238
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Accordingly, this variable was not included in the propensity score analyses. Other variables
were still included in the propensity score analysis as they were specified a priori based on
associations seen in the literature and were seen to be confounders.189
In addition to multivariable adjustment, inverse-probability treatment weighting (IPTW)
(with stabilized weights) was used as the primary propensity score adjustment method to control
for measured confounding to estimates of the average effect of treatment in the study population.
The kernel densities for the propensity score plots are shown in Appendix figure 1. After
examining individual covariates included in the propensity score model, the ones most
contributing to the non-overlap seen in the warfarin group (solid line) were the baseline
prescription benefits’ generosity and venous thromboembolism covariates. Applying stabilized
weights, the mean probabilities of receiving anticoagulation with dabigatran and warfarin
(referent) were 1.01 (SD: 1.25) and 1.00 (SD: 0.23), respectively. For the newly-diagnosed new
users, after applying stabilized weights, the groups’ mean probabilities were 1.00 (SD: 0.78) for
dabigatran and 1.00 (SD: 0.24) for warfarin, respectively. The balance of the covariates for the
new user groups following the IPTW is shown in Appendix table 10. Based on absolute
standardized differences (whereby >10 indicates imbalance), there was no imbalance in
covariates after weighting in the IPTW propensity score, which indicates good balance. The cstatistic for the propensity score for the new user group was 0.69, indicating good fit.
Standardized mortality ratio (SMR) propensity score weighting was also conducted as
another adjustment method to estimate the comparative effectiveness of anticoagulants. As
previously described in Chapter 3, in SMR weighting, weights are applied standardized to the
treated group, estimating the average treatment effects among treated patients (e.g., in this
setting, dabigatran patients). The mean SMR weight for the warfarin new user group was 0.48
(SD: 0.34) (as by definition, the dabigatran group’s mean was 1 with SD equal to 0).
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4.3.3. Main Results
4.3.3.1. Composite outcomes
These comparative effectiveness and safety of dabigatran and warfarin among new
anticoagulant initiators is shown in Table 22 for unadjusted, multivariable-adjusted, and
propensity score-adjusted models. The estimated treatment effects comparing new users of
dabigatran to warfarin on risk of outcomes among only outcomes that occurred in the inpatient
setting are shown in Appendix table 11.
For the primary analyses, applying propensity scores using IPTW yielded a point
estimate closer to the null, yielding a 30% reduction in the hazard of experiencing one of the
clinical effectiveness outcomes (adjusted HR: 0.70, 95% CI: 0.67-0.73). By contrast, dabigatran
users were no less likely to experience one of the harm outcomes included in the composite
endpoint (adjusted HR: 1.02, 95% CI: 0.99-1.05) compared with warfarin, after multivariable
adjustment.
For the multivariate analysis, compared with warfarin, dabigatran showed a 38%
reduction in the hazard of experiencing one of the clinical effectiveness composite outcomes
(adjusted [Hazard Ratio] HR: 0.62, 95% CI: 0.59-0.66). Multivariable models included
adjustment for the covariates that were described in Appendix table 10. The full model results
are shown in Appendix table 12 for the multivariable analyses among new users. Applying
SMR weighting moved the effect estimates slightly closer to the null, but the estimates of the
risk of harm were still similar as multivariable-adjusted and IPTW-weighted analyses. The
testing of assumptions, functional forms and model diagnostics are shown in Section 4.3.3.3.
In addition, applying trimming (5%) to the propensity scores did not appreciably change
the effect estimates. Applying trimming to the IPTW propensity scores resulted in an adjusted
HR of 0.68 (95% CL: 0.65-0.71) for the clinical effectiveness composite and an adjusted HR of
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1.01 (95% CL: 0.98-1.04) for the harm outcome composite in the survival analysis regresssion.
These findings are very similar to the original stabilized IPTW estimates shown in Table 22
below.

133

Table 22. Multivariable Cox models comparing dabigatran and warfarin use
and outcomes in atrial fibrillation
Outcome Type

Unadjusted
HR (95% CI)

MV Adjusted
HR (95% CI)

PS-IPTW
HR (95% CI)

PS-SMR
HR (95% CI)

Clinical
Effectiveness
Ischemic stroke
0.66 (0.62-0.70)**
0.85 (0.80-0.91)**
0.92 (0.87-0.98)*
0.90 (0.83-0.96)*
TIA
0.83 (0.70-0.97)*
0.97 (0.82-1.16)
1.07 (0.92-1.25)
1.00 (0.82-1.22)
VTE
0.25 (0.23-0.27)**
0.41 (0.38-0.45)**
0.51 (0.47-0.54)**
0.52 (0.47-0.56)**
Composite
0.43 (0.41-0.45)**
0.62 (0.59-0.66)**
0.70 (0.67-0.74)**
0.74 (0.69-0.78)**
Harm
Hemorrhagic
stroke/intracranial
hemorrhage
0.47 (0.40-0.57)**
0.62 (0.51-0.74)**
0.64 (0.54-0.75)**
0.65 (0.53-0.80)**
GI hemorrhage
0.85 (0.80-0.90)**
1.08 (1.01-1.15)*
1.19 (1.12-1.26)**
1.08 (1.00-1.15)
Other bleeding
0.80 (0.76-0.84)**
0.91 (0.86-0.96)**
0.91 (0.86-0.96)**
0.91 (0.86-0.97)*
Hospitalization
0.84 (0.81-0.86)**
0.97 (0.94-1.01)
1.00 (0.97-1.02)
0.98 (0.95-1.01)
Composite
0.85 (0.83-0.88)**
1.00 (0.97-1.03)
1.02 (0.99-1.05)
1.00 (0.97-1.03)
0.66 (0.57-0.76)**
0.86 (0.74-0.99)*
0.88 (0.77-1.00)
0.87 (0.74-1.02)
AMI
*p<0.05; **p<0.001
Abbreviations: HR, Hazard Ratio; CI, Confidence interval; MV, multivariable model; PS, Propensity score; IPTW,
Inverse probability treatment weighting; SMR, Standardized Mortality Ratio; TIA, Transient ischemic attack; VTE,
venous thromboembolism; GI, gastrointestinal; AMI, Acute Myocardial Infarction

4.3.3.2. Cause-specific outcomes
The cause-specific survival analyses yielded similar results. In these analyses, patients
were followed from anticoagulant initiation until any outcome was experienced, they lost
continuous eligibility or they were censored administratively at 12/31/2012. In these primary
analyses using IPTW, initiating dabigatran resulted in a statistically significant reduction in the
hazard of VTE (adjusted HR: 0.51, 95% CI: 0.47-0.54), ischemic stroke (adjusted HR: 0.92, 95%
CI: 0.87-0.98), hemorrhagic stroke (adjusted HR: 0.64, 95% CI: 0.54-0.76), other bleeding
(adjusted HR: 0.91, 95% CI: 0.86-0.96), and myocardial infarction (adjusted HR: 0.88, 95% CI:
0.77-1.00) compared with warfarin initiation. However, dabigatran was also associated with an
increased hazard of GI hemorrhage (adjusted HR: 1.19, 95% CI: 1.12-1.26). Hospitalizations and
TIAs did not differ between the anticoagulant groups.
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4.3.3.3. Model diagnostics
The deviance residuals showed appropriate distribution for the main covariates assessed.
Proportional hazards assumptions were also tested for both the composite of effectiveness and
composite of harm outcomes. These tests did not reveal any violations of the assumption for the
models. These tests are shown here in the Kaplan Meier plots (Appendix figure 2) for the
association of anticoagulation with the clinical effectiveness and harm composites among new
users. In addition, examining the Schoenfeld residuals also did not yield any violations of the
proportional hazards assumptions. Including an interaction term for time in the models also did
not indicate a violation of the proportional hazards assumption. In addition, supremum tests for
heterogeneity of treatment effect were non-significant. The AICs were lower for the full
multivariable model compared with other models.

4.3.4. Sensitivity analyses
4.3.4.1. Subgroup analyses
4.3.4.1.1. Newly-diagnosed new users
The effect estimates for the comparative effectiveness and safety of anticoagulation
among newly-diagnosed new users as a sensitivity analysis are shown in Table 23. Similar to
new users, the subgroup of newly-diagnosed new users also showed a significant reduction in the
hazard of experiencing a clinical effectiveness outcome when initiating dabigatran compared
with warfarin. The overall associations are very similar; in fact, a stronger reduction in clinical
outcomes was observed when examining the newly-diagnosed new users (e.g., the HR is further
away from the null). Thus, if there was unmeasured confounding, it would be likely to bias the
estimates down and away from the null (as the warfarin group would likely have higher rates of
frailty compared with dabigatran as seen in Aim 1). This suggests that perhaps unmeasured
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confounding may be more present among the newly-diagnosed new users than the overall new
user sample (or that dabigatran is more beneficial in newly-diagnosed patients). When examining
the comparative safety of the agents via the safety composite, dabigatran and warfarin appeared
to be no different in reducing the hazard of experiencing an adverse outcome. These results were
also similar to the overall new user subgroup.
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Table 23. Multivariable Cox models comparing the use of dabigatran
with warfarin and outcomes in newly-diagnosed AF patients
Outcome Type

Unadjusted
HR (95% CI)

MV Adjusted
HR (95% CI)

PS-IPTW
HR (95% CI)

PS-SMR
HR (95% CI)

Clinical
Effectiveness
Ischemic stroke 0.68 (0.62-0.74)** 0.86 (0.78-0.94)**
0.89 (0.82-0.97)*
0.90 (0.81-1.00)
TIA
0.73 (0.57-0.93)*
0.84 (0.65-1.09)
0.86 (0.68-1.10)
0.83 (0.63-1.11)
VTE
0.29 (0.26-0.32)** 0.45 (0.40-0.51)**
0.45 (0.40-0.50)**
0.55 (0.49-0.63)**
Composite
0.46 (0.43-0.50)** 0.65 (0.60-0.70)**
0.67 (0.62-0.71)**
0.75 (0.69-0.82)**
Harm
Hemorrhagic
stroke/intracranial
hemorrhage
0.46 (0.35-0.60)** 0.58 (0.44-0.76)**
0.58 (0.45-0.75)**
0.62 (0.46-0.83)*
GI hemorrhage
0.88 (0.81-0.96)*
1.08 (0.99-1.19)
1.10 (1.01-1.19)**
1.09 (0.98-1.21)
Other bleeding 0.78 (0.72-0.84)** 0.86 (0.79-0.93)**
0.86 (0.80-0.93)**
0.85 (0.78-0.93)**
Hospitalization 0.86 (0.83-0.90)**
0.98 (0.94-1.02)
0.98 (0.94-1.02)
0.98 (0.93-1.03)
Composite
0.88 (0.84-0.91)**
1.00 (0.96-1.04)
1.00 (0.96-1.04)
1.00 (0.95-1.05)
0.63 (0.52-0.76)** 0.80 (0.66-0.98)*
0.85 (0.71-1.01)
0.82 (0.66-1.02)
AMI
Abbreviations: AF, Atrial Fibrillation; HR, Hazard Ratio; MV, Multivariate; PS, Propensity score; IPTW, Inverse
probability treatment weighting; SMR, Standardized Mortality Ratio; TIA, transient ischemic attack; VTE, venous
thromboembolism; GI, gastrointestinal; AMI, Acute Myocardial Infarction

4.3.4.1.2. Stratification by commercial insurance and Medicare patients
The analyses were also conducted separately among commercially-insured beneficiaries
and Medicare supplement beneficiaries (Appendix table 13) for both new users and newlydiagnosed new users. No statistically significant differences in the harm composite were seen
between the users of dabigatran compared with warfarin for any subgroup. However, dabigatran
was seen to be even more protective in terms of the clinical effectiveness endpoint compared
with warfarin within commercially-insured beneficiaries (adjusted HR: 0.46, 95% CI: 0.42-0.51
for new users). While still statistically significant, the effect of dabigatran in reducing the hazard
of experiencing a clinical effectiveness outcome was less pronounced among only the Medicare
supplement beneficiaries (adjusted HR: 0.77, 95% CI: 0.73-0.81). All in all, the associations
were similar across the groups, only the strength of the associations slightly differed for the
clinical effectiveness endpoint.
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4.3.4.1.3. Stratification by dabigatran strengths
The comparative effectiveness and safety of the two dabigatran strengths (75mg and
150mg) were also studied in separate survival analyses using warfarin as the referent group.
These results are shown in Appendix table 14. Using both multivariable and PS-adjustment,
dabigatran 150mg showed a statistically significant reduction in the hazard of experiencing one
of the composite outcomes compared with warfarin. However, the comparative safety of
dabigatran 150mg did not differ compared to warfarin. By contrast, there was no statistical
difference in clinical effectiveness seen between dabigatran 75mg and warfarin; however,
dabigatran 75mg showed an increased hazard of experiencing one of the harm outcomes, which
could possibly be due to some unmeasured confounding.

4.3.4.2. Sensitivity analyses
4.3.4.2.1. Influence of mortality
A known limitation of the Truven Health MarketScan® is that when patients lose
continuous eligibility, it is unknown whether they are changing plans or whether they have
actually died. Death occurrences, outside of the hospital setting, within these data are unknown.
First, to attempt to explore this limitation, the discharge location of the patients who experienced
a hospital admission as their censoring outcome for the harm outcome composite was examined.
Of the 14,219 warfarin patients who were hospitalized in the follow-up period after initiation,
381 (2.7%) patients were coded as “Died” or “Other died status” upon discharge from their
hospitalization outcome. By contrast, of the 5,932 dabigatran patients who were hospitalized, 95
(1.6%) were coded with “Died” or “Other died status” for their discharge dispensation location.
Crude test statistics on this difference in the proportion of hospitalizations associated with
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mortality yielded a chi-square of 22.44 (p<0.001), suggesting that there was a significant
difference in the proportion of hospitalizations in the follow-up period that resulted in death.
Secondly, the proportion of patients who were lost to follow-up (and not censored
administratively on 12/31/2012) was also examined. In sum, 5,543 (12.6%) of warfarin patients
and 2,314 (11.0%) of dabigatran patients were lost to follow-up (chi-square 35.97, p<0.001),
suggestive of possible significant differences in the proportion of patients who were lost to
follow-up. These patients, by definition, did not experience any one of the composite outcomes.
Finally, this limitation was explored by again conducting the multivariable survival
analysis between anticoagulant initiation and the hazard of experiencing one of the composite
outcomes – this time applying a statistical assumption that every patient who lost continuous
eligibility actually died. In other words, those who were lost to follow-up were included in the
composite endpoints as another outcome, censored at the date they were lost to follow up. These
findings, along with the other sensitivity analyses in this section are shown in Table 24. The
sensitivity analyses on mortality suggest that dabigatran only slightly reduced the hazard of
experiencing both a clinical effectiveness and harm outcomes when assuming that all patients
who lost continuous eligibility actually died. These results were in contrast to the primary
findings particularly when considering magnitude, whereby in the original results, no significant
difference in the reduction of the harm outcomes was found.
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Table 24. Sensitivity analyses comparing the use of dabigatran with warfarin and
outcomes in AF patients initiating anticoagulation
Outcome Type

Effectiveness composite
HR (95% CI)

Harm composite
HR (95% CI)

Original results
MV-adjusted
0.62 (0.59-0.66)**
1.00 (0.97-1.03)
PS-IPTW
0.70 (0.67-0.74)**
1.02 (0.99-1.05)
Sensitivity analysis 1
MV-adjusted
0.96 (0.93-0.99)*
0.92 (0.89-0.96)*
PS-IPTW
0.92 (0.89-0.96)**
0.97 (0.94-0.99)*
Sensitivity analysis 2
MV-adjusted
0.63 (0.60-0.66)**
N/A
PS-IPTW
0.71 (0.68-0.74)**
N/A
Sensitivity analysis 3
MV-adjusted
0.63 (0.60-0.66)**
N/A
PS-IPTW
0.71 (0.68-0.74)**
N/A
*p<0.05; **p<0.001
Abbreviations: AF, Atrial Fibrillation; HR, Hazard Ratio; MV, Multivariate; PS, Propensity score; IPTW, Inverse
probability treatment weighting; SMR, Standardized Mortality Ratio; TIA, transient ischemic attack; VTE, venous
thromboembolism; GI, gastrointestinal; AMI, Acute Myocardial Infarction
NOTE: Sensitivity analysis 1: Influence of mortality by including patients lost-to-follow-up; Sensitivity analysis 2:
Inclusion of transient ischemic attack; Sensitivity analysis 3: Inclusion of hemorrhagic stroke

Overall, these explorations suggest that there could be some differential effects of
dabigatran on the risk of mortality compared with warfarin, in that dabigatran may lead to
slightly lower mortality risk. Specifically, there were fewer dabigatran patients who experienced
morality upon hospitalization, and fewer dabigatran patients were lost to follow-up – outside of
being censored administratively on 12/31/2012. However, none of these explorations were direct
measures, and the re-analyses of the Cox proportional hazards regression relied on the very
unlikely assumption that everyone who was lost to follow-up actually died. Thus, it could be
reasonably assumed that not being able to have mortality as part of the composite outcomes may
not have significantly affected the results, but it is still a possible limitation of the Truven Health
MarketScan® database.
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4.3.4.2.2. Inclusion of transient ischemic attacks (TIAs)
While some algorithms have recommended including transient ischemic attacks as part of
the composite endpoint for the effectiveness of anticoagulants, the specificity of identifying them
in claims data has been called into question. To test the robustness of results, TIA was removed
as part of the composite clinical effectiveness endpoint, which reduced the overall number of
events by 186 in the composite endpoint. Because the overall event rate was almost the exact
same, the multivariate-adjusted survival analysis yielded the exact same hazard ratios, which
were the same as the initial results without including TIA (Table 24). Among the newlydiagnosed new users, the results were similar: adjusted HR: 0.65, 95% CL: 0.61-0.70) and PSIPTW HR: 0.67 (95% CL: 0.63-0.71). These findings suggest that the overall results were robust
to the removal of TIA in the clinical effectiveness composite.

4.3.4.2.3. Inclusion of hemorrhagic stroke
To perhaps provide a closer analog to the RE-LY trial that was used for FDA-approval of
dabigatran, an outcome of hemorrhagic stroke was also included in the primary clinical
effectiveness endpoint. Specifically, the RE-LY trial included hemorrhagic stroke in the primary
stroke or systemic embolism in their primary endpoint. In our study’s sensitivity analysis,
patients were then followed from anticoagulation initiation until they experienced either
ischemic stroke, VTE, TIA, or hemorrhagic stroke/intracranial hemorrhage or were censored due
to loss of continuous eligibility or administratively on 12/31/2012. In total, an additional 283
events were identified in our study and included in the composite clinical effectiveness endpoint.
The multivariable survival analysis and analysis using IPTW were very similar to the primary
results (Table 24). Among newly-diagnosed new users, the adjusted HR was 0.65 (95% CI: 0.61-
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0.70). These findings suggest that the overall results were robust to the inclusion of hemorrhagic
stroke in the clinical composite of effectiveness.

4.3.4.2.4. Heterogeneity of treatment effects
When examining the IPTW propensity score deciles, a little underlying heterogeneity for
the estimated treatment effects was seen, particularly for the composite of the risk of harm
outcomes (Appendix figure 3). However, there does appear to be some treatment effect
heterogeneity in the lower IPTW propensity score deciles, indicating that dabigatran treatment
was more beneficial in patients less likely to be treated with dabigatran. Said another way,
anticoagulation with warfarin was less beneficial in patients who were more likely to be treated
with warfarin. These finding suggest there could still be some imbalance in covariates, although
covariate distributions post-propensity score weighting were similar (Appendix table 10). There
were, however, few individuals treated with dabigatran contrary to prediction, as can be seen in
the kernel density plots.
As previously described, subgroup analyses stratifying by baseline characteristics were
also conducted to examine any treatment effect heterogeneity. Specifically, strata of patients with
ischemic stroke, VTE, CHF, AMI and levels of prescription benefits’ generosity, ATRIA,
CHA2DS2-VASc, and ages were examined using stratum-specific propensity scores and Cox
proportional hazards regression (Appendix table 15). Some treatment effect heterogeneity was
noted in the hazard of experiencing the clinical effectiveness composite of dabigatran compared
with warfarin, particularly among patients with previous VTE (HR: 0.50, 95% CI: 0.35-0.72),
ATRIA ≥ 5 (HR: 0.73, 95% CI: 0.60-0.90), CHA2DS2-VASc ≥ 2 (HR: 0.84, 95% CI: 0.77-0.92),
and age ≥ 75 years (HR: 0.89, 95% CI: 0.79-1.01). Dabigatran patients with higher ATRIA (≥ 5),
CHA2DS2-VASc ≥ 2 and age ≥ 75 years were also noted to have a slightly lower hazard of
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experiencing the harm composite compared with patients on warfarin with the same
characteristics.

4.3.4.3. Exploratory analyses
4.3.4.3.1. Assessment of International Normalized Ratios (INRs)
The International Normalized Ratio laboratory results were collected from the laboratory
data files in the Truven Health MarketScan® database for the AF patients included in the cohort.
The Laboratory Observation Identifiers Names and Codes (LOINC) identifier for the INR test
was “5902-2”, describing a coagulation assay that included an INR test. CPT procedure codes
known to be associated with INR test were assessed, and the code “85610” was found to be the
only one in the laboratory files. Of these, the only LOINC identifier associated with INRs was
the 5902-2. Of the available INRs in the database, INRs were captured when they occurred on or
after the index prescription fill date, before one of the outcomes included in the composite, and
before loss of continuous eligibility or administrative censoring on 12/31/2012.
In total, 463 warfarin initiators had any INR laboratory values available within the
follow-up period for a total of 1,816 INRs measured. The mean INR laboratory value was 2.24
(SD: 0.91). Each patient’s available measured INRs were summed, averaged, and calculated for
the proportion of INRs which were in therapeutic range (2.0-3.0). Two-hundred and three
warfarin initiators had only 1 INR measured in the eligible follow-up period; the mean number
of INRs measured for each patient was 3.92 (SD: 5.03). For these 463 warfarin patients, the
average mean INR value over the follow-up period was 2.10 (SD: 0.87). Of the 260 warfarin
patients with at least 2 INRs measured in the data, more than 56.2% had <60% of their measured
INRs within the therapeutic range of 2.0-3.0 for anticoagulation in atrial fibrillation.
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4.3.4.3.2. Medication adherence
Medication adherence and refill patterns were also examined descriptively. The
proportion of patients refilling their anticoagulation therapy at least once was also calculated
post-initiation. Of the 43,865 patients initiating warfarin, 81.8% refilled their warfarin
prescription at least once. Of the 21,070 patients initiating dabigatran, 77.7% refilled their
prescription at least once. Comparing the two anticoagulants using multivariate logistic
regression, adjusting for the measured baseline characteristics, demonstrated that the dabigatran
patients were indeed significantly less likely to refill their prescription. Specifically, initiating
dabigatran was associated with a 20% lower odds of refilling dabigatran (OR: 0.80, 95% CI:
0.76-0.83). The bivariate OR comparing dabigatran refill likelihood to warfarin refill likelihood
was also very similar before adjusting for the baseline characteristics (OR: 0.78, 95% CI: 0.740.81).
Adherence to each anticoagulant was calculated as the proportion of days covered (PDC)
by the prescription supply calculated from refill records in the claims in the 12-months postanticoagulation initiation. Conforming to current literature, if the patient had ≥80% of days
covered with prescription supply, a patient was defined as adherent. In total, 33,711 patients
were continuously enrolled for at least 12 months post-anticoagulation initiation and had their
medication adherence patterns assessed. Among these patients, the mean PDC was 0.62 (SD:
0.33) and 0.64 (SD: 0.35) for warfarin and dabigatran initiators, respectively. In total, 41.3%
were adherent to warfarin, and 48.6% were adherent to dabigatran. Multivariable logistic
regression was used to compared the odds of being adherent to dabigatran compared with
warfarin over the 12-months post anticoagulation initiation, adjusting for the measured baseline
characteristics. This analysis indicated that patients filling dabigatran had a higher (45%)
likelihood of being adherent (OR: 1.45, 95% CI: 1.38-1.52). Notably, patients were more likely
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to be adherent with high ischemic stroke risk (OR: 1.57, 95% CI: 1.21-1.50) compared with
those with low ischemic stroke risk. However, elevated bleeding risk was not statistically
associated with adherence.
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AIM 3: CLINICAL EFFECTS OF SWITCHING ANTICOAGULANTS

4.4. AIM 3: CLINICAL EFFECTS ASSOCIATED WITH SWITCHING
4.4.1. Descriptive statistics
4.4.1.1. Cohort identification
In total, 64,935 AF patients were treatment-naïve and met overall study criteria. Of the
43,865 patients who initiated warfarin, 42,752 patients were included in the cohort. For this
study, only patients switching to dabigatran or warfarin were assessed, so 1,113 patients were
excluded as switchers because they switched from warfarin to rivaroxaban in the follow-up
period. In total, 2,373 warfarin initiators also contributed follow-up time as “switchers”, because
they switched to dabigatran after initiating warfarin before they experienced any of the measured
outcomes, lost continuous eligibility or were censored administratively. These patients are
characterized as “warfarin switchers” throughout this aim. Of the 20,070 patients who initiated
dabigatran, 19,799 patients were included in the cohort; 1,271 patients were excluded because
they switched from dabigatran to rivaroxaban in the follow-up period. In addition, 959
dabigatran initiators also contributed follow-up time as “switchers” and are characterized as
“dabigatran switchers” through this aim. Of the patients who switched, warfarin patients
switched in a mean 114.5 days (SD: 125.0), and dabigatran patients switched in a mean 116.8
days (SD: 134.6).

4.4.1.2. Baseline characteristics
Baseline characteristics are shown in Table 25. Patients were only included once in the
descriptive statistics. If patients contributed any follow-up time as “switchers”, they were
classified as “switchers” and not as “non-switchers” for the numbers and percentages of the
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baseline characteristics, because these are baseline characteristics measured in the 12-month
period prior to the first anticoagulant initiation.
As expected, the distribution of the baseline characteristics concur with the findings in
Aim 1b, which examined characteristics associated with switching over the 12-month follow-up
period in patients who retained continuous eligibility for 12 months. Here in Aim 3, patients who
initiated warfarin and switched to dabigatran were younger, have slightly better prescription
benefits generosity, and were less likely to have had ischemic stroke, congestive heart failure, or
other comorbidities. Patients who switched from warfarin to dabigatran also had lower baseline
ischemic stroke risk and bleeding risk. In addition, warfarin switchers were slightly more likely
to be using concomitant antiarrhythmic therapies compared with non-switchers.
Similarly to Aim 1b, patients who initiated dabigatran and then switched to warfarin were
mostly similar to those who did not switch to warfarin – with some small exceptions. Patients
who switched were slightly more likely to be older, female and have higher ischemic stroke risk
compared with non-switchers. However, patients who switched were also slightly less likely to
have ischemic stroke, congestive heart failure, acute myocardial infarction, or higher bleeding
risk at baseline compared with non-switchers. Overall, the characteristics were more
descriptively similar among dabigatran switchers and non-switchers compared with warfarin
switchers and non-switchers.
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Table 25. Baseline characteristics of warfarin and dabigatran switchers
and non-switchers
Warfarin
Baseline Characteristic switcher, N
(%)
Demographic
Age
< 55 years
55-64 years
65-74 years
≥ 75 years
Male Gender
Region
Northeast
North Central
South
West
Insurance plan
Comprehensive
HMO
POS
PPO
CDHP
Benefits generosity
No/poor coverage
Fair coverage
Good coverage
Clinical
Ischemic Stroke
Congestive Heart Failure
VTE
Hyperlipidemia
Hypertension
Myocardial infarction
Coronary artery disease
Peripheral vascular
disease
Renal impairment
Diabetes
Major bleeding
Anemia
Peptic Ulcer disease
Sleep Apnea
Cognitive deficiency
CCI
0
1-2
3-5
6-8

Warfarin
nonswitcher, N
(%)

Absolute
SD

224 (9.4)
3,557 (8.8)
681 (28.7)
9,143 (22.6)
600 (25.3)
8,914 (22.1)
868 (36.6) 18,765 (46.5)
1,435 (60.5) 23,467 (58.1)

Dabigatran
switcher,
N (%)

Dabigatran
non-switcher,
N (%)

Absolute
SD

2.8
17.1
9.4
24.6
5.5

100 (10.3)
283 (29.2)
235 (24.3)
350 (36.2)
534 (55.2)

2,728 (14.5)
5,812 (30.9)
4,290 (22.8)
6,001 (31.9)
12,082 (64.2)

18.3
4.6
4.5
10.9
20.8

7,090 (17.6)
14,373 (35.6)
10,982 (27.2)
7,099 (17.6)

12.7
13.3
15.3
3.0

156 (16.1)
282 (29.1)
357 (36.9)
162 (16.7)

3,177 (16.9)
5,509 (29.3)
6,971 (37.0)
2,874 (15.3)

2.8
0.5
0.3
4.9

863 (36.4) 14,439 (35.8)
192 (8.1)
6,086 (15.1)
150 (6.3)
1,762 (4.4)
1,000 (42.1) 15,398 (38.1)
47 (2.0)
635 (1.6)

1.5
34.0
10.8
9.7
4.0

334 (34.5)
89 (9.2)
60 (6.2)
423 (43.7)
21 (2.2)

6,030 (32.0)
1,543 (8.2)
1,083 (5.8)
8,766 (46.6)
422 (2.2)

6.4
4.7
2.3
6.9
0.0

77 (3.2)
1,508 (3.7)
1,108 (46.7) 19,762 (49.0)
1,188 (50.1) 19,079 (47.3)

3.9
5.4
6.5

3 (0.3)
458 (47.3)
507 (52.4)

55 (0.3)
8,748 (46.5)
10,028 (53.3)

0.0
1.9
2.1

141 (5.9)
4,476 (11.1)
488 (20.6) 11,676 (28.9)
71 (3.0)
5,236 (13.0)
1,094 (46.1) 20,074 (49.7)
1,660 (70.0) 2,980 (73.3)
59 (2.5)
1,898 (4.7)
674 (28.4) 13,971 (34.6)

29.7
25.9
78.5
8.4
7.9
19.5
16.9

43 (4.4)
162 (16.7)
28 (2.9)
488 (50.4)
684 (70.7)
16 (1.7)
294 (30.4)

1,366 (7.3)
3,480 (18.5)
480 (2.6)
9,344 (49.6)
12,991 (69.0)
457 (2.4)
5,264 (28.0)

19.3
6.3
2.5
1.8
4.0
7.6
20.2

337 (14.2)
726 (30.6)
782 (33.0)
440 (18.5)

136 (5.7)

3,680 (9.1)

55 (5.7)

1,011 (5.4)

5,299 (13.1)
12,913 (32.0)
5,608 (13.9)
8,301 (20.6)
306 (0.8)
4,137 (10.3)
420 (1.0)

19.9
37.4
6.5
17.3
35.4
8.9
6.3
18.0

149 (6.3)
702 (29.6)
236 (10.0)
281 (11.8)
9 (0.4)
279 (11.8)
8 (0.3)

57 (5.9)
239 (24.7)
81 (8.4)
96 (9.9)
3 (0.3)
115 (11.9)
3 (0.3)

1,089 (5.8)
5,016 (26.6)
1,760 (9.4)
2,028 (10.8)
88 (0.5)
2,271 (12.1)
111 (0.6)

1.8
0.6
5.6
4.9
4.1
5.2
0.8
7.7

715 (30.1)
9,014 (22.3)
1,051 (44.3) 16,123 (39.9)
514 (21.7) 11,107 (27.5)
73 (3.1)
3,045 (7.5)

21.5
10.5
17.8
34.7

329 (34.0)
419 (43.3)
187 (19.3)
23 (2.4)

6,362 (33.8)
8.068 (42.8)
3,549 (18.9)
636 (3.4)

0.5
21.8
1.3
9.1
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≥9
CHADS2
0
1
≥2
CHA2DS2-VASc
0
1
≥2
ATRIA
0-3
4
≥5
HAS-BLED
0-2
≥3
Hospitalizations
≥1
Catheter ablation
Medication Use
Antiplatelet therapy
Gastroprotective agent
Antiarrhythmic
Digoxin
Beta-blocker
Calcium channel blocker
ACEI/ARB
Statin
Hormone

20 (0.8)

1,090 (2.7)

29.8

10 (1.0)

216 (1.2)

2.8

318 (13.4)
3,963 (9.8)
743 (31.3) 10,275 (25.5)
1,312 (55.3) 26,141 (64.7)

14.2
15.7
21.8

141 (14.6)
330 (34.1)
497 (51.3)

3,022 (16.1)
6,331 (33.6)
9,478 (50.3)

5.6
1.3
2.3

209 (8.8)
2,629 (6.5)
468 (19.7)
5,684 (14.1)
1,696 (71.5) 32,066 (79.4)

11.1
18.6
19.7

96 (9.9)
209 (21.6)
663 (68.5)

2,234 (11.9)
4,203 (22.3)
12,394 (65.8)

9.0
2.2
6.3

1,927 (81.2) 27,852 (69.0)
193 (8.1)
3,882 (9.6)
253 (10.7)
8,645 (21.4)

30.2
7.4
44.9

817 (84.4)
68 (7.0)
83 (8.6)

15,715 (83.5)
1,341 (7.1)
1,775 (9.4)

2.6
0.5
3.9

2,207 (93.0) 35,020 (86.7)
166 (7.0)
5,359 (13.3)

21.5
32.9

914 (94.4)
54 (5.6)

17,511 (93.0)
1,320 (7.0)

5.9
8.3

1,119 (47.2) 23,546 (58.3)
17 (0.7)
364 (0.9)

26.0
3.4

413 (42.7)
11 (1.1)

8,530 (45.3)
431 (2.3)

6.2
16.1

268 (11.3)
262 (11.0)
577 (24.3)
406 (17.1)
1,554 (65.5)
1,047 (44.1)
1,413 (59.5)
1,275 (53.7)
120 (5.1)

7.6
7.7
5.1
0.3
4.4
4.8
6.4
2.3
9.5

106 (11.0)
109 (11.3)
247 (25.5)
142 (14.7)
667 (68.9)
410 (42.4)
535 (55.3)
517 (53.4)
60 (6.2)

2,409 (12.8)
2,009 (10.7)
4,788 (25.4)
2,650 (14.1)
12,595 (66.9)
7,634 (40.5)
10,628 (56.4)
10,006 (53.1)
832 (4.4)

7.7
2.5
0.3
2.2
4.7
19.4
2.5
0.7
10.3

5,305 (13.1)
5,162 (12.8)
9,116 (22.6)
6,848 (17.0)
27,194 (67.4)
17,009 (42.1)
22,909 (56.7)
22,073 (54.7)
1,445 (3.6)

Abbreviations: HMO, Health maintenance organization; POS, Point-of-service; PPO, Preferred provider organization; CDHP,
consumer-driven health plan; CCI, Charlson Comorbidity Index; ACEI, angiotensin-converting-enzyme inhibitor; ARB,
angiotensin receptor blocker

4.4.1.3. Crude outcome rates
The outcome rates of patients who switched anticoagulation following initiation were
also examined standardized by 1,000 person-years of exposure in the cohort. These rates are
shown in Table 26 for the clinical effectiveness composite, harm composite, and AMI below;
just as in Aim 2, AMI was not included in either of the aforementioned composites but was
followed separately as an outcome. As described in Chapter 3, patients were not censored for the
other two outcomes if they experienced the outcome of interest for each analysis. Said another
way, patients who experienced an ischemic stroke were censored for the clinical effectiveness
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composite but not for the harm composite or the acute myocardial infarction outcome. As seen in
the table, the crude outcome rates were higher among patients who were non-switchers compared
with switchers for both warfarin and dabigatran switchers. For instance,, patients who did not
switch from warfarin to dabigatran had a crude clinical effectiveness outcome rate of 238.5
events/1,000 person-years compared with those who switched (51.2 events/1,000 person years).
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Table 26. Outcome rates per 1,000 person-years by warfarin and
dabigatran switching groups
Warfarin
§
Non-switchers
Switchers

Dabigatran
§
Non-switchers
Switchers

Outcome Type
Clinical effectiveness
51.2
238.5
66.8
92.7
composite
273.0
495.7
345.5
408.2
Harm Composite
8.8
19.5
9.4
11.9
Acute myocardial infarction
§
Warfarin switchers: patients who switched from warfarin to dabigatran; Dabigatran switchers: patients who
switched from dabigatran to warfarin

4.4.2. Main Results
4.4.2.1. Composite outcomes
The associations between anticoagulant switching and outcome composites were also
assessed using multivariable Cox proportional hazards regression (Table 27), using the
aforementioned methods and model specifications in Chapter 3. As previously described,
patients were censored at their first outcome, whether it was a clinical effectiveness or harm
outcome, or acute myocardial infarction.
Multivariable models were adjusted for the measured baseline characteristics in the 12months prior to anticoagulant initiation that were previously described in Chapter 3. The full
model results are shown in Appendix table 16 for warfarin analyses and Appendix table 17 for
dabigatran analyses. Patients who switched from warfarin to dabigatran were 32% less likely to
experience a clinical effectiveness outcome (adjusted HR: 0.68, 95% CI: 0.66-0.71), 32% less
likely to experience a harm composite outcome (adjusted HR: 0.68, 95% CI: 0.65-0.71), and
32% less likely to experience an AMI (HR: 0.68, 95% CI: 0.66-0.70). Patients who switched
from dabigatran to warfarin were no more likely to experience a clinical effectiveness outcome
(adjusted HR: 1.02, 95% CI: 0.97-1.08), a harm outcome (adjusted HR: 1.06, 95% CI: 0.971.15), or an AMI (adjusted HR: 0.99, 95% CI: 0.94-1.04).
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Table 27. Multivariable Cox models of the association between anticoagulant switching and
clinical effectiveness and harm outcomes
Anticoagulant groups
(referent: non-switchers)

Clinical
effectiveness
composite
HR (95% CI)

Harm composite
HR (95% CI)

Acute myocardial
infarction
HR (95% CI)

Warfarin to dabigatran switchers
Unadjusted
0.67 (0.65-0.70)** 0.67 (0.64-0.70)** 0.66 (0.64-0.68)**
MV-adjusted
0.68 (0.66-0.71)** 0.68 (0.65-0.71)** 0.68 (0.66-0.70)**
Dabigatran to warfarin switchers
Unadjusted
1.02 (0.97-1.08)
1.05 (0.97-1.14)
0.99 (0.94-1.04)
MV-adjusted
1.02 (0.97-1.08)
1.06 (0.97-1.15)
0.99 (0.94-1.04)
*p<0.05; **p<0.001
Abbreviations: HR, Hazard Ratio; CI, Confidence interval; MV, multivariable model
REF: Non-switching
4.4.2.2. Model diagnostics and specifications

Categories of covariates with fewer than 2% of patients with that characteristic were
combined with another relevant level (e.g., “No”, “Poor”, and “Fair” prescription benefits
generosity) or omitted from the model adjustments (e.g., consumer-driven health plan, cognitive
deficiency, and peptic ulcer disease), when possible. These were done to ensure that very small
cell sizes for certain categories would not affect the model dispersion or the positivity
assumption. The deviance residuals showed appropriate distributions. Proportional hazards
assumptions were tested for both composite outcomes and the AMI for the models. These tests
did not reveal any violations of the assumptions for the models, using either Schoenfeld residuals
or including an interaction term for time.

4.4.3. Sensitivity analyses
4.4.3.1. Primary analysis: Stratification by commercial insurance and Medicare beneficiaries
Just as in Aim 1a, the cohorts were also stratified based on the data sources into
commercially-insured and Medicare supplemental claims, and the analyses were conducted
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separately (Appendix table 18). The associations between switching anticoagulants were similar
to the main results. Switching from dabigatran to warfarin trended towards an increased risk of
the harm composite compared with non-switching when examining the Medicare supplement
group separately. Despite the small sample sizes, dabigatran switching was seen to be slightly
more harmful among Medicare beneficiaries compared with commercially-insured patients
alone. The other associations were very similar when analyzing the subgroups individually.
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CHAPTER 5: DISCUSSION
The goal of the dissertation was to examine the utilization, comparative effectiveness and
safety, and clinical effects of switching anticoagulation among patients with atrial fibrillation
(AF) in real-world US clinical practice. These three aims document the results of this research.
In summary, in Aim 1, we sought to examine the utilization and switching of anticoagulation
among patients initiating anticoagulation for the prevention of ischemic stroke and systemic
embolism in atrial fibrillation, focusing in particular on how predictions of ischemic stroke and
bleeding risk influenced anticoagulant selection. In Aim 2, we examined the comparative
effectiveness of dabigatran and warfarin among patients with non-valvular atrial fibrillation
newly-initiating anticoagulation. In Aim 3, we examined the clinical effects of switching
anticoagulation and whether switching to a different anticoagulant was associated with a higher
risk of stroke and other clinical effects. This concluding chapter synthesizes the findings from
these three aims, discusses the findings’ implications, highlights the strengths and weaknesses of
the study, and provides suggestions for further work in this area.

5.1. SUMMARY OF FINDINGS
5.1.1. Aim 1: Patterns of use and switching of anticoagulants
5.1.1.1. Aim 1a: Patterns of anticoagulant utilization
In this large study of 64,935 AF patients initiating anticoagulation, we found that
demographic and clinical characteristics differed strongly between new users of warfarin and
dabigatran. Patients using warfarin for the first time were more likely to be older and have
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previous clinical comorbidities, particularly ischemic stroke, congestive heart failure and venous
thromboembolism. Patients initiating warfarin were also more likely to have higher ischemic
stroke risk (as assessed by the CHADS2 or CHA2DS2-VASc scores), higher bleeding risk (as
assessed by the HAS-BLED or ATRIA scores), and lower prescription benefits’ generosity,
which measures how much patients paid for their prescription medications relative to how much
their insurance paid. The lower the prescription benefits’ generosity, the higher the patient’s
relative out-of-pocket prescription drug cost burden.
When adjusting for patient baseline characteristics using multivariable regression, we still
found that the strong associations with ischemic stroke risk and bleeding risk between warfarin
initiators compared with dabigatran initiators persisted. Patients using dabigatran were 8% less
likely to have high ischemic stroke risk and 28% less likely to have high bleeding risk compared
with warfarin users. Other patient characteristics were also still associated with anticoagulant
selection, including prescription benefits’ generosity which was one of the strongest predictors of
initiation of dabigatran in this analysis. Patients with good prescription benefits’ coverage (<20%
paid out of pocket in the previous 12 months) were 10 times more likely to initiate dabigatran
compared with warfarin.

5.1.1.2. Aim 1b: Anticoagulant switching patterns
In Aim 1b, among the 33,712 patients with atrial fibrillation initiating anticoagulation
who were still enrolled in their insurance plans 12 months later, we found that approximately
12% switched their initial anticoagulant therapy. Approximately 30% of the patients who
switched anticoagulants did so within 60 days of initiation. Notably, dabigatran initiators and
warfarin initiators switched anticoagulants at relatively equal rates. However, characteristics of
switchers compared with non-switchers of the two anticoagulants differed drastically.
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Patients who switched away from warfarin had fewer comorbidities, low ischemic stroke
risk, and low bleeding risk. By contrast, on most other measures, dabigatran switchers did not
appear to differ systematically from non-switchers, with the exception of age, gender, coronary
artery disease and increased ischemic stroke risk. After controlling for baseline patient
characteristics, dabigatran patients were 35% more likely to switch with higher baseline ischemic
stroke risk but were no different than non-switchers with regard to baseline bleeding risk.
Prevalent users of warfarin followed similar switching patterns to new initiators of warfarin in
that they were more likely to switch if they had lower rates of comorbidities, lower ischemic
stroke, and lower bleeding risk.
These results suggest that patients initiating warfarin may be more concerned with the
risk of harm (bleeding) of dabigatran and may be less likely to switch to dabigatran with higher
bleeding risk. These findings are in concert with the patterns of use observed by new initiators in
Aim 1, in which dabigatran patients were less likely to have higher bleeding risk. Of all the
clinical and prognostic characteristics associated with dabigatran switching, the association
between high ischemic stroke risk and not switching from dabigatran to warfarin was the
greatest. These findings could suggest two possibilities: 1) patients with high ischemic stroke
risk may be more likely to persist with initial therapy because of the high possibility of stroke, or
2) patients with high ischemic stroke risk may have been more likely to see a noticeable benefit
in dabigatran altogether compared with patients with low ischemic stroke risk (and thus not
experienced therapeutic failure leading to the need to switch). Either way, now that there are
more treatment options for non-valvular atrial fibrillation, a significant number of patients are
switching anticoagulation options within the first year of treatment, but there were equal
proportions of patients switching their initial anticoagulants.
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5.1.2. Aim 2: Comparative effectiveness and safety of anticoagulants
In Aim 2, in this large study of 64,935 patients with non-valvular atrial fibrillation, after
multivariable adjustment using survival analysis, we found that patients initiating dabigatran
were approximately 30% less likely to experience ischemic stroke, venous thromboembolism, or
transient ischemic attacks compared with patients initiating warfarin. However, when examining
the comparative safety of experiencing an adverse event, patients initiating dabigatran were
equally likely to experience one of the harm outcomes (e.g., hemorrhage, bleeding, or
hospitalization) with two notable exceptions. First, dabigatran patients were approximately 40%
and 15% less likely to experience a hemorrhagic stroke and other bleeding event compared with
warfarin patients. However, dabigatran patients were also 10% more likely to experience a
gastrointestinal bleeding event after initiating anticoagulation. Notably, myocardial infarction
risk also did not differ between the two anticoagulant groups. These results were also confirmed
among a subset of patients who were newly-diagnosed with atrial fibrillation. Overall, these
results suggest that dabigatran has better comparative effectiveness and safety compared with
warfarin among non-valvular atrial fibrillation patients in real-world clinical practice in the US.
We also found some potential areas of treatment effect heterogeneity among patients
receiving different strengths of dabigatran. The comparative effectiveness in preventing ischemic
stroke or VTE did not differ between warfarin initiators and dabigatran 75mg initiators; however,
patients using the lower dabigatran dose were more likely to experience harmful outcomes
compared with warfarin initiators. By contrast, when stratifying on dose, the comparative
effectiveness and safety of dabigatran 150mg was even more pronounced compared with
warfarin initiators.
Certain characteristics known to be associated with comparative effectiveness in the realworld were also noted in this aim. For instance, medication adherence and refill patterns were
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also seen to notably differ across the anticoagulant groups. Patients initiating dabigatran had a
20% lower likelihood of refilling dabigatran after the initial prescription compared with warfarin
initiators. Overall medication adherence was also low in this study (<50% PDC in the 12-months
post-anticoagulation initiation). Even though they were less likely to refill initially, patients
filling dabigatran were found to have 45% higher likelihood of being adherent (PDC ≥ 80%)
compared with warfarin initiators, even after adjustment for patient baseline characteristics.
However, patients with high ischemic stroke risk were more likely to be adherent compared with
those with low ischemic stroke risk.

5.1.3. Aim 3: Clinical effects of switching anticoagulants
In Aim 3, the goal was to examine whether patients who switched anticoagulants were at
a higher risk of adverse events compared with patients who remained on one medication. We
were particularly interested in isolating patients who switched for reasons unlikely to be
associated with therapeutic failure, motivating the use of a time-varying exposure design that
censored patients if they had experienced a clinical outcome prior to the switch.
In this study, we found notable differences in clinical outcomes among patients who
switched anticoagulants (and had not experienced an outcome prior to the switch) compared with
those who did not switch anticoagulation. After adjustment for patient baseline characteristics,
we also found that patients who switched from warfarin to dabigatran were 32% less likely to
experience ischemic stroke, VTE, or TIA compared with non-switchers. However, these warfarin
switchers were also 32% less likely to experience a harm outcome, including bleeding,
hemorrhage or hospitalization. Overall, these results suggest the risk of switching between
anticoagulants is unlikely to result in any clinically-significant increases in clinical effectiveness
or harm outcomes.
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5.2. IMPLICATIONS OF FINDINGS
These results concur in part with previous research suggesting that some selection (or
channeling) away from dabigatran has occurred, particularly away from patients with high
ischemic stroke and bleeding risk.40,241 Specifically, patients at higher risk of clinical outcomes
like ischemic stroke or bleeding were much more likely to initiate the standard of care, warfarin.
While these studies were generally small in sample size or limited to younger patients, they too
found that patients who were newly-initiating dabigatran had lower bleeding risk and fewer
comorbidities. However, in contrast to a recent study published by Steinberg et al, we found that
bleeding risk was more strongly associated with initial anticoagulant selection than ischemic
stroke risk.242 In our study, we found that patients with higher bleeding risk initiated dabigatran
more often than warfarin. Moreover, the associations with initial anticoagulation selection were
higher in magnitude for the risk of bleeding compared with the risk of ischemic stroke in our
study. Their study found an overall lack of familiarity with bleeding risk guidelines by
physicians for patients enrolled in the ORBIT-AF registry; however, the study was limited by
participants enrolling through October 2011 and did not examine either rivaroxaban or the
contribution of patients’ prescription benefits. By comparison, the results in our study suggest
that there may be selective use of dabigatran for patients at lower risk of bleeding. Concerns over
lack of a bleeding antidote may indeed prevail in this risk-benefit paradox.40,241
Our findings suggest that clinicians may be differentially choosing warfarin in real-world
clinical practice for patients with both high stroke risk and bleeding risk, which may indicate
possible concerns about the complications with the lack of a convenient reversal agent for the
NOACs in general. In addition, these findings are in contrast to some other studies examining
newly-approved pharmaceuticals. In other contexts, patients using newly-approved
pharmaceuticals have tended to be sicker than those on the comparator medication; our findings
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were opposite, which may have implications for studying comparative effectiveness.181,243 If
patients using the newly-approved therapies are more likely to be sicker (and these confounders
are not properly controlled for), then the new therapy is more likely to appear inferior to the
standard of care. For our study, the patients using the newly-approved therapy were healthier, in
which case the new therapy is more likely to appear superior. These observations could have
implications for the process and outcomes of treatment decision-making in clinical practice in
that researchers should strive to consider which way their estimates are likely to skew and
control for confounding using the best possible methodologies.
Further, providers appear to base anticoagulant selection on factors other than predictions
of treatment benefit, which has implications for studying the anticoagulants’ comparative
effectiveness. At the time of this research, clinical guidelines had recommended continuing with
warfarin in currently-treated patients but have been less clear with anticoagulant selection in
treatment-naïve patients, which were the focus of this dissertation.2-4 Until early 2014, warfarin
was still considered the preferred agent in the US; however, as early as 2012, European
guidelines had begun to prefer the novel agents for anticoagulant-naïve patients with nonvalvular atrial fibrillation.3 On the other hand, recent guidelines from the American Heart
Association/American College of Cardiology/Heart Rhythm Society (AHA/ACC/HRS)
published in March 2014 suggested that clinical equipoise may exist between all the
anticoagulants for patients at high risk of stroke.5
These guidelines also recommend that clinicians weigh the balance of benefit with the
risk of harm of available treatment options, but also consider that treatment selection may be in
large part influenced by clinicians through preferences or other factors unrelated to patient
clinical or prognostic characteristics.244 In our study, while both ischemic stroke risk and
bleeding risk were associated with overall anticoagulant selection, other clinical and
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demographic factors, including prescription benefits’ generosity were also strongly associated
with selection. Because there is some clinical equipoise in our study, this finding may be
exploited when assessing the comparative effectiveness of these anticoagulants. Because factors
not clinical and prognostic may be related to initial anticoagulant selection and may lessen
potential bias, we can have more faith in our estimates.
Comorbidity and co-medications may also play a role in anticoagulation switching. We
saw in this study that patient comorbidity burden may play a role in lessening the likelihood of
switching in that patients with more cardiovascular comorbidities were less likely to switch.
Moreover, using antiarrhythmic or beta-blocker medications at baseline was also associated with
switching from warfarin but not dabigatran. These factors together suggest that patients who are
frailer are less likely to switch anticoagulants. It is also possible that patients using warfarin may
have higher comorbidities at baseline and be more cautious with switching to avoid side effects,
as has been seen in previous studies.40,41,245 All in all, switching anticoagulants does not appear
to be consistent across anticoagulants and may be due to the underlying reasons why the patients
were initially placed on those medications to begin with.224 Most recent guidelines and
commentaries have recommended maintaining patients on warfarin if they were previously
stabilized using warfarin, and these findings can be reassuring that indeed most patients are
remaining on their initial anticoagulant as is recommended.5 Either way, switching medications
generally requires more time from the provider, pharmacist, and health care system to ensure the
patient has the adequate knowledge to manage the new medication, which is enough reason to be
cautious to avoid unnecessary switching.224
When considering the anticoagulants’ clinical effectiveness, the large randomizedcontrolled trials used for initial approval of dabigatran and the other NOACs broadly found
similar or better efficacy in preventing ischemic stroke and systemic embolism compared with
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warfarin but significantly better safety, particularly in reducing intracranial bleeding and
hemorrhagic stroke.13,15,18 The results of this study concur with the RE-LY trial, in that
dabigatran appears to be more effective than warfarin in preventing ischemic stroke and systemic
embolism.13 Just as in the RE-LY trial, gastrointestinal bleeding was higher among dabigatran
patients compared with warfarin patients, but there were otherwise no general differences in the
risk of harm or adverse outcomes. A very recent report by the FDA of a very large cohort of
Medicare patients with atrial fibrillation found similar associations with lower risk of clot-related
strokes, intracranial bleeding and death compared with warfarin.246
Our study also found a similar risk for AMI compared with warfarin and an increased
risk of major gastrointestinal bleeding. Overall, while the use of dabigatran should be cautioned
in patients at high bleeding risk, high risk of gastrointestinal bleeding or in renal insufficiency,
dabigatran should otherwise be considered a safe and effective alternative to warfarin, even in
real-world clinical practice.17,122 We did note some underlying treatment effect heterogeneity
among certain characteristics of AF patients, particularly patients with prior VTE and higher
bleeding risk, which warrants further exploration. In addition, sensitivity analyses on the
outcome definition and the subgroups yielded similar associations with slightly differing
magnitudes, but the overall conclusions were robust to these modifications. Either way, insurers
and policy-makers alike can have some reassurance that dabigatran users are no more likely to
have worsened clinical outcomes compared with warfarin users, even outside the tightlymonitored clinical trials, particularly once underlying comorbidity differences are controlled for,
as in this study.
Unlike the RE-LY trial, patients in our study were not regularly followed up as part of a
protocol; in our study, these were patients in real-world practice. Some have felt that the clinical
efficacy in the RE-LY trial was largely due to the regular monitoring of dabigatran that would
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not necessarily take place in the real world but was done in the study to maintain blinding with
warfarin, and a recent article by the BMJ in July 2014 raised some concerns about the trial’s
conduct and possible underrepresentation of bleeding events.247,248 In addition, the rates of
adverse events submitted to the FDA have also been higher for dabigatran compared with
warfarin since dabigatran’s market availability, but the FDA has since found that more events
were likely to be reported, because dabigatran is a newer medication.138 For both these concerns,
the results of Aim 2 could be used to reassure patients and providers, because the results do
indicate that dabigatran can be considered a safe and possibly more effective alternative to
warfarin, even in patients outside clinical trials. Moreover, the fact that in Aim 1b, there were no
differences in the rates of switching away from dabigatran compared with switching away from
warfarin bolsters this assumption. Had there been major differences in switching, one could
attribute those differences in switching to differences in therapeutic failure or adverse
complications, but this was not the case in our study.
Due to the dependence on adherence and persistence to warfarin and dabigatran for the
prevention of ischemic stroke and thrombosis, the low rate of adherence to both warfarin and
dabigatran is concerning. Dabigatran patients were less likely to refill their medication again, but
warfarin patients were less likely to be adherent over a 12-month period (even taking into
account switching to a different anticoagulant). In this way, discontinuation would not be
inappropriately attributed to not continuing anticoagulation altogether. While this study did not
specifically examine persistence or discontinuation to warfarin, the low overall rate of adherence
(less than 50%) to anticoagulation is troubling. Indeed, Tsai et al recently found that 40% of
beneficiaries discontinued dabigatran within 6 months among a cohort of 17,000 US
beneficiaries, most of whom did not continue any anticoagulation.248 Our finding of adherence
less than 50% at 12-months post-initiation concur with their results. These results continue to
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suggest a need for healthcare professionals to provide additional support with these medications,
particularly if the need for weekly face-to-face interactions through INR monitoring is no longer
necessary in the novel oral anticoagulants. In addition, dabigatran is also dosed twice-daily,
compared with warfarin’s once-daily dosing, which could play a role in medication adherence
and potential adverse events with a missed dosed.
Further, the findings from Aim 3 could possibly be attributed to physiologic differences
between the agents. Warfarin’s half-life is much longer than dabigatran’s half-life..5 As a result,
switching from warfarin to dabigatran could be less problematic for both clinical effectiveness
and harm outcomes compared with switching from dabigatran to warfarin. Indeed, switching to
dabigatran was associated with similar (or lower) risk of harmful outcomes compared with
remaining on warfarin. By comparison, switching to warfarin from dabigatran resulted in no
clinically-significant differences in risk for the outcomes studied. While guidelines are clearer
about how to bridge to dabigatran from warfarin (initiate dabigatran once INR<2.0) compared
with vice versa, neither switching direction resulted in clinically or statistically significant
increases in outcomes, which is generally the largest concern in switching medications. While
guidelines recommended maintaining prevalent users of warfarin on warfarin, these findings can
be reassure that switching anticoagulants is unlikely to results in any large risk of outcomes.
Further, the analysis of switching anticoagulants also poses an interesting question. In
Aim 2, we found that the comparative effectiveness of dabigatran was superior to warfarin.
However, how can one adequately measure the actual “risk” of switching anticoagulant
altogether compared with the advantages in comparative safety of switching to the new agent?
Indeed, we found that the clinical effects of switching from warfarin to dabigatran were superior
to staying on warfarin – at least unilaterally in terms of reducing ischemic stroke and systemic
embolisms. Had we been only measuring the comparative effectiveness of the agents (and not
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the effects of switching), we would have seen a corresponding increase in the risk of adverse
outcomes when switching from dabigatran to warfarin. However, we saw no difference in the
risk of outcomes when examining switching from dabigatran to warfarin.
We know that incident user designs are usually preferred when measuring comparative
effectiveness and safety, because prevalent user designs are more fraught with biases such as
survivor bias and confounding by indication.189,199,249 However, in the real world, patients are not
always incident users, and warfarin has been thought to have major issues with switching
between manufacturers – let alone different agents. The design employed in Aim 3 is intended to
disentangle this question and point to why examining “switching” – as compared with just
prevalent or incident use – can be useful in its own right. Indeed, studying prevalent users is not
the same as examining switching between medications. Despite the comprehensive literature
search for this dissertation, there was a relative lack of literature examining methods to address
medication switching itself as an exposure and resulting outcomes. More attention should be paid
towards developing methods to try to better assess medication switching.

5.3. STRENGTHS AND WEAKNESSES
As previously described in the Chapter 3 (Methods), our study has several limitations.
First, prescription refill records from commercial claims databases may not fully reflect
medication use. However, prescription refill records have been shown to have good validity,
correlation, and similar sensitivity and specificity as other measurements, including self-report,
pill counts, and electronic records.209,250 Some warfarin prescriptions may also not be captured
due to concomitant market influences, such as the low-cost generic prescription programs
available in community pharmacies; however, these patients would merely not be included in
this study.201 The ATRIA score has also been used less frequently in research; however, it has
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shown to be better validated in administrative claims data compared with other measures of
bleeding risk.107,113 In addition, the use of a 12-month baseline period for covariate identification,
while standard in the literature and avoids unnecessary sample size truncations, may have led to
some underidentification of covariates, although this was unlikely to be differential between the
anticoagulant groups.251 While this study could not measure mortality, the recent findings from
the FDA and the sensitivity analyses help reduce the likelihood this impacted the study results.246
In addition, as previously discussed, unmeasured confounding, especially healthy user
biases, may impact the study’s findings. While underlying characteristics were adjusted for in the
regression analyses, warfarin patients may be sicker (or frailer) in other confounding
characteristics that could not be measured. The fact that the unadjusted analyses were down and
away from the null and adjusting through multivariate analyses and propensity scores move the
estimates closer to the null indicates that some residual confounding may exist. Provider-level
and health-system level covariates could also not be measured due to the limitations of the
database.
The findings from Aim 3 may also be impacted, because technically the “switcher”
follow-up time may have led to some survivor bias, as the switchers had to avoid an outcome in
order to be considered an anticoagulant switcher. While this censoring may also have impacted
generalizability of the findings, it also limited confounding by indication. Ideally, marginal
structural models could be an approach to address this issue and could be considered in future
research to address issues of time-varying exposure and time-varying covariates.
In addition, in Aim 3, by virtue of the design and the intention-to-treat approach, patients
were not removed from the cohort if they discontinued medications or had poor medication
adherence. Our study found that patients who switched medications were no less likely to
experience a harm outcome compared with patients who did not switch. If patients had actually
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discontinued the medication, they would have contributed exposure time to the “non-switching”
group. In theory, that could have actually made the “non-switching” group slightly less at risk of
a harmful outcome; however, it also could have left the “non-switching” group at higher risk of
ischemic stroke and systemic embolism (because of the discontinuation). In actuality, this
finding was only noted in the warfarin switcher group and not in the dabigatran switcher group.
If this assumption was to have hugely biased the study, it likely would have biased both the
warfarin switchers and the dabigatran switchers.
There are, however, also several strengths of this study. This research used a large
database of nationally-representative commercially-insured patients, including some Medicare
beneficiaries in the United States. To our knowledge, most previous research examining the use
of the novel anticoagulants has been conducted in Europe, in smaller, less representative
databases, or by synthesizing results from randomized-controlled trials in meta-analyses. In
addition, this study assessed general patterns of use and effectiveness of dabigatran a full two
years after NOACs have been available, which have not been previously published. Lastly, while
the clinical prediction risk scores have been thought to be only moderately associated with true
risk of the outcomes in atrial fibrillation, the use of the CHA2DS2-VASc in particular has been
thought to have better real-world concordance than the CHADS2 and could also be considered a
strength of our study compared with previous analyses.

5.4. RECOMMENDATIONS FOR FUTURE RESEARCH
First and foremost, due to the availability of data, this dissertation focuses on dabigatran.
While dabigatran is now just one of the (currently) three FDA-approved NOACs for the
prevention of stroke and systemic embolism, rivaroxaban and apixaban have more recently been
available. Much work will be needed in general in this growing area – examining not just
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dabigatran but the other NOACs as well. Early evidence indicates that each of the NOACs could
have slightly different advantages and disadvantages. Dabigatran, in particular, may lead to more
gastrointestinal side effects, and may be more problematic for patients with renal insufficiency.
On the other hand, dabigatran may have fewer drug-drug interactions than either rivaroxaban or
apixaban, because it is not metabolized via CYP3A4 and may be better for patients with hepatic
disease. Either way, the clearest recommendation for future research lies in the need to
disentangle the advantages and disadvantages of the NOACs, as most research to date in the realworld setting has examined dabigatran exclusively.
Relatedly, another trend worth noting is that the number of patients initiating warfarin
decreased somewhat over time, while the number of patients initiating dabigatran increased from
baseline in late 2010 and peaked in early 2012. Beginning in the 1st quarter of 2012, dabigatran
initiation too began to decline. The introduction of rivaroxaban in late 2011 for the prevention of
ischemic stroke and systemic embolism may have affected trends in anticoagulation use over the
study time period. Future research should examine how utilization patterns of rivaroxaban (and
other NOACs such as apixaban and edoxaban) have influenced medication selection and how
they fare in comparative effectiveness and safety. Head-to-head studies are unlikely due to cost
and feasibility issues, and salient and sound observational research studies in a variety of
populations will be needed to ascertain not only how these medications are really being used
clinically but also how safe and effective they are for different populations. Beyond the need to
generalize the study of NOACs beyond dabigatran, when examining dabigatran specifically, this
dissertation research points to a few other clear directions for future research.
First of all, this research was not designed to directly examine heterogeneity in
effectiveness and safety of the differing dabigatran strengths, and these doses were FDAapproved with different target populations in mind. Dabigatran 75mg is intended for patients
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with renal insufficiency; however, dabigatran 110mg was actually studied in clinical trials. Even
if it was not our intention, some secondary findings in our research have several implications for
patients with renal insufficiency. First, in Aim 1a, this research found that almost 10% of patients
receiving dabigatran 150mg had diagnosed chronic kidney disease for whom the 150mg dose is
neither FDA-approved nor recommended per clinical guidelines, and 22% of patients were using
the 75mg dose without an indication of any kidney disease. Both groups of these patients could
be subject to additional adverse events or harmful outcomes, because of the inappropriate doses;
however, this has not yet been examined. In Aim 2, this research suggested that dabigatran 75mg
was similarly effective as warfarin in the prevention of ischemic stroke and systemic embolism
but that it was slightly more harmful. By contrast, patients using the dabigatran 150mg strength
were less likely to experience an ischemic stroke or systemic embolic event without any
increased risk of a harmful outcome. Even less work has been done examining how
anticoagulation should be managed in patients undergoing dialysis, and none of the new oral
anticoagulants are currently recommended. In sum, further examining this sub-population and
the utilization patterns and comparative effectiveness and safety is highly relevant.
Secondly, this research was not originally designed to examine other types of treatment
effect heterogeneity, including the comparative effectiveness and safety among patients with
different types of comorbidity patterns. Before the application of propensity-score weighting, the
largest absolute differences between baseline characteristics of warfarin and dabigatran initiators
were renal impairment, anemia, venous thromboembolism, and congestive heart failure. These
clinical comorbidities are known to be associated with ischemic stroke risk in patients with atrial
fibrillation. While this research did explore some heterogeneity among subgroups, further
examining the comparative effectiveness among strata of patients with atrial fibrillation
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combined with one of these comorbidities may yield some potential areas for treatment effect
heterogeneity and patients who may benefit more or less from certain anticoagulants.
Similarly, this study was not designed to specifically examine how medication adherence
differed between the different users of anticoagulants, to some degree because a previous study
undertaken by the authors had noticed potential missing warfarin prescription in the
MarketScan® database.201 Because dabigatran, the comparator, is a brand-name medication and
more expensive for patients, prescriptions are likely to be less frequent in the warfarin group,
resulting in differences in fill rates between the groups affecting the relative medication
adherence calculations. Medication adherence has been known to be disentangled with
comparative effectiveness, because medications traditionally work better in patients who take
them regularly. Initiating an appropriate “as-treated” analysis in addition to the “intention-totreat” approach used here would be warranted in the examination of anticoagulants; however,
using medication adherence as an “exposure” and measuring resultant outcomes can be difficult
methodologically.
Lastly, in addition to assessing the comparative effectiveness and safety of these new oral
anticoagulants, which was one of the primary purposes of this dissertation, further work still
needs to be done to examine and understand the cost implications of the agents. Particularly,
analyses are needed that incorporate both the increased cost of the NOACs as well as the
potential cost savings resulting from the prevention of outcomes and the avoidance of the need
for INR measurements. Because of the current lack of an approved, affordable reversal agent in
the event of a bleeding incident for the NOACs, these cost implications could also change over
time once one does become available. Vigilance to developments in this area and the
management of complications will also be an area where research will be much warranted.

170

5.5. CONCLUSION
In this large, nationwide cohort of non-valvular patients initiating anticoagulation from
2010-2012, we found that the uptake and utilization of dabigatran since its market entry has
differed drastically from warfarin. Despite the rapid uptake of dabigatran, patients initiating
dabigatran were healthier than those initiating warfarin and had lower risk of adverse outcomes.
When examining the comparative effectiveness and safety of the medications, dabigatran was
found to equally safe and even more effective than warfarin, even after adjusting for these
differences in comorbidities and risk of outcomes. These results can provide some reassurance
for patients, clinicians, and policymakers that dabigatran may be considered a safe and effective
alternative to warfarin, even when used in real-world clinical practice and outside tightlycontrolled clinical trials.
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APPENDIX TABLES AND FIGURES
Appendix Table 1. Sensitivity analyses: Bivariate associations of continuous
covariates with dabigatran and warfarin selection
New users
Baseline Characteristic
(Assessed as continuous
value)
Age
CCI
CHADS2
CHA2DS2-VASc
ATRIA
HAS-BLED
Number of hospitalizations

Newly-diagnosed new users

RR

95% CI

RR

95% CI

0.99
0.89
0.85
0.87
0.88
0.84
0.77

0.98-0.99**
0.89-0.90**
0.84-0.86**
0.86-0.88**
0.87-0.88**
0.83-0.86**
0.76-0.78**

0.99
0.90
0.85
0.87
0.88
0.84
0.74

0.98-0.99**
0.89-0.90**
0.84-0.87**
0.86-0.88**
0.87-0.89**
0.83-0.86**
0.72-0.76**

Abbreviations: RR, Relative risk; ref, referent group; CI, confidence interval; CCI, Charlson comorbidity index
NOTE: Warfarin: referent group
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Appendix Table 2. Multivariable associations between dabigatran compared
with warfarin and other baseline covariates in the 12-month baseline period
Baseline Characteristic
Demographic
Region (ref: Northeast)
North Central
South
West
Insurance plan (ref:
Comprehensive)
HMO
POS
PPO
CDHP
Prescription generosity
(ref: None/Poor)
Fair coverage
Good coverage
Clinical (ref: 0/None
unless specified)
VTE
Hyperlipidemia
Peptic Ulcer disease
Sleep Apnea
Cognitive deficiency
CCI (ref: 0)
1-2
3-5
6-8
≥9
≥1 hospitalizations
Catheter ablation
Medication use
Antiplatelet therapy
Gastroprotective agent
Antiarrhythmic
Digoxin
Beta-blocker
Calcium channel blocker
ACEI/ARB
Statin
Hormone

New Users
RR
95% CI

Newly-diagnosed new users
RR
95% CI

0.93
1.20
1.01

0.90-0.96**
1.16-1.24**
0.97-1.05

0.89
1.14
0.86

0.85-0.93**
1.10-1.19**
0.82-0.91**

0.65
1.00
0.99
0.89

0.62-0.68**
0.95-1.05
0.97-1.02
0.82-0.95*

0.59
0.95
0.96
0.85

0.55-0.63**
0.89-1.01
0.93-0.99*
0.77-0.93**

9.18
10.30

7.18-11.74**
8.07-13.21**

7.44
8.21

5.50-10.05**
6.07-11.10**

0.32
1.04
0.93
1.06
0.98

0.30-0.35**
1.02-1.06*
0.78-1.11
1.03-1.10**
0.85-1.14

0.34
1.07
0.87
1.08
0.82

0.30-0.38**
1.04-1.11**
0.67-1.12
1.03-1.13*
0.64-1.04

0.92
0.81
0.67
0.71
0.87
1.30

0.90-0.95**
0.78-0.84**
0.63-0.73**
0.63-0.79**
0.85-0.89**
1.22-1.38**

0.95
0.84
0.71
0.79
0.81
1.28

0.92-0.98*
0.80-0.88**
0.64-0.79**
0.67-0.92*
0.79-0.84**
1.05-1.56*

1.12
0.95
1.04
0.91
1.04
1.01
1.04
0.99
1.13

1.08-1.16**
0.92-0.99*
1.01-1.06*
0.88-0.94**
1.01-1.06*
0.99-1.03
1.02-1.07*
0.97-1.01
1.07-1.19**

1.02
0.93
1.01
0.91
0.97
0.96
1.03
0.97
1.09

0.97-1.07
0.89-0.98*
0.97-1.05
0.87-0.96**
0.94-1.00*
0.93-0.98*
1.00-1.06
0.94-1.00
1.02-1.17*

NOTE: For covariates not already included in ischemic stroke or bleeding risk scores
*p<0.05
**p<0.001
Abbreviations: RR, Relative risk; ref, referent group; CI, confidence interval; HMO, health maintenance organization; POS,
point of service; PPO, preferred provider organization; CDHP, consumer driven health plan; VTE, venous thromboembolism;
CCI, Charlson comorbidity index; ACEI/ARB, angiotensin converting enzyme inhibitor/angiotensin receptor blocker
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Appendix table 3. Ischemic stroke and bleeding risk score model predictor
options and associations with dabigatran use compared with warfarin use
New Users
Model Option:
QIC
1:
NU: 125,890.05
Ndx: 71,272.10

2:
NU: 126,253.76
Ndx: 71,395.15

3:
NU: 125,957.39
Ndx: 71,272.46

4:
NU: 126,227.92
Ndx: 71,398.17

Baseline Characteristic
CHA2DS2-VASc (ref: 0)
1
≥2
ATRIA (ref: 0-3)
4
≥5
CHA2DS2-VASc (ref: 0)
1
≥2
HAS-BLED (ref: 0-2)
≥5
CHADS2 (ref: 0)
1
≥2
ATRIA (ref: 0-3)
4
≥5
CHADS2 (ref: 0)
1
≥2
HAS-BLED (ref: 0-2)
≥5

Newly-diagnosed new users

RR

95% CI

RR

95% CI

0.97
0.91

0.94-1.01
0.87-0.95**

0.97
0.92

0.92-1.02
0.87-0.98*

0.86
0.72

0.82-0.89**
0.69-0.76**

0.85
0.71

0.80-0.91**
0.67-0.76**

0.97
0.91

0.93-1.00
0.87-0.95**

0.97

0.92-1.02

0.93

0.87-0.99*

0.80

0.76-0.85**

0.78

0.73-0.85**

0.98
0.94

0.95-1.01
0.90-0.98*

0.99
0.98

0.95-1.04
0.92-1.03

0.85
0.72

0.82-0.89**
0.69-0.76**

0.85
0.71

0.80-0.90**
0.67-0.76**

0.97
0.94

0.94-1.01
0.90-0.98*

0.99
0.98

0.95-1.03
0.93-1.03

0.80

0.76-0.85**

0.78

0.73-0.85**

Abbreviations: RR, Relative risk; Ref, referent group; CI, confidence interval; QIC, Quasilikelihood under the Independence
model Criterion; NU, new user; Ndx, Newly-diagnosed new user
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Appendix table 4. Sensitivity analyses: Multivariable associations between
dabigatran compared with warfarin and ischemic stroke and bleeding risk scores

Baseline Characteristic
Demographic
CHA2DS2-VASc (ref=0)
1
≥2
ATRIA (ref: 0-3)
4
≥5

New Users
Commercial
Medicare
RR
RR
(95% CI)
(95% CI)

0.99 (0.95-1.03)
0.94 (0.89-0.99)*

1.01 (0.95-1.07)
0.98 (0.91-1.05)

0.80 (0.75-0.86)**
0.57 (0.50-0.65)**

0.90 (0.85-0.95)**
0.75 (0.72-0.79)**

Newly-diagnosed new users
Commercial
Medicare
RR
RR
(95% CI)
(95% CI)

0.99 (0.94-1.04)
0.95 (0.88-1.02)

1.04 (0.96-1.13)
1.04 (0.95-1.14)

0.80 (0.73-0.87)* 0.91 (0.84-0.99)*
0.53 (0.43-0.64)** 0.75 (0.70-0.80)**

*p<0.05
**p<0.001
NOTE: By definition, Medicare supplement beneficiaries cannot have CHA2DS2-VASc=0. For these patients, CHADS2 was
calculated and used in the relative risk estimations. Warfarin is the referent group.
Abbreviations: RR, Relative risk; ref, referent group; CI, confidence interval
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Appendix table 5. Patient prescription cost-sharing of index anticoagulation
and switching characteristics
All Warfarin New Users
NonIndex prescription
Switcher,
Absolute
Switcher,
generosity
N (%)
SD
N (%)
No coverage
1,023 (36.5) 7,247 (37.8)
3.3
Poor coverage
224 (8.0)
1635 (8.5)
2.5
Fair coverage
742 (26.5) 4,805 (25.0)
4.3
Good coverage
811 (29.0) 5,502 (28.7)
0.8
Prevalent Users
NonAbsolute
Switcher, N Switcher, N
SD
(%)
(%)
No coverage
2,997 (28.4) 24,288 (34.7) 17.2
Poor coverage
572 (5.4)
4982 (7.1)
10.3
Fair coverage
3,671 (34.8) 24,689 (35.3)
1.3
Good coverage
3,321 (31.4) 15,969 (22.8) 23.4
Abbreviations: SD, Standardized Differenced
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All Dabigatran New Users
Switcher, N Non-Switcher, Absolute
(%)
N (%)
SD
3 (0.21)
1 (0.07)
295 (20.8)
1,117 (78.9)

30 (0.29)
7 (0.07)
2,398 (23.3)
7,872 (76.4)

2.5
0.0
7.9
6.4

Appendix table 6. Multivariable associations between anticoagulant
switching and the other baseline covariates in the 12-month follow-up period
Baseline Characteristic
Demographic
Region (ref: Northeast)
North Central
South
West
Insurance plan (ref:
Comprehensive)
HMO
POS
PPO
CDHP
Prescription generosity
(ref: None/Poor)
Fair coverage
Good coverage
Clinical (ref: 0/None
unless specified)
VTE
Hyperlipidemia
Peptic Ulcer disease
Sleep Apnea
Cognitive deficiency
≥1 hospitalizations
Catheter ablation
Newly-diagnosed AF
Medication use
Antiplatelet therapy
Gastroprotective agent
Antiarrhythmic
Digoxin
Beta-blocker
Calcium channel blocker
ACEI/ARB
Statin
Hormone

Warfarin New Users
RR
95% CI

Dabigatran New Users
RR
95% CI

Prevalent Users
RR
95% CI

0.95
1.17
1.16

0.86-1.06
1.06-1.30*
1.03-1.31*

0.99
1.09
1.13

0.85-1.15
0.95-1.26
0.96-1.34

0.80
1.23
1.17

0.75-0.84**
1.17-1.29**
1.10-1.24**

0.54
1.12
1.09
0.96

0.46-0.62**
0.96-1.31
1.01-1.18*
0.75-1.24

0.94
0.80
0.95
0.97

0.76-1.16
0.63-1.01
0.85-1.06
0.67-1.39

0.38
1.11
1.09
0.88

0.35-0.42**
1.03-1.20*
1.05-1.14**
0.75-1.03

1.07
1.24

0.86-1.32
1.00-1.53*

1.66
1.57

0.43-6.37
0.41-6.01

1.43
1.71

1.19-1.71**
1.43-2.04**

0.56
0.98
0.78
1.22
0.93
0.95
0.89
1.29

0.48-0.66**
0.91-1.05
0.45-1.34
1.10-1.36**
0.58-1.50
0.88-1.03
0.62-1.29
1.20-1.39**

1.11
1.08
0.5
1.12
0.98
0.84
0.26
1.05

0.83-1.48
0.97-1.20
0.17-1.48
0.97-1.30
0.51-1.89
0.75-0.93*
0.12-0.55**
0.95-1.16

0.61
1.12
1.11
1.24
0.99
1.09
1.31
N/A

0.56-0.67**
1.08-1.17**
0.86-1.44
1.18-1.31**
0.80-1.24
1.04-1.13*
1.16-1.48**
N/A

1.06
1.01
1.16
1.02
1.01
1.04
1.11
1.06
1.36

0.95-1.18
0.91-1.13
1.07-1.26**
0.93-1.12
0.94-1.09
0.97-1.12
1.03-1.19*
0.99-1.15
1.17-1.57**

0.93
1.06
1.11
0.97
1.26
1.06
0.91
0.9
1.06

0.80-1.09
0.90-1.24
0.99-1.25
0.84-1.12
1.12-1.41**
0.96-1.18
0.82-1.01
0.81-1.00
0.85-1.31

1.12
1.02
1.23
0.98
1.09
1.13
1.07
1.05
1.12

1.05-1.20**
0.96-1.07
1.18-1.28**
0.94-1.02
1.05-1.14**
1.09-1.17**
1.03-1.12*
1.01-1.09*
1.03-1.22*

NOTE: For covariates not already included in ischemic stroke or bleeding risk scores; REF: Non-switching; *p<0.05 **p<0.001
Abbreviations: RR, Relative risk; ref, referent group; CI, confidence interval; HMO, health maintenance organization; POS,
point of service; PPO, preferred provider organization; CDHP, consumer driven health plan; VTE, venous thromboembolism;
AF, Atrial Fibrillation; ACEI/ARB, angiotensin converting enzyme inhibitor/angiotensin receptor blocker
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Appendix table 7. Ischemic stroke and bleeding risk score model
predictor options and associations with anticoagulant switching

Model Option: QIC
Risk Score
1:
CHA2DS2-VASc (ref: 0)
WNU: 19153.8948
1
DNU: 10000.1665
≥2
PU: 71836.1822
ATRIA (ref: 0-3)
4
≥5
2:
CHA2DS2-VASc (ref: 0)
WNU: 19215.4250
1
DNU: 9984.9208
≥2
PU: 71903.7451
HAS-BLED (ref: 0-2)
≥5
3:
CHADS2 (ref: 0)
WNU: 19156.6780
1
DNU: 9988.5815
≥2
PU: 71825.2560
ATRIA (ref: 0-3)
4
≥5
4:
CHADS2 (ref: 0)
WNU:19220.4114
1
DNU:9980.0506
≥2
PU: 71884.1138
HAS-BLED (ref: 0-2)
≥5

Warfarin New
User
RR (95% CI)

Dabigatran New
User
RR (95% CI)

1.01 (0.87-1.17)
0.88 (0.76-1.02)

1.07 (0.86-1.31)
1.35 (1.09-1.66)*

1.12 (1.02-1.22)*
0.91 (0.84-0.99)*

0.95 (0.83-1.08)
0.69 (0.61-0.79)**

0.91 (0.74-1.12)
1.12 (0.94-1.33)

0.96 (0.90-1.03)
0.82 (0.77-0.87)**

1.00 (0.86-1.16)
0.86 (0.74-0.99)*

1.05 (0.85-1.30)
1.32 (1.07-1.62)*

1.12 (1.03-1.22)*
0.90 (0.83-0.98)*

0.94 (0.85-1.05)

0.95 (0.82-1.10)

1.00 (0.95-1.05)

0.92 (0.81-1.04)
0.91 (0.80-1.03)

1.06 (0.90-1.26)
1.20 (0.99-1.44)

0.94 (0.89-1.00)
0.83 (0.78-0.88)**

0.95 (0.83-1.08)
0.69 (0.61-0.78)**

0.91 (0.74-1.12)
1.11 (0.93-1.33)

0.97 (0.91-1.04)
0.83 (0.78-0.88)**

0.91 (0.80-1.02)
0.99 (0.78-1.01)

1.07 (0.90-1.26)
1.21 (1.01-1.46)*

0.94 (0.88-1.00)*
0.81 (0.76-0.87)**

0.94 (0.85-1.03)

0.96 (0.82-1.11)

1.01 (0.96-1.06)

Prevalent User
RR (95% CI)

*p<0.05
**p<0.001
NOTE: REF: Non-switching
Abbreviations: QIC, Quasilikelihood under the Independence model Criterion; RR, Relative risk, ref, referent group; CI,
confidence interval; WNU, Warfarin new user; D, Dabigatran new user; P, Prevalent user
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Appendix table 8. Sensitivity analyses: Multivariable associations
between anticoagulant switching and ischemic stroke and bleeding risk scores
Warfarin New Users
Commercial
Medicare
RR
RR
(95% CI)
(95% CI)

Risk Score
CHA2DS2-VASc (ref=0)
1
≥2
ATRIA (ref: 0-3)
4
≥5

CHA2DS2-VASc (ref=0)
>0
§
ATRIA (ref: 0-3)
≥3

1.04 (0.88-1.22)
1.10 (0.89-1.35)

Prevalent Users
Commercial
Medicare
RR
RR
(95% CI)
(95% CI)

0.83 (0.68-1.00)*
0.83 (0.69-1.00)*

1.13 (1.03-1.25)*
1.06 (0.93-1.20)

0.85 (0.78-0.93)**
0.76 (0.69-0.82)**

0.87 (0.70-1.08)
1.00 (0.86-1.18)
0.51 (0.34-0.78)* 0.72 (0.63-0.83)**
Dabigatran New Users
Commercial
Medicare
RR
RR
(95% CI)
(95% CI)

0.78 (0.70-0.90)*
0.81 (0.66-1.00)*

1.03 (0.95-1.11)
0.86 (0.80-0.91)**

§

1.09 (0.87-1.36)

1.05 (0.82-1.35)

0.75 (0.54-1.06)

1.10 (0.95-1.28)

*p<0.05
**p<0.001
§
Due to small cell size issues (and non-convergence of the original model), the risk score levels were combined and some nonsignificant covariates omitted (e.g., prescription benefits generosity, peptic ulcer disease)
NOTE: By definition, Medicare supplement beneficiaries are unlikely to have CHA2DS2-VASc=0 (due to age). For these
patients, CHADS2 was calculated and used in the relative risk estimations; REF: Non-switching
Abbreviations: RR, Relative risk; ref, referent group; CI, confidence interval
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Appendix table 9. Propensity score assessments: Testing variables’ crude
associations with risk of effectiveness and harm outcomes in new users
Exposure
association
Baseline Characteristic

RR (95% CI)

Demographic
Age (ref: <55 years)
55-64 years
0.90 (0.87-0.93)
65-74 years
0.76 (0.74-0.79)
≥ 75 years
0.59 (0.57-0.61)
Gender (ref: Female)
1.16 (1.13-1.19)
Region (ref: Northeast)
North Central
0.92 (0.89-0.95)
South
1.27 (1.23-1.31)
West
0.96 (0.92-0.99)
Insurance plan (ref: Comprehensive)
HMO
0.70 (0.67-0.73)
POS
1.25 (1.20-1.32)
PPO
1.20 (1.17-1.23)
CDHP
1.30 (1.21-1.39)
Prescription generosity (ref: None/Poor)
Fair coverage
8.66 (6.77-11.09)
Good coverage
9.69 (7.57-12.40)
Clinical (ref: 0/None
unless specified)
Ischemic Stroke
0.72 (0.69-0.76)
Congestive Heart Failure 0.67 (0.65-0.69)
VTE
0.26 (0.24-0.28)
Hyperlipidemia
1.00 (0.98-1.03)
Hypertension
0.88 (0.86-0.90)
Myocardial infarction
0.61 (0.56-0.66)
Coronary artery disease 0.83 (0.80-0.85)
PVD
0.69 (0.58-0.83)
Renal impairment
0.53 (0.50-0.56)
Diabetes
0.84 (0.82-0.86)
Major bleeding
0.74 (0.71-0.77)
Anemia
0.59 (0.56-0.61)
Peptic Ulcer disease
0.69 (0.58-0.83)
Sleep Apnea
1.11 (1.08-1.15)
Cognitive deficiency
0.69 (0.59-0.80)
CCI (ref: 0)
1-2
0.82 (0.80-0.84)
3-5
0.61 (0.59-0.63)
6-8
0.43 (0.40-0.46)
≥9
0.42 (0.37-0.47)
CHA2DS2-VASc (ref: 0)
1
0.93 (0.90-0.97)
≥2
0.63 (0.61-0.65)

Outcome association

Variable classification

Effectiveness
RR (95% CI)

Harm
HR (95% CI)

1.05 (0.96-1.14)
1.16 (1.07-1.26)
1.58 (1.46-1.70)
0.73 (0.70-0.76)

1.13 (1.07-1.20)
1.27 (1.20-1.34)
1.55 (1.48-1.63)
0.86 (0.84-0.88)

X
X

1.01 (0.95-1.06) 1.04 (1.00-1.08)
0.92 (0.87-0.98) 0.95 (0.91-0.98)
0.98 (0.92-1.05) 0.89 (0.85-0.93)

X

0.83 (0.78-0.88)
0.74 (0.67-0.82)
0.84 (0.80-0.87)
0.59 (0.49-0.71)

0.87 (0.83-0.90)
0.83 (0.78-0.88)
0.81 (0.78-0.83)
0.70 (0.63-0.78)

X

1.18 (1.04-1.34) 1.30 (1.18-1.43)
1.35 (1.18-1.53) 1.43 (1.31-1.58)

X

6.26 (6.01-6.53)
1.31 (1.26-1.37)
7.83 (7.51-8.17)
0.99 (0.95-1.03)
1.35 (1.29-1.42)
1.40 (1.28-1.52)
1.14 (1.10-1.19)
1.81 (1.71-1.92)
1.45 (1.37-1.53)
1.05 (1.00-1.09)
1.69 (1.61-1.78)
1.70 (1.62-1.78)
1.91 (1.59-2.30)
0.95 (0.91-1.00)
4.15 (3.67-4.68)

1.35 (1.30-1.41)
1.67 (1.62-1.72)
1.35 (1.29-1.41)
0.98 (0.95-1.00)
1.21 (1.18-1.25)
1.50 (1.41-1.59)
1.40 (1.36-1.44)
1.56 (1.49-1.63)
1.67 (1.61-1.74)
1.27 (1.23-1.30)
1.47 (1.41-1.52)
1.61 (1.56-1.66)
1.68 (1.46-1.94)
1.15 (1.10-1.20)
1.35 (1.18-1.54)

X
X
X

1.79 (1.69-1.91)
2.91 (2.74-3.10)
4.11 (3.80-4.45)
5.32 (4.78-5.91)

1.37 (1.32-1.42)
1.99 (1.92-2.07)
2.69 (2.55-2.84)
3.19 (2.94-3.46)

X

1.08 (0.96-1.21) 1.09 (1.03-1.17)
2.24 (2.03-2.47) 1.67 (1.58-1.77)

X
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X1

X2

X3

None

X
X
X
X
X
X
X
X
X
X
X
X

ATRIA (ref: 0-3)
4
≥5
≥1 hospitalizations
Catheter ablation
Medication use
Antiplatelet therapy
Gastroprotective agent
Antiarrhythmic
Digoxin
Beta-blocker
Calcium channel blocker
ACEI/ARB
Statin
Hormone

0.73 (0.70-0.76)
0.49 (0.47-0.51)
0.71 (0.69-0.72)
1.68 (1.58-1.79)

1.58 (1.49-1.69)
1.86 (1.78-1.95)
2.89 (2.76-3.02)
0.48 (0.37-0.62)

1.37 (1.31-1.43)
1.84 (1.79-1.90)
1.56 (1.52-1.60)
0.72 (0.63-0.82)

0.98 (0.95-1.01)
0.88 (0.85-0.91)
1.10 (1.07-1.13)
0.86 (0.83-0.89)
0.99 (0.97-1.02)
0.96 (0.94-0.99)
0.98 (0.96-1.01)
0.96 (0.94-0.98)
1.15 (1.09-1.21)

1.49 (1.42-1.57)
1.41 (1.33-1.48)
0.88 (0.84-0.92)
0.95 (0.90-0.99)
1.00 (0.96-1.04)
1.04 (1.00-1.08)
1.00 (0.95-1.03)
1.15 (1.10-1.19)
1.05 (0.95-1.16)

1.50 (1.45-1.55)
1.30 (1.25-1.35)
1.09 (1.06-1.12)
1.16 (1.12-1.20)
1.16 (1.13-1.19)
1.17 (1.14-1.20)
1.15 (1.12-1.19)
1.11 (1.08-1.14)
1.00 (0.94-1.07)

X
X
X
X
X
X
X
X
XH

XE

XH

XE

X
X
X

Abbreviations: HMO, Health maintenance organization; POS, Point-of-service; PPO, Preferred provider organization; CDHP,
consumer-driven health plan; CCI, Charlson Comorbidity Index; ACEI, angiotensin-converting-enzyme inhibitor; ARB,
angiotensin receptor blocker; VTE, venous thromboembolism; PVD, Peripheral vascular disease
NOTE: E: Effectiveness Outcome; H: Harm Outcome; X1: variable only associated with exposure; X2: variable associated with
both exposure and outcome; X3: variable associated with only outcome; None: variable associated with neither exposure nor
outcome
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Appendix figure 1. Estimated propensity score kernel densities among
new users of anticoagulation
A. New Users

B. Newly-diagnosed new users
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C. New Users excluding venous thromboembolism and prescription benefits generosity
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Appendix table 10. Balance of covariates after applying the stabilized IPTW
propensity scores among new users of dabigatran and warfarin
Baseline Characteristic
Demographic
Age
< 55 years
55-64 years
65-74 years
≥ 75 years
Male Gender
Region
Northeast
North Central
South
West
Insurance plan
Comprehensive
HMO
POS
PPO
CDHP
Benefits generosity
No/poor coverage
Fair coverage
Good coverage
Clinical
Ischemic Stroke
Congestive Heart Failure
VTE
Hyperlipidemia
Hypertension
Myocardial infarction
Coronary artery disease
Peripheral vascular
disease
Renal impairment
Diabetes
Major bleeding
Anemia
Peptic Ulcer disease
Sleep Apnea
Cognitive deficiency
CCI
0
1-2
3-5
6-8
≥9
CHA2DS2-VASc
0

Warfarin, %

Dabigatran, %

Absolute SD

10.51%
25.57%
22.55%
41.37%
59.91%

10.07%
25.40%
23.35%
41.18%
59.18%

1.9
0.5
2.4
0.5
1.7

16.76%
33.12%
30.91%
16.93%

17.10%
33.11%
31.43%
16.92%

1.2
0.0
1.4
0.0

34.43%
12.39%
4.93%
41.02%
1.80%

35.59%
12.02%
4.78%
41.49%
1.92%

3.0
1.5
1.0
1.1
1.3

2.60%
48.00%
49.41%

3.13%
48.08%
48.79%

4.6
0.2
1.4

9.59%
25.10%
9.13%
49.57%
71.82%
3.86%
32.32%

10.30%
26.69%
10.76%
49.65%
72.63%
3.91%
32.94%

3.2
4.6
7.6
0.2
1.9
0.4
1.6

7.79%
10.36%
30.12%
12.26%
16.90%
0.64%
10.95%
0.86%

9.12%
11.20%
30.88%
13.31%
17.90%
1.18%
11.31%
0.89%

6.7
3.7
2.1
4.3
3.5
9.5
1.5
0.5

26.37%
41.13%
24.49%
5.93%
2.09%

25.56%
40.36%
25.07%
6.39%
2.62%

2.3
1.9
1.7
2.7
5.2

8.26%

7.85%

2.0
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1
≥2
ATRIA
0-3
4
≥5
≥1 hospitalizations
Catheter ablation
Medication Use
Antiplatelet therapy
Gastroprotective agent
Antiarrhythmic
Digoxin
Beta-blocker
Calcium channel blocker
ACEI/ARB
Statin

16.96%
74.78%

16.69%
75.46%

0.9
1.7

74.32%
8.72%
16.96%
53.35%
1.31%

73.19%
8.83%
17.98%
54.11%
1.31%

2.8
0.5
3.5
1.7
0.0

13.03%
12.04%
23.68%
16.09%
67.22%
41.81%
56.88%
54.18%

14.05%
11.72%
23.68%
16.71%
68.11%
42.19%
57.09%
54.29%

4.0
1.3
0.0
2.2
2.1
0.9
0.5
0.3

Abbreviations: SD, Standardized difference; HMO, Health maintenance organization; POS, Point-of-service; PPO, Preferred
provider organization; CDHP, consumer-driven health plan; CCI, Charlson Comorbidity Index; ACEI, angiotensin-convertingenzyme inhibitor; ARB, angiotensin receptor blocker
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Appendix figure 2. Kaplan-Meier curves of anticoagulant initiators
A. Composite of clinical effectiveness outcomes
Warfarin

Dabigatran

B. Composite of risk of harm outcomes

Warfarin

Dabigatran
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C. Acute myocardial infarction outcome
Warfarin

Dabigatran
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Appendix figure 3. Estimated treatment effects and 95% confidence
Interval bounds for deciles of the estimated propensity scores for new users
A. Effectiveness composites
1.2
1

Point estimates

0.8
HR

0.6

Lower 95% CL

0.4

Upper 95% CL

0.2
0
Decile Decile Decile Decile Decile Decile Decile Decile Decile Decile
1
2
3
4
5
6
7
8
9
10

B. Harm composites
1.4
1.2

Point estimates

1
0.8

HR

0.6

Lower 95% CL
Upper 95% CL

0.4
0.2
0
Decile Decile Decile Decile Decile Decile Decile Decile Decile Decile
1
2
3
4
5
6
7
8
9
10
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C. Acute myocardial infarction
1.8
1.6

Point estimates

1.4
1.2
1

HR

0.8

Lower 95% CL

0.6

Upper 95% CL

0.4
0.2
0
Decile Decile Decile Decile Decile Decile Decile Decile Decile Decile
1
2
3
4
5
6
7
8
9
10
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Appendix Table 11. Estimated treatment effects comparing new users
of dabigatran to warfarin on risk of outcomes: Inpatient outcomes only

Outcome Type

Original
PS-IPTW
HR (95% CI)

Inpatient-only
PS-IPTW
HR (95% CI)

Warfarin
Events/1,000
person-years
(Inpatient-only)

Dabigatran
Events/1,000
person-years
(Inpatient-only)

Effectiveness
Ischemic stroke
0.92 (0.87-0.98)*
0.91 (0.81-1.02)
35.6
17.3
TIA
1.07 (0.92-1.25)
1.07 (0.91-1.25)
11.3
9.2
VTE
0.51 (0.47-0.54)**
0.70 (0.60-0.80)**
20.4
9.1
Composite
0.70 (0.67-0.74)**
0.86 (0.79-0.93)**
48.6
30.2
Harm
Hemorrhagic stroke
0.64 (0.54-0.75)**
0.51 (0.40-0.65)**
8.0
3.3
GI hemorrhage
1.19 (1.12-1.26)**
1.11 (1.02-1.22)*
32.1
21.8
Other bleeding
0.91 (0.86-0.96)**
0.76 (0.65-0.89)**
14.4
8.1
Hospitalization
1.00 (0.97-1.02)
0.99 (0.97-1.02)
343.4
295.8
Composite
1.02 (0.99-1.05)
0.99 (0.97-1.02)
343.4
295.8
0.88 (0.77-1.00)*
0.88 (0.77-1.00)*
19.1
13.1
AMI
*p<0.05; **p<0.001
Abbreviations: AF, Atrial Fibrillation; HR, Hazard Ratio; MV, Multivariate; PS, Propensity score; IPTW, Inverse
probability treatment weighting; SMR, Standardized Mortality Ratio; TIA, transient ischemic attack; VTE, venous
thromboembolism; GI, gastrointestinal; AMI, Acute Myocardial Infarction
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Appendix table 12. Full multivariable survival analysis model results comparing
dabigatran with warfarin use among new users of anticoagulation
Effectiveness Composite
HR
95% CI
0.59-0.66**
Dabigatran (ref: Warfarin) 0.62
Baseline Demographic Characteristic
Age (ref: <55 years)
55-64 years
0.99
0.91-1.08
65-74 years
0.84
0.77-0.92**
≥75 years
0.94
0.86-1.03
Male Gender (ref: Female)
0.91
0.87-0.95**
Region (ref: Northeast)
North Central
1.04
0.98-1.10
South
1.01
0.95-1.07
West
1.06
1.00-1.14
Insurance plan (ref:
Comprehensive)
HMO
0.96
0.90-1.03
POS
0.92
0.83-1.02
PPO
1.02
0.97-1.06
CDHP
0.81
0.67-0.98*
Prescription generosity (ref:
None/Poor)
Fair coverage
0.95
0.84-1.09
Good coverage
1.01
0.89-1.15
Baseline Clinical Characteristic (ref: 0/None)
Ischemic stroke
4.07
3.88-4.27**
Congestive Heart Failure
0.81
0.77-0.85**
Acute Myocardial infarction 0.87
0.80-0.96*
Coronary artery disease
0.89
0.85-0.93**
Hypertension
1.06
1.00-1.12*
Peripheral vascular disease
0.97
0.81-1.03
Diabetes Mellitus
0.80
0.76-0.84**
VTE
5.82
5.56-6.09**
Renal insufficiency
0.90
0.82-0.96*
Hyperlipidemia
0.97
0.93-1.01
Anemia
1.07
1.00-1.15
Peptic Ulcer disease
1.00
0.83-1.20
Sleep Apnea
1.02
0.96-1.09
Cognitive deficiency
1.22
1.08-1.38
Major bleeding
1.05
0.99-1.11
CHA2DS2-VASc
1
1.02
0.90-1.16
≥2
1.25
1.10-1.42**
ATRIA
4
1.00
0.93-1.08
≥5
0.92
0.84-1.01
CCI (ref: 0)
1-2
1.30
1.21-1.40**
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Harm Composite

Acute Myocardial
Infarction
HR
95% CI
0.86
0.74-0.99*

HR
1.00

95% CI
0.97-1.03

1.03
1.01
1.13
0.91

0.98-1.09
0.95-1.08
1.06-1.21**
0.89-0.94**

1.39
1.42
1.62
1.00

1.00-1.92*
1.01-2.00*
1.15-2.29*
0.97-1.13

1.02
0.99
0.93

0.95-1.03
0.95-1.03
0.89-0.98*

0.84
0.83
1.02

0.71-0.99*
0.69-0.98*
0.84-1.25

0.99
0.99
0.93
0.91

0.95-1.04
0.93-1.06
0.90-0.96**
0.81-1.01

0.78
0.69
0.80
0.89

0.63-0.96*
0.49-0.97*
0.69-0.93*
0.50-1.56

1.07
1.11

0.97-1.17
1.01-1.22*

0.68
0.72

0.46-1.01
0.49-1.07

1.02
1.21
0.99
1.11
1.01
1.10
1.00
1.06
1.05
0.93
1.16
1.17
1.13
1.02
1.18

0.97-1.06
1.17-1.25**
0.93-1.06
1.08-1.15**
0.97-1.05
1.05-1.15**
0.97-1.03
1.01-1.11*
1.00-1.11
0.90-0.95**
1.09-1.22**
1.01-1.34*
1.08-1.18**
0.89-1.17
1.14-1.23**

0.93
1.38
3.64
1.44
1.03
0.96
1.13
0.83
1.30
0.82
0.92
1.13
1.01
1.32
0.95

0.76-1.12
1.20-1.59**
3.06-4.32**
1.25-1.66**
0.88-1.22
0.79-1.17
0.98-1.31
0.68-1.02
1.04-1.63*
0.72-0.93*
0.74-1.14
0.60-2.11
0.83-1.24
0.78-2.26
0.80-1.15

0.97
1.01

0.91-1.05
0.93-1.09

1.40
1.65

0.85-2.28
0.99-2.74

1.01
1.06

0.96-1.07
0.99-1.13

1.04
1.02

0.82-1.31
0.77-1.34

1.16

1.11-1.21**

1.25

1.00-1.56

3-5
1.62
6-8
2.02
≥9
1.87
≥1 hospitalizations
1.64
Catheter ablation
0.67
Baseline Medication Use (ref: None)
Antiplatelet therapy
1.05
Gastroprotective agent
1.05
Antiarrhythmic
0.89
Digoxin
0.88
Beta-blocker
0.94
Calcium channel blocker
0.91
ACEI/ARB
0.94
Statin
1.05

1.50-1.76**
1.81-2.25**
1.64-2.12**
1.56-1.73**
0.53-0.89*

1.41
1.59
1.87
1.18
0.80

1.34-1.48**
1.47-1.71**
1.70-2.05**
1.15-1.22**
0.70-0.92*

1.41
1.50
1.56
1.31
1.01

1.08-1.83*
1.05-2.12*
1.00-2.42
1.13-1.53**
0.52-1.95

1.00-1.11
0.99-1.11
0.85-0.94**
0.83-0.93**
0.90-0.98*
0.88-0.95**
0.90-0.98*
1.00-1.10*

1.16
1.11
1.05
1.05
1.03
1.08
1.00
0.96

1.12-2.21**
1.07-1.15**
1.01-1.08*
1.02-1.09*
1.00-1.06
1.05-1.11**
0.97-1.03**
0.93-0.98*

1.29
1.11
0.90
1.05
1.14
0.87
1.08
1.10

1.11-1.51*
0.94-1.31
0.78-1.04
0.90-1.22
0.98-1.33
0.76-0.98*
0.84-1.24
0.95-1.26

*p<0.05
**p<0.001
Abbreviations: HR, Hazard Ratio; ref, referent group; CI, confidence interval; HMO, health maintenance organization; POS,
point of service; PPO, preferred provider organization; CDHP, consumer driven health plan; VTE, venous thromboembolism;
CCI, Charlson comorbidity index; ACEI/ARB, angiotensin converting enzyme inhibitor/angiotensin receptor blocker
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Appendix table 13. Stratification by insurance status: Clinical effectiveness
and safety of dabigatran compared with warfarin
Commercially-insured (CCAE)
Effectiveness
Harm Composite
Composite
HR (95% CI)
HR (95% CI)

Medicare Supplement (MDCR)
Effectiveness
Harm Composite
Composite
HR (95% CI)
HR (95% CI)

New Users
Unadjusted
0.28 (0.25-0.31)**
0.87 (0.83-0.91)**
0.55 (0.52-0.58)**
0.89 (0.86-0.92)**
MV-adjusted
0.46 (0.41-0.50)**
0.99 (0.94-1.04)
0.72 (0.68-0.77)**
1.00 (0.97-1.04)
PS-IPTW
0.46 (0.42-0.51)**
0.98 (0.94-1.03)
0.77 (0.73-0.81)**
1.02 (0.98-1.05)
PS-SMRW
0.60 (0.53-0.67)**
0.99 (0.93-1.04)
0.81 (0.75-0.87)**
1.00 (0.96-1.05)
Newly-diagnosed new
users
Unadjusted
0.31 (0.27-0.35)**
0.89 (0.83-0.95)**
0.58 (0.54-0.64)**
0.91 (0.86-0.95)**
MV-adjusted
0.47 (0.41-0.54)**
1.00 (0.94-1.08)
0.76 (0.70-0.83)**
1.00 (0.95-1.05)
PS-IPTW
0.52 (0.46-0.59)**
1.00 (0.94-1.07)
0.72 (0.67-0.79)**
0.99 (0.94-1.04)
PS-SMRW
0.61 (0.52-0.71)**
0.99 (0.92-1.06)
0.83 (0.76-0.93)**
1.00 (0.94-1.06)
*p<0.05; p<0.001
Abbreviations: MV, Multivariable; IPTW, Inverse-probability treatment weighting;
HR, Hazard Ratio; CI, Confidence interval; SMRW, Standardized Mortality Ratio Weighting
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Appendix table 14. Dabigatran strength subgroups: Association between
anticoagulation and outcomes compared with warfarin
Outcome Type

Unadjusted
HR (95% CI)

MV Adjusted
HR (95% CI)

PS-IPTW
HR (95% CI)

Dabigatran 75mg
Effectiveness Composite 0.80 (0.71-0.90)** 0.93 (0.82-1.05) 0.96 (0.86-1.08)
Harm Composite
1.17 (1.09-1.26)** 1.03 (0.96-1.12) 1.19 (1.10-1.28)**
Dabigatran 150mg
Effectiveness Composite 0.40 (0.38-0.42)** 0.59 (0.56-0.63)** 0.67 (0.64-0.71)**
Harm Composite
0.83 (0.80-.0.85)** 0.99 (0.96-1.02) 1.00 (0.97-1.03)
*p<0.05; p<0.001
Abbreviations: MV, Multivariable; IPTW, Inverse-probability treatment weighting;
HR, Hazard Ratio; CI, Confidence interval
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Appendix Table 15. Estimated treatment effects among strata of new user
AF patients with certain characteristics
Patient Subgroups
Original
Ischemic stroke
VTE
CHF
AMI
ATRIA < 4
ATRIA = 4
ATRIA ≥ 5
CHA2DS2-VASc =1
CHA2DS2-VASc ≥2
Age <55 years
Age 55-64 years
Age 65-74 years
Age ≥75 years
Fair prescription generosity
Good prescription generosity
*p<0.05; **p<0.001

Effectiveness
HR (95% CI)
0.86 (0.79-0.93)**
0.85 (0.70-1.02)
0.50 (0.35-0.72)**
0.88 (0.75-1.03)
0.95 (0.63-1.43)
0.89 (0.80-0.99)*
0.84 (0.64-1.09)
0.73 (0.60-0.90)*
1.01 (0.77-1.31)
0.84 (0.77-0.92)**
0.94 (0.70-1.26)
0.59 (0.57-0.84)**
0.79 (0.65-0.96)*
0.89 (0.79-1.01)
0.85 (0.75-0.96)*
0.91 (0.81-1.02)

Harm Outcome
HR (95% CI)
0.99 (0.97-1.02)
1.07 (0.97-1.17)
1.04 (0.91-1.20)
0.98 (0.93-1.04)
1.06 (0.91-1.22)
1.01 (0.98-1.05)
0.97 (0.88-1.07)
0.93 (0.86-1.00)*
1.00 (0.93-1.08)
0.96 (0.93-1.00)*
0.95 (0.86-1.05)
1.01 (0.95-1.07)
1.04 (0.98-1.11)
0.91 (0.87-0.95)**
1.02 (0.97-1.06)
0.98 (0.94-1.02)
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Appendix table 16. Full multivariable survival analysis model results comparing warfarin
switchers to dabigatran versus warfarin non-switchers
Effectiveness
HR
(95% CI)
Switcher
0.68 (0.66-0.71)**
(ref: non-switcher)
Demographic baseline characteristic
Age (ref: <55 years)
55-64 years
1.06 (1.02-1.11)*
65-74 years
1.01 (0.96-1.06)
≥75 years
1.04 (0.99-1.09)
Male Gender (ref: Female)
0.98 (0.96-1.00)
Region (ref: Northeast)
North Central
1.03 (1.00-1.06)
South
0.99 (0.96-1.03)
West
0.99 (0.96-1.02)
Insurance plan (ref:
Comprehensive)
HMO
1.13 (1.09-1.17)**
POS
1.06 (1.01-1.12)*
PPO
1.18 (1.15-1.21)**
CDHP
1.09 (1.00-1.19)*
Prescription generosity (ref:
None/Poor)
Fair coverage
0.88 (0.83-0.93)**
Good coverage
0.87 (0.82-0.92)**
Clinical baseline characteristic (ref: 0/None)
Ischemic stroke
1.00 (0.95-1.05)
Congestive Heart Failure
1.05 (1.02-1.08)*
Acute Myocardial infarction 1.04 (0.98-1.10)
Coronary artery disease
0.99 (0.96-1.01)
Hypertension
1.08 (1.05-1.11)*
Peripheral vascular disease
1.03 (0.99-1.07)
Diabetes Mellitus
0.97 (0.95-1.00)
VTE
1.03 (0.98-1.07)
Renal insufficiency
1.01 (0.96-1.06)
Hyperlipidemia
1.09 (1.07-1.12)**
Anemia
1.03 (0.99-1.08)
Peptic Ulcer disease
1.00 (0.87-1.15)
Sleep Apnea
1.03 (0.99-1.06)
Cognitive deficiency
1.23 (1.08-1.41)*
Major bleeding
1.00 (0.96-1.03)
CHA2DS2-VASc
1
0.95 (0.90-1.00)*
≥2
0.94 (0.88-0.99)*
ATRIA
4
1.02 (0.97-1.06)
≥5
1.04 (0.98-1.10)
CCI (ref: 0)

Harm
HR
(95% CI)

AMI
HR
(95% CI)

0.68 (0.65-0.71)**

0.68 (0.66-0.70)**

1.07 (1.02-1.12)*
1.01 (0.96-1.07)
1.03 (0.97-1.08)
0.98 (0.95-1.00)

1.06 (1.02-1.10)*
1.00 (0.95-1.04)
1.04 (1.00-1.09)
0.99 (0.97-1.01)

1.03 (1.00-1.07)
0.99 (0.96-1.03)
0.98 (0.94-1.02)

1.04 (1.01-1.07)*
1.00 (0.97-1.03)
1.00 (0.97-1.03)

1.15 (1.11-1.20)**
1.08 (1.02-1.14)*
1.20 (1.16-1.22)**
1.12 (1.02-1.23)*

1.11 (1.08-1.15)*
1.06 (1.01-1.11)*
1.17 (1.14-1.20)**
1.12 (1.03-1.21)*

0.88 (0.83-0.94)**
0.86 (0.81-0.92)**

0.89 (0.85-0.94)**
0.87 (0.83-0.92)**

1.05 (1.00-1.09)*
1.04 (1.01-1.08)*
1.07 (1.00-1.15)*
0.99 (0.97-1.02)
1.09 (1.05-1.12)*
1.03 (0.95-1.08)
0.97 (0.94-1.00)
1.05 (1.01-1.09)*
0.99 (0.93-1.04)
1.11 (1.08-1.14)**
1.01 (0.96-1.06)
1.02 (0.88-1.19)
1.01 (0.97-1.05)
1.26 (1.11-1.42)**
1.02 (0.98-1.06)

1.06 (1.03-1.10)*
1.05 (1.02-1.07)*
1.02 (0.97-1.08)
0.98 (0.96-1.01)
1.08 (1.05-1.11)*
1.01 (0.97-1.04)
0.97 (0.95-1.00)*
1.06 (1.02-1.09)*
0.99 (0.95-1.04)
1.10 (1.07-1.12)**
1.03 (0.99-1.07)
0.98 (0.88-1.09)
1.01 (0.98-1.05)
1.20 (1.09-1.33)**
1.00 (0.97-1.03)

0.95 (0.89-1.00)
0.94 (0.88-1.01)

0.95 (0.91-1.00)
0.95 (0.90-1.00)

1.05 (1.00-1.11)*
1.07 (1.00-1.14)*

1.03 (0.99-1.07)
1.03 (0.98-1.08)

196

1-2
1.06 (1.03-1.09)*
3-5
1.11 (1.06-1.15)*
6-8
1.16 (1.08-1.24)**
≥9
1.46 (1.33-1.60)**
≥1 hospitalizations
1.00 (0.98-1.03)
Catheter ablation
0.88 (0.79-0.98)*
Baseline Medication characteristic (ref: None)
Antiplatelet therapy
1.00 (0.96-1.04)
Gastroprotective agent
1.04 (1.00-1.07)*
Antiarrhythmic
1.01 (0.99-1.04)
Digoxin
0.97 (0.94-0.99)*
Beta-blocker
1.04 (1.01-1.06)*
Calcium channel blocker
1.02 (1.00-1.04)*
ACEI/ARB
0.97 (0.95-1.00)*
Statin
0.99 (0.97-1.01)
Hormone
0.98 (0.92-1.04)

1.04 (1.01-1.08)*
1.09 (1.04-1.14)*
1.15 (1.06-1.24)*
1.34 (1.21-1.48)**
1.00 (0.97-1.03)
0.78 (0.69-0.88)**

1.05 (1.02-1.07)*
1.10 (1.06-1.14)*
1.18 (1.12-1.25)**
1.42 (1.33-1.54)**
1.01 (0.99-1.03)
0.86 (0.78-0.95)*

1.00 (0.96-1.04)
1.04 (1.01-1.08)*
1.02 (1.00-1.06)
0.95 (0.92-0.98)*
1.02 (0.99-1.04)
1.03 (1.00-1.06)*
0.97 (0.95-1.00)*
0.99 (0.97-1.02)
0.97 (0.91-1.03)

1.00 (0.97-1.03)
1.05 (1.02-1.08)*
1.01 (0.99-1.03)
0.97 (0.95-1.00)*
1.03 (1.01-1.06)*
1.02 (1.00-1.04)*
0.98 (0.96-1.00)*
0.98 (0.96-1.00)
0.99 (0.94-1.04)

*p<0.05
**p<0.001
Abbreviations: AMI, Acute Myocardial infarction; HR, Hazard Ratio; ref, referent group; CI, confidence interval; HMO, health
maintenance organization; POS, point of service; PPO, preferred provider organization; CDHP, consumer driven health plan;
VTE, venous thromboembolism; CCI, Charlson comorbidity index; ACEI/ARB, angiotensin converting enzyme
inhibitor/angiotensin receptor blocker
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Appendix table 17. Full multivariable survival analysis model results comparing
dabigatran patients switching to warfarin versus dabigatran non-switchers
Effectiveness
HR
(95% CI)
Switcher
1.02 (0.97-1.08)
(ref: non-switcher)
Demographic baseline characteristic
Age (ref: <55 years)
55-64 years
1.04 (0.99-1.09)
65-74 years
0.94 (0.88-0.99)*
≥75 years
0.89 (0.83-0.95)*
Male Gender (ref: Female) 0.96 (0.93-1.00)*
Region (ref: Northeast)
North Central
1.05 (1.01-1.10)*
South
0.90 (0.87-0.94)*
West
0.97 (0.92-1.02)
Insurance plan (ref:
Comprehensive)
HMO
1.19 (1.12-1.27)**
POS
0.98 (0.92-1.05)
PPO
1.07 (1.03-1.11)*
CDHP
1.12 (1.01-1.24)*
Prescription generosity (ref:
None/Poor)
Fair coverage
1.07 (0.85-1.36)
Good coverage
1.08 (0.85-1.37)
Clinical baseline characteristic (ref: 0/None)
Ischemic stroke
0.99 (0.92-1.07)
Congestive Heart Failure
1.05 (1.00-1.09)*
Acute Myocardial infarction 1.02 (0.92-1.13)
Coronary artery disease
1.01 (0.98-1.05)
Hypertension
1.06 (1.02-1.11)*
Peripheral vascular disease
0.99 (0.92-1.05)
Diabetes Mellitus
0.98 (0.94-1.02)
VTE
0.88 (0.80-0.97)*
Renal insufficiency
0.95 (0.87-1.04)
Hyperlipidemia
1.05 (1.02-1.09)*
Anemia
1.04 (0.96-1.12)
Peptic Ulcer disease
0.98 (0.76-1.26)
Sleep Apnea
1.03 (0.98-1.07)
Cognitive deficiency
1.15 (0.89-1.48)
Major bleeding
0.92 (0.87-0.97)*
CHA2DS2-VASc
1
0.99 (0.93-1.05)
≥2
1.00 (0.92-1.08)
ATRIA
4
1.00 (0.93-1.08)
≥5
1.09 (0.99-1.20)
CCI (ref: 0)

Harm
HR
(95% CI)

AMI
HR
(95% CI)

1.06 (0.97-1.15)

0.99 (0.94-1.04)

1.07 (1.01-1.12)
0.98 (0.91-1.05)
0.92 (0.86-1.00)*
0.96 (0.92-0.99)*

1.04 (1.00-1.09)
0.95 (0.90-1.01)
0.92 (0.86-0.98)*
0.96 (0.93-0.99)

1.05 (1.00-1.11)*
0.90 (0.86-0.94)*
0.96 (0.90-1.02)

1.06 (1.02-1.10)*
0.91 (0.88-0.95)*
0.97 (0.93-1.02)

1.22 (1.14-1.31)**
0.99 (0.91-1.06)
1.09 (1.04-1.13)*
1.14 (1.01-1.28)*

1.18 (1.11-1.25)**
0.99 (0.93-1.05)
1.07 (1.03-1.11)*
1.09 (0.99-1.20)

1.05 (0.81-1.37)
1.06 (0.81-1.38)

1.08 (0.84-1.38)
1.08 (0.84-1.39)

1.01 (0.94-1.08)
1.06 (1.01-1.12)*
1.04 (0.92-1.17)
1.01 (0.97-1.05)
1.09 (1.03-1.14)*
0.96 (0.88-1.04)
0.97 (0.93-1.02)
0.89 (0.79-1.00)*
1.01 (0.90-1.13)
1.08 (1.04-1.12)*
1.04 (0.95-1.14)
1.00 (0.79-1.28)
1.02 (0.96-1.07)
1.24 (0.98-1.57)
0.95 (0.89-1.02)

1.01 (0.95-1.07)
1.05 (1.01-1.10)*
1.01 (0.92-1.12)
1.00 (0.97-1.04)
1.06 (1.02-1.10)*
1.00 (0.94-1.06)
0.99 (0.95-1.03)
0.93 (0.85-.101)
0.97 (0.89-1.05)
1.05 (1.02-1.09)*
1.04 (0.97-1.11)
0.99 (0.78-1.23)
1.01 (0.97-1.05)
1.18 (0.97-1.43)
0.92 (0.87-0.97)*

0.97 (0.91-1.04)
0.94 (0.86-1.03)

0.99 (0.92-1.06)
0.98 (0.90-1.05)

0.99 (0.91-1.09)
1.07 (0.95-1.21)

0.99 (0.92-1.06)
1.07 (0.97-1.17)
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1-2
1.02 (0.98-1.06)
3-5
1.08 (1.02-1.14)*
6-8
1.14 (1.02-1.28)*
≥9
1.37 (1.18-1.59)**
≥1 hospitalizations
1.04 (1.01-1.07)*
Catheter ablation
1.02 (0.93-1.12)
Baseline Medication characteristic (ref: None)
Antiplatelet therapy
0.89 (0.85-0.94)*
Gastroprotective agent
1.01 (0.97-1.06)
Antiarrhythmic
1.01 (0.98-1.05)
Digoxin
0.98 (0.94-1.02)
Beta-blocker
1.04 (1.00-1.07)*
Calcium channel blocker
1.01 (0.98-1.05)
ACEI/ARB
0.98 (0.95-1.01)
Statin
0.95 (0.92-0.99)*
Hormone
0.95 (0.89-1.02)

1.03 (0.98-1.08)
1.07 (1.00-1.14)
1.14 (1.00-1.30)*
1.21 (1.02-1.44)*
1.04 (1.00-1.08)*
1.21 (1.02-1.44)*
0.89 (0.84-0.94)*
1.01 (0.95-1.07)
1.00 (0.96-1.04)
0.96 (0.91-1.10)
1.02 (0.99-1.06)
1.01 (0.98-1.05)
0.98 (0.95-1.02)
0.94 (0.90-0.97)
0.93 (0.86-1.01)

1.03 (0.99-1.07)
1.09 (1.03-1.15)*
1.14 (1.02-1.26)*
1.44 (1.26-1.65)**
1.04 (1.01-1.07)*
1.03 (0.94-1.13)
0.90 (0.86-0.94)*
1.01 (0.97-1.06)
1.01 (0.98-1.04)
0.97 (0.93-1.01)
1.03 (1.00-1.06)*
1.01 (0.98-1.04)
0.98 (0.95-1.01)
0.95 (0.92-0.98)*
0.95 (0.89-1.02)

*p<0.05
**p<0.001
Abbreviations: AMI, Acute Myocardial infarction; HR, Hazard Ratio; ref, referent group; CI, confidence interval; HMO, health
maintenance organization; POS, point of service; PPO, preferred provider organization; CDHP, consumer driven health plan;
VTE, venous thromboembolism; CCI, Charlson comorbidity index; ACEI/ARB, angiotensin converting enzyme
inhibitor/angiotensin receptor blocker

199

Appendix table 18. Stratification by insurance status: Clinical effectiveness
and safety of switching anticoagulants
Effectiveness Composite
Harm Composite
AMI HR (95% CI)
HR (95% CI)
HR (95% CI)
Commercially-insured (CCAE)
§
Warfarin switchers (ref: non-switchers)
Unadjusted
0.71 (0.67-0.75)**
0.71 (0.67-0.76)**
0.71 (0.67-0.74)**
MV-adjusted
0.70 (0.67-0.74)**
0.70 (0.66-0.75)**
0.71 (0.67-0.74)**
§
Dabigatran switchers (ref: non-switchers)
Unadjusted
1.04 (0.95-1.14)
1.03 (0.90-1.18)
0.99 (0.91-1.07)
MV-adjusted
1.03 (0.94-1.12)
1.02 (0.90-1.17)
0.97 (0.90-1.06)
Medicare Supplement (MDCR)
§
Warfarin switchers (ref: non-switchers)
Unadjusted
0.65 (0.62-0.68)**
0.64 (0.60-0.68)**
0.64 (0.62-0.66)**
MV-adjusted
0.67 (0.64-0.70)**
0.66 (0.63-0.70)**
0.66 (0.64-0.69)**
§
Dabigatran switchers (ref: non-switchers)
Unadjusted
1.03 (0.95-1.10)
1.09 (0.98-1.21)
1.01 (0.94-1.07)
MV-adjusted
1.02 (0.95-1.09)
1.08 (0.97-1.19)
1.00 (0.94-1.07)
§
Warfarin switchers: patients who switched from warfarin to dabigatran; Dabigatran switchers: patients who
switched from dabigatran to warfarin
NOTE: REF: Non-switching
*p<0.05; p<0.001
Abbreviations: MV, Multivariable; HR, Hazard Ratio; CI, Confidence interval
Outcome Type
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